Anti-CDH6 antibody and its antibody-drug conjugate

Enhanced anti-CDH6 antibodies conjugated with cytotoxic drugs provide targeted cancer therapy, addressing the limitations of existing ADCs by improving efficacy and safety in treating resistant cancers.

JP2024545170APending Publication Date: 2024-12-05MULTITUDE THERAPEUTICS INC
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2024534514
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-10
Filing Date
2022-12-09
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Current CDH6-targeting antibody-drug conjugates (ADCs) like DS-6000a lack sufficient safety and efficacy data, and there is a need for improved methods to treat cancers resistant or prone to resistance to tyrosine kinase inhibitors, serine/threonine kinase inhibitors, and chemotherapy.

Method used

Development of anti-CDH6 antibodies with enhanced binding affinity and internalization capabilities, specifically designed to target CDH6-expressing cells, conjugated with cytotoxic drugs via cleavable linkers to form antibody-drug conjugates (ADCs) for targeted cancer therapy.

Benefits of technology

The anti-CDH6 ADCs demonstrate potent antitumor effects with improved safety profiles, effectively reducing tumor growth and metastasis in CDH6-expressing cancers.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024545170000078
    Figure 2024545170000078
  • Figure 2024545170000079
    Figure 2024545170000079
  • Figure 2024545170000080
    Figure 2024545170000080
Patent Text Reader

Abstract

The present invention provides an antigen-binding protein that has the properties of (a) specifically binding to CDH6 and (b) having the activity of being internalized into CDH6-expressing cells by binding to CDH6. The present invention also provides an immune complex comprising an antibody or an antigen-binding fragment thereof that specifically binds to CDH6 and has internalization activity, a pharmaceutical product comprising said immune complex and having a therapeutic effect against tumors, and a method for treating tumors using said immune complex or said pharmaceutical product.
Need to check novelty before this filing date? Find Prior Art

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This patent application claims priority to PCT application PCT / CN2021 / 136994, filed on December 10, 2021, and CN application CN2021115076855, filed on December 10, 2021. Priority is claimed to these prior applications, the disclosures of which are deemed to be part of the disclosure of this application, and the entire contents of said applications are incorporated herein.

[0002] This application incorporates by reference an XML file entitled "0283-PA-002.xml", created on November 1, 2022, having a size of 149,920 bytes, as the Sequence Listing of this application. [Background technology]

[0003] Cadherin 6 (CDH6) is specifically expressed in the brain and kidney during development and has been reported to play an important role in the formation of the central nervous system circuits and the development of nephrons in the kidney. In normal adult tissues, CDH6 expression is localized in renal tubules, bile duct epithelial cells, etc.

[0004] On the other hand, CDH6 is known to be specifically overexpressed at the tumor site in several types of adult cancers. The correlation between CDH6 expression and poor prognosis in human renal cell carcinoma, especially renal clear cell carcinoma and papillary renal cell carcinoma, and its applicability as a tumor marker have been reported. High expression of CDH6 has also been reported in human ovarian cancer. It has also been reported that CDH6 is involved in the epithelial-mesenchymal transition of human thyroid cancer. Furthermore, CDH6 expression has been reported in human cholangiocarcinoma and human small cell lung cancer.

[0005] Antibody-drug conjugates ("ADCs") have been used for localized delivery of cytotoxic drugs in cancer therapy (see, e.g., Lambert, Curr. Opinion In Pharmacology, 5:543-549, 2005). ADCs allow for targeted delivery of the drug moiety for maximum efficacy with minimum toxicity. Although six new antibody-drug conjugates (ADCs) recently approved by the FDA show promise, consumption of ADCs in clinical development remains high.

[0006] The only reported CDH6-targeting antibody-drug conjugate (ADC) currently in investigational (Phase I clinical trial) is DS-6000a, developed by Daiichi Sankyo. DS-6000a consists of a humanized anti-CDH6 IgG1 monoclonal antibody linked to an exatecan-derived topoisomerase I inhibitor payload via a tetrapeptide-based targeting cleavable linker. DS-6000a has not been approved for any indication in any country, and its safety and efficacy remain to be confirmed.

[0007] Thus, there remains a need for improved methods of treating cancers that are resistant or prone to developing resistance to tyrosine kinase inhibitors, serine / threonine kinase inhibitors, and / or chemotherapy, particularly using CDH6-ADCs. Summary of the Invention

[0008] The present application, i) the ability to bind to CDH6 protein with a sensitivity of less than 12.5 ng / mL in an ELISA assay; ii) Approximately 3.1 × 10 in the ELISA assay -9 It is capable of binding to CDH6 protein with a K value of less than M; and iii) having the ability to be internalized by CDH6-expressing cells upon binding to CDH6; Antigen binding proteins having one or more of the above properties are provided.

[0009] In some embodiments, the CDH6 is a mammalian CDH6 protein.

[0010] In some embodiments, the CDH6 is a human CDH6 protein.

[0011] In some embodiments, the antigen binding protein competes for binding to the CDH6 protein with a reference antibody, the reference antibody comprising a light chain variable region (VL) and a heavy chain variable region (VH), wherein: the VH comprises the amino acid sequence set forth in SEQ ID NO: 18, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 23; or The VH comprises the amino acid sequence shown in SEQ ID NO:41, and the VL comprises the amino acid sequence shown in SEQ ID NO:46.

[0012] In some embodiments, the antigen binding protein comprises an antibody or an antigen-binding fragment thereof.

[0013] In some embodiments, the antibody comprises a monoclonal antibody, a polyclonal antibody, a dimer, a multimer, a complete antibody, a human antibody, a humanized antibody, and / or a chimeric antibody.

[0014] In some embodiments, the antigen-binding fragment comprises a Fab, a Fab', an Fv fragment, a F(ab')2, a scFv, a di-scFv, and / or a dAb.

[0015] In some embodiments, the antibody is a monoclonal antibody.

[0016] In some embodiments, the antibody is a chimeric antibody, a humanized antibody and / or a human antibody.

[0017] In some embodiments, the antibody or antigen-binding fragment comprises at least one CDR (complementarity determining region) of a heavy chain variable region (VH), wherein the VH comprises the amino acid sequence set forth in SEQ ID NO:18, SEQ ID NO:66, SEQ ID NO:41, SEQ ID NO:67, SEQ ID NO:95, or SEQ ID NO:103.

[0018] In some embodiments, the antibody or antigen-binding fragment comprises at least one CDR of a light chain variable region (VL), wherein the VL comprises the amino acid sequence set forth in SEQ ID NO:23, SEQ ID NO:68, SEQ ID NO:46, SEQ ID NO:69, SEQ ID NO:96, or SEQ ID NO:104.

[0019] In some embodiments, the antigen binding protein comprises a VH, wherein the VH comprises HCDR1, HCDR2, HCDR3, and wherein the HCDR1 comprises the amino acid sequence set forth in SEQ ID NO:1.

[0020] In some embodiments, the antigen binding protein comprises a VH, wherein the VH comprises HCDR1, HCDR2, HCDR3, and wherein the HCDR1 comprises the amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:8, SEQ ID NO:89, or SEQ ID NO:97.

[0021] In some embodiments, the antigen binding protein comprises a VH, wherein the VH comprises HCDR1, HCDR2, HCDR3, and the HCDR2 comprises the amino acid sequence set forth in SEQ ID NO:3, SEQ ID NO:9, SEQ ID NO:90, or SEQ ID NO:98.

[0022] In some embodiments, the antigen binding protein comprises a VH, wherein the VH comprises an HCDR1, an HCDR2, an HCDR3, and the HCDR3 comprises the amino acid sequence set forth in SEQ ID NO:4, SEQ ID NO:10, SEQ ID NO:91, or SEQ ID NO:99.

[0023] In some embodiments, the antigen binding protein comprises a VH, wherein the VH comprises an HCDR1, an HCDR2, and an HCDR3, wherein the HCDR1 comprises the amino acid sequence set forth in SEQ ID NO:1, the HCDR2 comprises the amino acid sequence set forth in SEQ ID NO:3 or SEQ ID NO:9, and the HCDR3 comprises the amino acid sequence set forth in SEQ ID NO:4 or SEQ ID NO:10.

[0024] In some embodiments, the antigen binding protein comprises a VH, wherein the VH comprises an HCDR1, an HCDR2, and an HCDR3, wherein the HCDR1 comprises the amino acid sequence set forth in SEQ ID NO:2, the HCDR2 comprises the amino acid sequence set forth in SEQ ID NO:3, and the HCDR3 comprises the amino acid sequence set forth in SEQ ID NO:4; or wherein said HCDR1 comprises the amino acid sequence shown in SEQ ID NO:8, said HCDR2 comprises the amino acid sequence shown in SEQ ID NO:9, and said HCDR3 comprises the amino acid sequence shown in SEQ ID NO:10; or wherein said HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 89, said HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 90, and said HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 91; or Here, the HCDR1 comprises the amino acid sequence shown in SEQ ID NO:97, the HCDR2 comprises the amino acid sequence shown in SEQ ID NO:98, and the HCDR3 comprises the amino acid sequence shown in SEQ ID NO:99.

[0025] In some embodiments, the antigen binding protein comprises a VH, wherein the VH comprises a framework region HFR1, the C-terminus of the HFR1 is directly or indirectly linked to the N-terminus of the HCDR1, and the HFR1 comprises the amino acid sequence set forth in SEQ ID NO: 14, SEQ ID NO: 24, SEQ ID NO: 37, SEQ ID NO: 47 or SEQ ID NO: 52.

[0026] In some embodiments, the antigen binding protein comprises a VH, wherein the VH comprises a framework region HFR2, wherein the HFR2 is located between the HCDR1 and the HCDR2, and wherein the HFR2 comprises the amino acid sequence set forth in SEQ ID NO: 15, SEQ ID NO: 28, SEQ ID NO: 38, or SEQ ID NO: 48.

[0027] In some embodiments, the antigen binding protein comprises a VH, wherein the VH comprises a framework region HFR3, wherein the HFR3 is located between the HCDR2 and the HCDR3, and wherein the HFR3 comprises the amino acid sequence set forth in SEQ ID NO: 16, SEQ ID NO: 25, SEQ ID NO: 39, SEQ ID NO: 49, or SEQ ID NO: 53.

[0028] In some embodiments, the antigen binding protein comprises a VH, wherein the VH comprises a framework region HFR4, wherein the N-terminus of the HFR4 is directly or indirectly linked to the C-terminus of the HCDR3, and wherein the HFR4 comprises the amino acid sequence set forth in SEQ ID NO: 17, SEQ ID NO: 26, SEQ ID NO: 40 or SEQ ID NO: 50.

[0029] In some embodiments, the antigen binding protein comprises a VH, wherein the VH comprises framework regions HFR1, HFR2, HFR3 and HFR4, wherein the C-terminus of HFR1 is directly or indirectly linked to the N-terminus of the HCDR1, the HFR2 is located between the HCDR1 and the HCDR2, the HFR3 is located between the HCDR2 and the HCDR3, and the N-terminus of the HFR4 is directly or indirectly linked to the C-terminus of the HCDR3, wherein the HFR1 comprises the amino acid sequence set forth in SEQ ID NO: 14, the HFR2 comprises the amino acid sequence set forth in SEQ ID NO: 15, the HFR3 comprises the amino acid sequence set forth in SEQ ID NO: 16, and the HFR4 comprises the amino acid sequence set forth in SEQ ID NO: 17; or the HFR1 comprises the amino acid sequence set forth in SEQ ID NO:24, the HFR2 comprises the amino acid sequence set forth in SEQ ID NO:15, the HFR3 comprises the amino acid sequence set forth in SEQ ID NO:25, and the HFR4 comprises the amino acid sequence set forth in SEQ ID NO:26; or the HFR1 comprises the amino acid sequence set forth in SEQ ID NO:24, the HFR2 comprises the amino acid sequence set forth in SEQ ID NO:28, the HFR3 comprises the amino acid sequence set forth in SEQ ID NO:25, and the HFR4 comprises the amino acid sequence set forth in SEQ ID NO:26; or the HFR1 comprises the amino acid sequence set forth in SEQ ID NO:37, the HFR2 comprises the amino acid sequence set forth in SEQ ID NO:38, the HFR3 comprises the amino acid sequence set forth in SEQ ID NO:39, and the HFR4 comprises the amino acid sequence set forth in SEQ ID NO:40; or the HFR1 comprises the amino acid sequence set forth in SEQ ID NO: 47, the HFR2 comprises the amino acid sequence set forth in SEQ ID NO: 48, the HFR3 comprises the amino acid sequence set forth in SEQ ID NO: 49, and the HFR4 comprises the amino acid sequence set forth in SEQ ID NO: 50; or The HFR1 comprises the amino acid sequence shown in SEQ ID NO:52, the HFR2 comprises the amino acid sequence shown in SEQ ID NO:38, the HFR3 comprises the amino acid sequence shown in SEQ ID NO:53, and the HFR4 comprises the amino acid sequence shown in SEQ ID NO:26.

[0030] In some embodiments, the antigen binding protein comprises a VH, wherein the VH comprises the amino acid sequence set forth in SEQ ID NO:18, SEQ ID NO:66, SEQ ID NO:41, SEQ ID NO:67, SEQ ID NO:95, or SEQ ID NO:103.

[0031] In some embodiments, the antigen binding protein comprises an antibody heavy chain constant region.

[0032] In some embodiments, the antibody heavy chain constant region comprises a constant region derived from human IgG, and optionally, the antibody heavy chain constant region comprises a constant region derived from human IgG1, IgG2, IgG3, or IgG4.

[0033] In some embodiments, the antibody heavy chain constant region comprises the amino acid sequence set forth in SEQ ID NO:70.

[0034] In some embodiments, the antibody heavy chain comprises the amino acid sequence set forth in SEQ ID NO:72, SEQ ID NO:85, SEQ ID NO:80, or SEQ ID NO:87.

[0035] In some embodiments, the antigen binding protein comprises a VL, wherein the VL comprises an LCDR1, an LCDR2, and an LCDR3, and wherein the LCDR1 comprises the amino acid sequence set forth in SEQ ID NO:5, SEQ ID NO:11, SEQ ID NO:92, or SEQ ID NO:100.

[0036] In some embodiments, the antigen binding protein comprises a VL, wherein the VL comprises an LCDR1, an LCDR2, an LCDR3, and wherein the LCDR2 comprises the amino acid sequence set forth in SEQ ID NO:6, SEQ ID NO:12, SEQ ID NO:93, or SEQ ID NO:101.

[0037] In some embodiments, the antigen binding protein comprises a VL, wherein the VL comprises an LCDR1, an LCDR2, an LCDR3, and the LCDR3 comprises the amino acid sequence set forth in SEQ ID NO:7, SEQ ID NO:13, SEQ ID NO:94, or SEQ ID NO:102.

[0038] In some embodiments, the antigen binding protein comprises a VL, wherein the VL comprises an LCDR1, an LCDR2, and an LCDR3, wherein the LCDR1 comprises the amino acid sequence set forth in SEQ ID NO:5, the LCDR2 comprises the amino acid sequence set forth in SEQ ID NO:6, and the LCDR3 comprises the amino acid sequence set forth in SEQ ID NO:7; or wherein the LCDR1 comprises the amino acid sequence shown in SEQ ID NO: 11, the LCDR2 comprises the amino acid sequence shown in SEQ ID NO: 12, and the LCDR3 comprises the amino acid sequence shown in SEQ ID NO: 13; or wherein the LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 92, the LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 93, and the LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 94; or Here, the LCDR1 comprises the amino acid sequence shown in SEQ ID NO:100, the LCDR2 comprises the amino acid sequence shown in SEQ ID NO:101, and the LCDR3 comprises the amino acid sequence shown in SEQ ID NO:102.

[0039] In some embodiments, the antigen binding protein comprises a VH and a VL, wherein the VH comprises an HCDR1, an HCDR2, and an HCDR3, and the VL comprises an LCDR1, an LCDR2, and an LCDR3, wherein the HCDR1 comprises the amino acid sequence set forth in SEQ ID NO:1, the HCDR2 comprises the amino acid sequence set forth in SEQ ID NO:3, the HCDR3 comprises the amino acid sequence set forth in SEQ ID NO:4, the LCDR1 comprises the amino acid sequence set forth in SEQ ID NO:5, the LCDR2 comprises the amino acid sequence set forth in SEQ ID NO:6, and the LCDR3 comprises the amino acid sequence set forth in SEQ ID NO:7, or Here, the HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 1, the HCDR2 comprises the amino acid sequence shown in SEQ ID NO: 9, the HCDR3 comprises the amino acid sequence shown in SEQ ID NO: 10, the LCDR1 comprises the amino acid sequence shown in SEQ ID NO: 11, the LCDR2 comprises the amino acid sequence shown in SEQ ID NO: 12, and the LCDR3 comprises the amino acid sequence shown in SEQ ID NO: 13.

[0040] In some embodiments, the antigen binding protein comprises a VH and a VL, wherein the VH comprises an HCDR1, an HCDR2, and an HCDR3, and the VL comprises an LCDR1, an LCDR2, and an LCDR3, wherein the HCDR1 comprises the amino acid sequence set forth in SEQ ID NO:2, the HCDR2 comprises the amino acid sequence set forth in SEQ ID NO:3, the HCDR3 comprises the amino acid sequence set forth in SEQ ID NO:4, the LCDR1 comprises the amino acid sequence set forth in SEQ ID NO:5, the LCDR2 comprises the amino acid sequence set forth in SEQ ID NO:6, and the LCDR3 comprises the amino acid sequence set forth in SEQ ID NO:7, or wherein the HCDR1 comprises the amino acid sequence shown in SEQ ID NO:8, the HCDR2 comprises the amino acid sequence shown in SEQ ID NO:9, the HCDR3 comprises the amino acid sequence shown in SEQ ID NO:10, the LCDR1 comprises the amino acid sequence shown in SEQ ID NO:11, the LCDR2 comprises the amino acid sequence shown in SEQ ID NO:12, and the LCDR3 comprises the amino acid sequence shown in SEQ ID NO:13, or wherein the HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 89, the HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 90, the HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 91, the LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 92, the LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 93, and the LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 94, or Here, the HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 97, the HCDR2 comprises the amino acid sequence shown in SEQ ID NO: 98, the HCDR3 comprises the amino acid sequence shown in SEQ ID NO: 99, the LCDR1 comprises the amino acid sequence shown in SEQ ID NO: 100, the LCDR2 comprises the amino acid sequence shown in SEQ ID NO: 101, and the LCDR3 comprises the amino acid sequence shown in SEQ ID NO: 102.

[0041] In some embodiments, the antigen binding protein comprises a VL, wherein the VL comprises a framework region LFR1, the C-terminus of the LFR1 is directly or indirectly linked to the N-terminus of the LCDR1, and the LFR1 comprises the amino acid sequence set forth in SEQ ID NO: 19, SEQ ID NO: 30, SEQ ID NO: 42, SEQ ID NO: 55, SEQ ID NO: 59 or SEQ ID NO: 64.

[0042] In some embodiments, the antigen binding protein comprises a VL, wherein the VL comprises a framework region LFR2, wherein the LFR2 is located between the LCDR1 and the LCDR2, and wherein the LFR2 comprises the amino acid sequence set forth in SEQ ID NO:20, SEQ ID NO:31, SEQ ID NO:43, SEQ ID NO:56, or SEQ ID NO:60.

[0043] In some embodiments, the antigen binding protein comprises a VL, wherein the VL comprises a framework region LFR3, wherein the LFR3 is located between the LCDR2 and the LCDR3, and wherein the LFR3 comprises the amino acid sequence set forth in SEQ ID NO:21, SEQ ID NO:32, SEQ ID NO:35, SEQ ID NO:44, SEQ ID NO:57, or SEQ ID NO:61.

[0044] In some embodiments, the antigen binding protein comprises a VL, wherein the VL comprises a framework region LFR4, the N-terminus of the LFR4 is directly or indirectly linked to the C-terminus of the LCDR3, and the LFR4 comprises the amino acid sequence set forth in SEQ ID NO:22, SEQ ID NO:33, SEQ ID NO:45 or SEQ ID NO:62.

[0045] In some embodiments, the antigen binding protein comprises a VL, wherein the VL comprises framework regions LFR1, LFR2, LFR3 and LFR4, wherein the C-terminus of LFR1 is directly or indirectly linked to the N-terminus of the LCDR1, the LFR2 is located between the LCDR1 and the LCDR2, the LFR3 is located between the LCDR2 and the LCDR3, and the N-terminus of LFR4 is directly or indirectly linked to the C-terminus of the LCDR3, wherein the LFR1 comprises the amino acid sequence set forth in SEQ ID NO: 19, the LFR2 comprises the amino acid sequence set forth in SEQ ID NO: 20, the LFR3 comprises the amino acid sequence set forth in SEQ ID NO: 21, and the LFR4 comprises the amino acid sequence set forth in SEQ ID NO: 22; or the LFR1 comprises the amino acid sequence shown in SEQ ID NO: 30, the LFR2 comprises the amino acid sequence shown in SEQ ID NO: 31, the LFR3 comprises the amino acid sequence shown in SEQ ID NO: 32, and the LFR4 comprises the amino acid sequence shown in SEQ ID NO: 33; or the LFR1 comprises the amino acid sequence shown in SEQ ID NO: 30, the LFR2 comprises the amino acid sequence shown in SEQ ID NO: 31, the LFR3 comprises the amino acid sequence shown in SEQ ID NO: 35, and the LFR4 comprises the amino acid sequence shown in SEQ ID NO: 33; or the LFR1 comprises the amino acid sequence shown in SEQ ID NO: 42, the LFR2 comprises the amino acid sequence shown in SEQ ID NO: 43, the LFR3 comprises the amino acid sequence shown in SEQ ID NO: 44, and the LFR4 comprises the amino acid sequence shown in SEQ ID NO: 45; or the LFR1 comprises the amino acid sequence set forth in SEQ ID NO:55, the LFR2 comprises the amino acid sequence set forth in SEQ ID NO:56, the LFR3 comprises the amino acid sequence set forth in SEQ ID NO:57, and the LFR4 comprises the amino acid sequence set forth in SEQ ID NO:45; or the LFR1 comprises the amino acid sequence shown in SEQ ID NO:59, the LFR2 comprises the amino acid sequence shown in SEQ ID NO:60, the LFR3 comprises the amino acid sequence shown in SEQ ID NO:61, and the LFR4 comprises the amino acid sequence shown in SEQ ID NO:62; or The LFR1 comprises the amino acid sequence shown in SEQ ID NO:64, the LFR2 comprises the amino acid sequence shown in SEQ ID NO:60, the LFR3 comprises the amino acid sequence shown in SEQ ID NO:61, and the LFR4 comprises the amino acid sequence shown in SEQ ID NO:62.

[0046] In some embodiments, the antigen binding protein comprises a VL, wherein the VL comprises the amino acid sequence set forth in SEQ ID NO:23, SEQ ID NO:68, SEQ ID NO:46, SEQ ID NO:69, SEQ ID NO:96, or SEQ ID NO:104.

[0047] In some embodiments, the antigen binding protein comprises a VH and a VL, wherein the VH comprises the amino acid sequence set forth in SEQ ID NO: 18 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 23; or wherein the VH comprises the amino acid sequence set forth in SEQ ID NO: 41 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 46; or wherein the VH comprises the amino acid sequence set forth in SEQ ID NO: 66 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 68; or wherein the VH comprises the amino acid sequence set forth in SEQ ID NO:67 and the VL comprises the amino acid sequence set forth in SEQ ID NO:69; or wherein the VH comprises the amino acid sequence set forth in SEQ ID NO: 95 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 96; or Here, the VH comprises the amino acid sequence shown in SEQ ID NO: 103, and the VL comprises the amino acid sequence shown in SEQ ID NO: 104.

[0048] In some embodiments, the antigen binding protein comprises an antibody light chain constant region.

[0049] In some embodiments, the antibody light chain constant region comprises a human Igκ constant region or a human Igλ constant region.

[0050] In some embodiments, the antibody light chain constant region comprises the amino acid sequence set forth in SEQ ID NO:71.

[0051] In some embodiments, the antibody light chain comprises the amino acid sequence set forth in SEQ ID NO:73, SEQ ID NO:86, SEQ ID NO:81, or SEQ ID NO:88.

[0052] In some embodiments, the antigen binding protein comprises an antibody heavy chain and an antibody light chain, wherein the antibody heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 72 and the antibody light chain comprises the amino acid sequence set forth in SEQ ID NO: 73; or wherein the antibody heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 85 and the antibody light chain comprises the amino acid sequence set forth in SEQ ID NO: 86; or wherein the antibody heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 80 and the antibody light chain comprises the amino acid sequence set forth in SEQ ID NO: 81; or wherein the antibody heavy chain comprises the amino acid sequence set forth in SEQ ID NO:87, and the antibody light chain comprises the amino acid sequence set forth in SEQ ID NO:88.

[0053] In another aspect, the present application provides a method for producing a method for manufacturing a pharmaceutical composition comprising: (i) a VL comprising a VL CDR1, CDR2 and CDR3 derived from a VL having an amino acid sequence consisting of SEQ ID NO: 18, and / or a VH comprising a VH CDR1, CDR2 and CDR3 derived from a VH having an amino acid sequence consisting of SEQ ID NO: 23; (ii) a VL comprising a VL CDR1, CDR2 and CDR3 derived from a VL having an amino acid sequence consisting of SEQ ID NO: 41, and / or a VH comprising a VH CDR1, CDR2 and CDR3 derived from a VH having an amino acid sequence consisting of SEQ ID NO: 46; (iii) a VL comprising a VL CDR1, CDR2 and CDR3 derived from a VL having an amino acid sequence consisting of SEQ ID NO: 66, and / or a VH comprising a VH CDR1, CDR2 and CDR3 derived from a VH having an amino acid sequence consisting of SEQ ID NO: 68; (iv) a VL comprising a VL CDR1, CDR2 and CDR3 derived from a VL having an amino acid sequence consisting of SEQ ID NO: 67, and / or a VH comprising a VH CDR1, CDR2 and CDR3 derived from a VH having an amino acid sequence consisting of SEQ ID NO: 69; (v) a VL comprising a VL CDR1, CDR2 and CDR3 derived from a VL having an amino acid sequence consisting of SEQ ID NO: 95, and / or a VH comprising a VH CDR1, CDR2 and CDR3 derived from a VH having an amino acid sequence consisting of SEQ ID NO: 96, or (vi) a VL comprising a VL CDR1, CDR2 and CDR3 derived from a VL having an amino acid sequence consisting of SEQ ID NO: 103, and / or a VH comprising a VH CDR1, CDR2 and CDR3 derived from a VH having an amino acid sequence consisting of SEQ ID NO: 104; The present invention provides an antigen-binding protein that specifically binds to CDH6, comprising the compound

[0054] In another aspect, the present application provides antigen binding proteins that compete for binding to CDH6 with the antigen binding proteins provided herein.

[0055] In another aspect, the present application provides a polypeptide comprising the antigen-binding protein described above.

[0056] In another aspect, the present application provides a nucleic acid molecule or molecules encoding said antigen binding protein or said polypeptide.

[0057] In another aspect, the present application provides a vector comprising the above-described nucleic acid molecule.

[0058] In another aspect, the present application provides a cell comprising said nucleic acid molecule or said vector, or expressing said antigen-binding protein or said polypeptide.

[0059] In another aspect, the present application provides a method of producing the antigen binding protein described above, comprising culturing the cell described above under conditions in which the antigen binding protein is expressed.

[0060] In another aspect, the present application provides a pharmaceutical composition comprising the antigen binding protein, the polypeptide, the nucleic acid molecule, the vector and / or the cell, and, optionally, a pharma- ceutically acceptable carrier.

[0061] In another aspect, the present application provides a kit comprising the above antigen-binding protein, the above polypeptide, or the above pharmaceutical composition.

[0062] In another aspect, the present application provides the use of said antigen binding protein, said polypeptide, said nucleic acid molecule, said vector and / or said cell and / or said pharmaceutical composition in the manufacture of a medicament for the prevention and / or treatment of a disease or disorder associated with CDH6.

[0063] In some embodiments, the CDH6-associated disease or disorder comprises a tumor.

[0064] In some embodiments, the tumor comprises a CDH6-expressing tumor.

[0065] In some embodiments, the tumor comprises renal cell carcinoma, renal clear cell carcinoma, papillary renal cell carcinoma, ovarian cancer, ovarian serous adenocarcinoma, thyroid cancer, cholangiocarcinoma, lung cancer, small cell lung cancer, liver cancer, glioblastoma, mesothelioma, uterine cancer, pancreatic cancer, Wilms' tumor, or neuroblastoma.

[0066] In some embodiments, the medicament further comprises an additional therapeutic agent.

[0067] In another aspect, the present application provides an immunoconjugate comprising the above antigen-binding protein, or a pharma- ceutically acceptable salt or solvate thereof.

[0068] In some embodiments, the immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof further comprises an active moiety attached to the antibody or antigen-binding fragment thereof.

[0069] In some embodiments, the active moiety comprises a drug moiety and / or a label.

[0070] In some embodiments, the drug moiety is selected from the group consisting of cytotoxic drugs, cytokines, nucleic acids, nucleic acid-associated molecules, radionuclides, chemokines, immune (co)stimulatory molecules, immunosuppressive molecules, death ligands, apoptosis-inducing proteins, kinases, prodrug converting enzymes, ribonucleases, agonist antibodies or antibody fragments, antagonist antibodies or antibody fragments, growth factors, hormones, clotting factors, fibrinolytic proteins, peptide mimetics thereof, and fragments, fusion proteins or derivatives thereof.

[0071] In some embodiments, the label is selected from the group consisting of a radiolabel, a fluorophore, a chromophore, an imaging agent, and a metal ion.

[0072] In some embodiments, the cytotoxic agent comprises a microtubule inhibitor and / or a DNA damaging agent.

[0073] In some embodiments, the cytotoxic agent comprises a tubulin inhibitor and / or a topoisomerase inhibitor.

[0074] In some embodiments, the cytotoxic agent comprises a topoisomerase I inhibitor.

[0075] In some embodiments, the cytotoxic agent comprises camptothecin (CPT) or a derivative thereof.

[0076] In some embodiments, the cytotoxic agent has the structure of Formula II below, or a tautomer, mesomer, racemate, enantiomer, or diastereomer thereof, or a mixture thereof, or a pharma- ceutically acceptable salt or solvate thereof. [ka] (II)

[0077] In some embodiments, the immunoconjugate, or a pharma- ceutically acceptable salt or solvate thereof, comprises an antibody-drug conjugate (ADC) of formula (I): Ab-(L-(D) m ) n (I) wherein Ab is an antigen-binding protein as defined above, L is a linker, D is a drug moiety; m is an integer from 1 to 8; and n is any number from 1 to 10.

[0078] In some embodiments, L is selected from a cleavable linker and a non-cleavable linker.

[0079] In some embodiments, L comprises a cleavable peptide.

[0080] In some embodiments, the cleavable peptide is cleavable by an enzyme.

[0081] In some embodiments, the enzyme comprises cathepsin B.

[0082] In some embodiments, the cleavable peptide or L comprises an amino acid unit.

[0083] In some embodiments, the amino acid unit comprises a dipeptide, a tripeptide, a tetrapeptide, or a pentapeptide.

[0084] In some embodiments, the amino acid unit is selected from Val-Cit, Val-Ala (VA), Glu-Val-Cit, Ala-Ala-Asn (AAN), Gly-Val-Cit, Gly-Gly-Gly (GGG), and Gly-Gly-Phe-Gly (GGFG).

[0085] In some embodiments, the L comprises a spacer.

[0086] In some embodiments, the spacer comprises a self-immolative spacer.

[0087] In some embodiments, the self-immolative spacer comprises a p-aminobenzoxycarbonyl group (PABC) or a p-aminobenzyl group (PAB).

[0088] In some embodiments, the cleavable peptide is spliced ​​directly to the spacer.

[0089] In some embodiments, L comprises -Val-Cit-PABC-, -Val-Ala-PABC-, -Glu-Val-Cit-PABC-, -Ala-Ala-Asn-PABC-, -Gly-Val-Cit-PABC-, -Gly-Gly-Gly-PABC-, -Gly-Gly-Phe-Gly-PABC-, -Val-Cit-PAB-, -Val-Ala-PAB-, -Glu-Val-Cit-PAB-, -Ala-Ala-Asn-PAB-, -Gly-Val-Cit-PAB-, -Gly-Gly-Gly-PAB-, or -Gly-Gly-Phe-Gly-PAB-.

[0090] In some embodiments, the spacer is -NH-(CH2)n 1 -La-Lb-Lc-, where La represents -O- or a single bond, and Lb represents -CR 2 (-CR 3 )- or a single bond, where R 2 and R 3are each independently a C1 to C6 alkyl group, -(CH2)n a -NH2, -(CH2)n b -COOH or -(CH2)n c -OH, n 1 represents an integer from 0 to 6, and n a , n b and n c each independently represents an integer of 1 to 4, provided that n a When is 0, R 2 and R 3 are not the same, and Lc represents -C(=O)-.

[0091] In some embodiments, the spacer comprises -NH-(CH2)3-C(=O)-, -NH-CH2-O-CH2-C(=O)-, or -NH-(CH2)2-O-CH2-C(=O)-.

[0092] In some embodiments, L comprises the structure -L1-L2-L3-, where L1 is -(succinimidyl-3-yl-N)-(CH2)n 2 -C(=O)-, -CH2-C(=O)-NH-(CH2)n 3 -C(=O)- or -C(=O)-(CH2)n 4 -C(=O)-, where n 2 represents an integer from 2 to 8, and n 3 represents an integer from 1 to 8, and n 4 represents an integer of 1 to 8, L2 represents an amino acid unit, and L3 represents a self-degrading spacer.

[0093] In some embodiments, L is -(Succinimidyl-3-yl-N)-CH2CH2-C(=O)-GGFG-PABC-, -(Succinimidyl-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-PABC-, -(Succinimidyl-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-PABC-, -(Succinimidyl-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-GGFG-PABC-, -(Succinimidyl-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-GGFG-PABC-, -CH2-C(=O)-NH-CH2CH2-C(=O)-GGFG-PABC-, -C(=O)-CH2CH2CH2CH2CH2CH2-C(=O)-GGFG-PABC-, -(Succinimidyl-3-yl-N)-CH2CH2-C(=O)-GGFG-NH-CH2CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2CH2CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2-O-CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2CH2-O-CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-GGFG-NH-CH2CH2-C(=O)-, -(succinimidyl-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-, -(succinimidyl-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-GGFG-NH-CH2CH2-C(=O)-, -CH2-C(=O)-NH-CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-, -C(=O)-CH2CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2-C(=O)-VA-PABC-, -(Succinimidyl-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-VA-PABC-, -(Succinimidyl-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-VA-NH-PABC-, -(Succinimidyl-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-VA-PABC-, -(Succinimidyl-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2o-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-VA-PABC-, -CH2-C(=O)-NH-CH2CH2-C(=O)-VA-PABC-, -C(=O)-CH2CH2CH2CH2CH2CH2-C(=O)-VA-PABC-, -(Succinimidyl-3-yl-N)-CH2CH2-C(=O)-VA-NH-CH2CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2-C(=O)-VA-NH-CH2CH2CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-VA-NH-CH2CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-VA-NH-CH2CH2CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-VA-NH-CH2CH2CH2CH2CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-VA-NH-CH2-O-CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-VA-NH-CH2CH2-O-CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-VA-NH-CH2CH2CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-VA-NH-CH2CH2-C(=O)-, -(succinimidyl-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-VA-NH-CH2CH2CH2-C(=O)-, -(succinimidyl-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-VA-NH-CH2CH2-C(=O)-, -CH2-C(=O)-NH-CH2CH2-C(=O)-VA-NH-CH2CH2CH2-C(=O)-, and -C(=O)-CH2CH2CH2CH2CH2CH2-C(=O)-VA-NH-CH2CH2CH2-C(=O)- Selected from.

[0094] In some embodiments, the p-aminobenzoxycarbonyl group (PABC) or p-aminobenzyl group (PAB) comprises a polysarcosine (poly-N-methylglycine) residue.

[0095] In some embodiments, L is [ka] and [ka] Selected from the above structures, where n 5 represents an integer from 0 to 20.

[0096] In some embodiments, the n 5 represents an integer from 1 to 15.

[0097] In some embodiments, the n 5 represents an integer from 1 to 7.

[0098] In some embodiments, the n 5 represents an integer from 8 to 15.

[0099] In some embodiments, L is [ka] , [ka] [ka] and [ka] It is selected from the above structures.

[0100] In some embodiments, the antibody drug conjugate comprises: [ka] , [ka] , [ka] and [ka] Selected from the above structures, Here, n is any number from 1 to 10.

[0101] In some embodiments, n is any number from 2 to 9.

[0102] The present application further provides a method for producing the immunoconjugate of the present application, comprising the step of reacting the antibody or antigen-binding fragment thereof of the present application with a drug-linker intermediate compound.

[0103] The present application further provides a pharmaceutical composition comprising the immunoconjugate of the present application, a salt thereof, or a hydrate of the conjugate or salt.

[0104] In some embodiments, the pharmaceutical composition further comprises a pharma- ceutically acceptable carrier or excipient.

[0105] The present application further provides the use of the immunoconjugate of the present application or the pharmaceutical composition of the present application in the manufacture of a medicament for treating a tumor.

[0106] In some embodiments, the tumor is a CDH6-expressing tumor.

[0107] In some embodiments, the tumor comprises renal cell carcinoma, renal clear cell carcinoma, papillary renal cell carcinoma, ovarian cancer, ovarian serous adenocarcinoma, thyroid cancer, cholangiocarcinoma, lung cancer, small cell lung carcinoma, glioblastoma, mesothelioma, uterine cancer, pancreatic cancer, Wilms' tumor, or neuroblastoma.

[0108] The present application further provides a method of treating a tumor comprising administering to a subject an immunoconjugate of the present application, a salt thereof, and / or a hydrate of the conjugate or salt.

[0109] In some embodiments, the tumor is a CDH6-expressing tumor.

[0110] In some embodiments, the tumor comprises renal cell carcinoma, renal clear cell carcinoma, papillary renal cell carcinoma, ovarian cancer, ovarian serous adenocarcinoma, thyroid cancer, cholangiocarcinoma, lung cancer, small cell lung carcinoma, glioblastoma, mesothelioma, uterine cancer, pancreatic cancer, Wilms' tumor, or neuroblastoma.

[0111] The present application further provides a method for treating a tumor, comprising administering to a subject simultaneously, separately or sequentially a pharmaceutical composition comprising at least one component selected from the immunoconjugate of the present application, a salt thereof, and a hydrate of the conjugate or salt, and at least one anti-tumor drug. Effect of the Invention

[0112] (Beneficial Effects of the Present Disclosure) The anti-CDH6 antibody-drug conjugate comprising the anti-CDH6 antibody of the present disclosure bound to a drug that exerts toxicity on cells via a linker having a specific structure is expected to provide excellent antitumor effects and safety when administered to patients with cancer cells expressing CDH6. Specifically, the anti-CDH6 antibody-drug conjugate of the present disclosure is useful as an antitumor agent.

[0113] Further aspects and advantages of the present disclosure will become readily apparent to those skilled in the art from the following detailed description, in which only illustrative embodiments of the present disclosure are shown and described. It will be appreciated that the present disclosure may have other and different embodiments, and that certain details thereof may be modified in various obvious respects without departing from the present disclosure. Accordingly, the drawings and description are to be regarded as illustrative in nature and not restrictive.

[0114] (Incorporated by reference) All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. [Brief description of the drawings]

[0115] The novel features of the invention are set forth with particularity in the appended claims. The features and advantages of the present invention will be better understood by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings (also referred to herein as "Figures" and "FIG."), in which: [Figure 1A] [Figure 1B] Figures 1A and 1B show the results of flow cytometry examining the binding of anti-CDH6 chimeric antibody (Ch069707) and its humanized variants (CL069707-H1L1, CL069707-H1L2, CL069707-H2L1, CL069707-H2L2) to the ovarian cancer cell line OVCAR-3. [Diagram 2] Figure 2 shows the results of flow cytometry examining the binding of anti-CDH6 chimeric antibody (Ch069463) and its humanized variants (CL069463-H1L1, CL069463-H2L2, CL069463-H2L3) to the ovarian cancer cell line OVCAR-3. [Diagram 3]FIG. 3 shows the results of ELISA examining the binding of CL069707-H1L1 to human CDH6-ECD-His, CDH9-ECD-His, and CDH10-ECD-His recombinant proteins. [Figure 4] FIG. 4 shows the results of ELISA examining the binding of CL069707-H1L1 to human, cynomolgus monkey, mouse, and rat CDH6-ECD-His recombinant proteins. [Figure 5A] FIG. 5A shows the SEC chromatogram of CL069707-H1L1 measured by routine procedure G. [Figure 5B] FIG. 5B shows the HIC chromatogram of CL069707-H1L1 measured by routine procedure H. [Figure 6A] FIG. 6A shows the SEC chromatogram of antibody drug conjugate CL069707-H1L1-LP1 measured by routine procedure G. [Figure 6B] FIG. 6B shows the HIC chromatogram of antibody drug conjugate CL069707-H1L1-LP1 measured by routine procedure H. [Figure 7A] FIG. 7A shows the SEC chromatogram of antibody drug conjugate CL069707-H1L1-LP2 measured by routine procedure G. [Figure 7B] FIG. 7B shows the HIC chromatogram of antibody drug conjugate CL069707-H1L1-LP2 measured by routine procedure H. [Figure 8A] FIG. 8A shows the SEC chromatogram of antibody drug conjugate CL069707-H1L1-GGFG-DXd measured by routine procedure G. [Figure 8B] FIG. 8B shows the HIC chromatogram of antibody drug conjugate CL069707-H1L1-GGFG-DXd measured by routine procedure H. [Figure 9A] FIG. 9A shows the SEC chromatogram of antibody-drug conjugate DS-6000a measured by routine procedure G. [Figure 9B] FIG. 9B shows the HIC chromatogram of antibody-drug conjugate DS-6000a measured by routine procedure H. [Figure 10A]FIG. 10A shows the SEC chromatogram of the antibody drug conjugate reference antibody-LP1 measured by routine procedure G. [Figure 10B] FIG. 10B shows the HIC chromatogram of the antibody drug conjugate reference antibody-LP1 measured by routine procedure H. [Figure 11A] FIG. 11A shows the SEC chromatogram of the antibody-drug conjugate human IgG-LP1 measured by routine procedure G. [Figure 11B] FIG. 11B shows the HIC chromatogram of the antibody-drug conjugate human IgG-LP1 measured by routine procedure H. [Figure 12A] FIG. 12A shows the SEC chromatogram of the antibody-drug conjugate human IgG-LP2 measured by routine procedure G. [Figure 12B] FIG. 12B shows the HIC chromatogram of the antibody-drug conjugate human IgG-LP2 measured by routine procedure H. [Figure 13A] FIG. 13A shows a SEC chromatogram of the antibody-drug conjugate human IgG-GGFG-DXd measured by routine procedure G. [Figure 13B] FIG. 13B shows the HIC chromatogram of the antibody-drug conjugate human IgG-GGFG-DXd measured by routine procedure H. [Figure 14] FIG. 14 shows internalization of CL069707-H1L1-LP1 by PA-1, OVCAR-3 and 786-O cells. [Figure 15A] [Figure 15B] [Figure 15C] [Figure 15D] Figures 15A to 15D show the results of evaluating the in vitro cell growth inhibitory activity of anti-CDH6 antibody-drug conjugates (CL069707-H1L1-LP1, CL069707-H1L1-LP2, CL069707-H1L1-GGFG-DXd, CL069707-H1L2-GGFG-DXd, CL069707-H2L1-GGFG-DXd, CL069707-H2L2-GGFG-DXd) against CDH6-positive tumor cell lines OVCAR-3 and PA-1. [Figure 16A]FIG. 16A shows the results of in vitro cytotoxicity of anti-CDH6 antibodies (CL069707, CL069439, CL069066) conjugated to vc-MMAE. [Figure 16B] FIG. 16B shows the results of in vitro cytotoxicity of anti-CDH6 antibodies (CL069707, CL069439, CL069066) bound to GGFG-DXd. [Figure 17A] Figure 17A shows the in vivo anti-tumor efficacy of three humanized anti-CDH6 antibody drug conjugates (CL069707-H1L1-LP1, CL069707-H1L1-LP2, CL069707-H1L1-GGFG-DXd). [Figure 17B] Figure 17B shows the effect of three humanized anti-CDH6 antibody-drug conjugates (CL069707-H1L1-LP1, CL069707-H1L1-LP2, CL069707-H1L1-GGFG-DXd) on mouse body weight. The evaluation was performed using an animal model in which CDH6-positive human ovarian teratoma cell line PA-1 was inoculated into immunodeficient mice. [Figure 18A] FIG. 18A shows that CL069707-H1L1-LP1, CL069707-H1L1-LP2 showed tumor regression in a dose-dependent manner after single dose administration. [Figure 18B] Figure 18B shows the effect of different doses of CL069707-H1L1-LP1 and CL069707-H1L1-LP2 on mouse body weight. The evaluation was performed using an animal model in which CDH6-positive human ovarian teratoma cell line PA-1 was inoculated into immunodeficient mice. [Figure 19A] FIG. 19A shows the in vivo antitumor effect of CL069707-H1L1-LP1. [Figure 19B] Figure 19B shows the effect of a single dose of CL069707-H1L1-LP1 on mouse body weight, which was evaluated using an animal model in which immunodeficient mice were inoculated with the CDH6-positive tumor cell line OVCAR-3. [Figure 20A] FIG. 20A shows the in vivo antitumor effect of CL069707-H1L1-LP1. [Figure 20B]Figure 20B shows the effect of CL069707-H1L1-LP1 on mouse body weight, which was evaluated using an animal model in which CDH6-positive tumor cell line 786-O was inoculated into immunodeficient mice. [Figure 21A] FIG. 21A shows the in vivo antitumor effect of CL069707-H1L1-LP1. [Figure 21B] Figure 21B shows the effect of CL069707-H1L1-LP1 on mouse body weight, which was evaluated using a renal cancer patient-derived xenograft (PDX) model. [Figure 22A] [Figure 22B] [Figure 22C] Figures 22A to 22C show the structures of CL069707-H1L1-LP1, CL069707-H1L1-LP2 and CL069707-H1L1-GGFG-DXd. [Figure 23] FIG. 23 shows the detection sensitivity of binding of the antibodies described herein to the CDH6 antigen. [Figure 24] FIG. 24 shows the specific recognition of the CDH6 antigen expressed on the cell surface by the antibodies described in this application. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0116] (Detailed description) While various embodiments of the present invention have been shown and described herein, it will be apparent to those skilled in the art that such embodiments are provided by way of example only. Numerous changes, modifications, and substitutions will occur to those skilled in the art without departing from the invention. It is understood that various alternatives to the embodiments of the invention described herein may be used.

[0117] (definition) Unless otherwise stated, the following terms and phrases used herein shall have the following meanings: In this application, the term "alkyl group" generally refers to a monovalent saturated hydrocarbon chain having a specified number of carbon atoms. For example, a C1-C6 alkyl group refers to an alkyl group having one to six carbon atoms. The alkyl group may be linear or branched. Representative branched alkyl groups have one, two, or three branches. Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl (n-propyl and isopropyl), butyl (n-butyl, isobutyl, sec-butyl, and t-butyl), pentyl (n-pentyl, isopentyl, and neopentyl), and hexyl.

[0118] In this application, the term "antibody" as used herein generally refers to a polypeptide of the immunoglobulin family that can non-covalently, reversibly, and specifically bind to a corresponding antigen. For example, naturally occurring IgG antibodies are tetramers that contain at least two heavy chains (H) and two light chains (L) interconnected by disulfide bonds. Each heavy chain is composed of a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region. The heavy chain constant region is composed of three domains: CH1, CH2, and CH3. Each light chain is composed of a light chain variable region (abbreviated herein as VL) and a light chain constant region. The light chain constant region is composed of one domain, CL. The VH and VL regions can be further subdivided into hypervariable regions called complementarity determining regions (CDRs) interspersed with more conserved regions called framework regions (FRs). Each VH and VL is composed of three CDRs and four FRs arranged from amino terminus to carboxy terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. The variable regions of the heavy and light chains contain a binding domain that interacts with an antigen. The constant region of the antibody may mediate the binding of the immunoglobulin to host tissues or factors, such as various cells of the immune system (e.g., effector cells), the first component of the classical complement system (Clq), and the like.

[0119] The term "antibody" includes, but is not limited to, monoclonal antibodies, human antibodies, humanized antibodies, camelid antibodies, and chimeric antibodies. The antibody may be of any isotype / class (e.g., IgG, IgE, IgM, IgD, IgA, IgY) or subclass (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, IgA2).

[0120] In this application, the term "complementarity determining domain" is used interchangeably with the term "complementarity determining region" ("CDR") herein and generally refers to the hypervariable regions of VL and VH. The CDRs are the target protein binding sites of the antibody chain and have specificity for such target protein. Each human VL or VH has three CDRs (CDR1-3, numbered sequentially from the N-terminus), which constitute about 15-20% of the variable domain. The CDRs may be referred to by their region and order. For example, "VH CDR1" or "HCDR1" both refer to the first CDR of the heavy chain variable region. The CDRs are directly responsible for binding specificity, since they are structurally complementary to the epitope of the target protein. The remaining parts of the VL or VH, the so-called framework regions, have less variation in amino acid sequence (Kuby, Immunology, 4th ed., Chapter 4, WH Freeman & Co., New York, 2000). In the art, the CDRs of an antibody may be defined by various methods, such as the Kabat definition rules based on sequence variability (see Kabat et al., protein sequence in immunology, 5th edition, National Institutes of Health, Bethesda, Maryland (1991)), the Chothia definition rules based on the location of structural loop regions (see A1-Lazikani et al., JMol Biol, 273:927-948, 1997), and the IMGT definition rules based on the IMGT-ONTOLOGY concepts and IMGT science chart rules. In certain embodiments, the present application defines the CDRs of an antibody using the IMGT rules. The present application also includes the Martin, PyIgClassify definition rules and the combined definition rules of Kabat, Chothia, IMGT, Martin and PyIgClassify (see Mark L. Chiu et al., Antibodies 8(4), 55, 2019). [Table 1]

[0121] Here, Laa-Lbb or Haa-Hbb may refer to the amino acid sequence of the light chain or heavy chain from the N-terminus, numbered aa to bb, respectively. For example, L24-L34 refers to the amino acid sequence of the light chain from numbered 24 to 34.

[0122] Both light and heavy chains are divided into regions of structural and functional homology. The terms "constant" and "variable" are used in a functional sense. In this regard, it should be understood that the variable domains of both the light (VL) and heavy (VH) chain portions determine antigen recognition and specificity. Conversely, the constant domains of the light chain (CL) and the constant domains of the heavy chain (CH1, CH2 or CH3) confer important biological properties such as secretion, transplacental mobility, Fc receptor binding, complement binding, etc. By convention, the numbering of the constant region domains increases the further away from the antigen-binding site or amino-terminus of the antibody. The N-terminus is the variable region, the C-terminus is the constant region, and the CH3 and CL domains actually comprise the carboxy-terminal domains of the heavy and light chains, respectively.

[0123] In this application, the term "antigen-binding fragment" as used herein generally refers to a polypeptide comprising one or more portions of an antibody that retains the ability to specifically interact with an epitope of an antigen (e.g., by binding, steric hindrance, stabilization / destabilization, spatial distribution). Examples of binding fragments include, but are not limited to, single-chain Fv (scFv), disulfide-linked Fv (sdFv), Fab fragments, F(ab') fragments, monovalent fragments consisting of the VL, VH, CL and CH1 domains, F(ab')2 fragments, which are bivalent fragments comprising two Fab fragments linked by a disulfide bridge at the hinge region, Fd fragments consisting of the VH and CH1 domains, Fv fragments consisting of the VL and VH domains of a single arm of an antibody, dAb fragments consisting of the VH domain (Ward et al., Nature, 341:544-546, 1989), isolated complementarity determining regions (CDRs) of an antibody, or other epitope-binding fragments.

[0124] Antigen-binding fragments also include single domain antibodies, maxibodies, minibodies, nanobodies, intrabodies, diabodies, triabodies, tetrabodies and bis-scFv (see, e.g., Hollinger and Hudson, Nature Biotechnology, 23:1126-1136, 2005). Antigen-binding fragments may also include single chain molecules comprising a pair of tandem Fv fragments (VH-CH1-VH-CH1) that form a pair of antigen-binding regions with complementary light chain polypeptides (Zapata et al., Protein Eng., 8:1057-1062, 1995). A fragment of a conventional antibody may be a single domain antibody, such as a heavy chain antibody or a VHH.

[0125] As used herein, the term "monoclonal antibody" generally refers to polypeptides, including antibodies and antigen-binding fragments, having substantially identical amino acid sequences or derived from the same genetic source. The term also includes preparations of single molecular component antibody molecules. A monoclonal antibody composition displays a single binding specificity and affinity for a particular epitope.

[0126] In the present application, the term "humanized antibody" generally refers to an antibody that comprises heavy and light chain variable region sequences derived from a non-human species (e.g., mouse), but in which at least a portion of the VH and / or VL sequences have been altered to resemble human germline variable sequences. For example, the term "humanized antibody" refers to an antibody or variant, derivative, analog, or fragment thereof that is capable of binding to a relevant antigen with immunospecificity and comprises a framework region (FR) that comprises substantially the amino acid sequence of a human antibody and a complementarity determining region (CDR) that comprises substantially the amino acid sequence of a non-human antibody. In the context of dealing with CDRs, the term "substantially" means that the amino acid sequence of the CDR has at least 80%, e.g., at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identity to the amino acid sequence of the CDR of the non-human antibody. A humanized antibody comprises at least one, and typically two, variable domains (Fab, Fab', F(ab')2, Fab, Fv) in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the framework regions have human immunoglobulin consensus sequences. In some embodiments, the humanized antibody may further comprise at least a portion of an immunoglobulin constant region (Fc), typically a human immunoglobulin constant region.

[0127] In this application, the term "human antibody" generally refers to an antibody having variable and constant regions derived from human germline immunoglobulin sequences. Human antibodies are well known in the art (see, e.g., van Dijk, MA and van de Winkel, JG, Curr. Opin. Chem. Biol., 5(2001):368-374). Human antibodies may be produced in transgenic animals (e.g., mice) capable of producing a complete or selected set of human antibodies in the absence of endogenous immunoglobulins produced following immunization (e.g., Jakobovits, A. et al., Proc. Natl. Acad. Sci. USA, 90(1993):2551-2555; Jakobovits, A. et al., Nature, 362(1993):255-258; Brueggemann, M. et al., Year Immunol., 7(1993):33-40). Human antibodies may be produced in phage display libraries (e.g., Hoogenboom, HR and Winter, G., J. Mol. Biol., 227(1992):381-388; Marks, JD et al., J. Mol. Biol., 222(1991):581-597). The term "human antibody" also includes antibodies in which the constant regions have been modified.

[0128] In the present application, the term "chimeric antibody" generally refers in its broadest sense to an engineered antibody that contains one or more regions of one antibody and one or more regions of one or more other antibodies. In particular, a chimeric antibody contains the VH and VL domains of an antibody derived from a non-human animal in combination with the CH and CL domains of another antibody, in particular a human antibody. The non-human animal may be any animal, such as a mouse, a rat, a hamster, a rabbit, etc. A chimeric antibody may represent a multispecific antibody having specificity for at least two different antigens.

[0129] When referring to a polypeptide (i.e., an antibody of the invention) or a nucleotide sequence, "purified" and "isolated" mean that the indicated molecule is present in the substantial absence of other biological macromolecules of the same type. As used herein, the term "purified" specifically refers to the presence of at least 75%, at least 85%, at least 95%, or at least 98% by weight of the same type of biological macromolecules. An "isolated" nucleic acid molecule encoding a particular polypeptide refers to a nucleic acid molecule that is substantially free of other nucleic acid molecules that do not encode the polypeptide of interest. However, the molecule may contain additional bases or moieties that do not adversely affect the basic properties of the composition. The invention may include, for example, an isolated antigen-binding protein, an isolated antibody or antigen-binding fragment thereof, an isolated polypeptide, an isolated nucleic acid molecule, or a group of molecules.

[0130] In this application, the term "affinity" is generally defined in terms of the equilibrium binding between a whole antibody and an antigen. Affinity can be measured, for example, by measuring the half-maximal effective concentration (EC 50 Affinity may be expressed as the equilibrium dissociation constant (KD) or the equilibrium dissociation constant (KD). Affinity can be measured by measuring the binding and dissociation rates by surface plasmon resonance or by the EC 50 This may be evaluated experimentally by various known methods, such as by measuring

[0131] "Half-maximal effective concentration" or "EC 50 " generally refers to the concentration of a drug, antibody, or toxin that elicits a response between baseline and maximum after a specified exposure time. 50 and affinity are inversely proportional, and EC 50 The lower the value, the higher the affinity of the antibody.

[0132] "KD" is the equilibrium dissociation constant between an antibody and its antigen, i.e., the ratio koff / kon. KD and affinity are inversely related. The KD value is related to the concentration of the antibody, and the lower the KD value, the higher the affinity of the antibody. Antibodies of the present disclosure generally have a concentration of about 10 -7 Less than M or 10 -8Less than m, e.g., about 10 -9 M or 10 -10 M or less, and in some embodiments, about 10 -11 Less than M, 10 -12 Less than M or 10 -13 It has an equilibrium dissociation constant less than M.

[0133] The term "conservatively modified variants" applies to both amino acid and nucleic acid sequences. With respect to a particular nucleic acid sequence, conservatively modified variants refer to nucleic acids that code for the same or essentially identical amino acid sequences, or essentially identical sequences if the nucleic acid does not code for an amino acid sequence. Due to the degeneracy of the genetic code, a large number of functionally identical nucleic acids code for any given protein. For example, the codons GCA, GCC, GCG, and GCU all code for the amino acid alanine. Thus, at every position where alanine is specified by a codon, the codon may be altered to any of the corresponding codons described without altering the encoded polypeptide. Such variations in nucleic acids are "silent variations," a species of conservatively modified variation. Every nucleic acid sequence encoding a polypeptide herein also describes every possible silent variation of the nucleic acid. One of skill in the art will recognize that each codon in a nucleic acid (except AUG, which is usually the only codon for methionine, and TGG, which is usually the only codon for tryptophan) can be modified to produce a functionally identical molecule. Thus, each silent variation of a nucleic acid encoding a polypeptide is implicit in each sequence described.

[0134] In the case of polypeptide sequences, "conservatively modified variants" include individual substitutions, deletions, or additions to a polypeptide sequence that result in the replacement of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. Such conservatively modified variants are in addition to, but do not exclude, polymorphic variants, interspecies homologs, and alleles. The following eight groups contain amino acids that are conservative substitutions for one another: 1) Alanine (A), Glycine (G), 2) Aspartic acid (D), Glutamic acid (E), 3) Asparagine (N), Glutamine (Q), 4) Arginine (R), Lysine (K), 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V), 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W), 7) Serine (S), Threonine (T), 8) Cysteine ​​(C), Methionine (M) (see, e.g., Creighton, Proteins (1984)). In some embodiments, the term "conservative sequence modifications" is used to refer to amino acid modifications that do not significantly affect or alter the binding characteristics of the antibody containing the amino acid sequence.

[0135] In this application, the term "percent identical" or "percent identity" in the context of dealing with two or more nucleic acid or polypeptide sequences refers to the degree to which two or more sequences or subsequences are the same. Two sequences are "identical" if they have the same amino acid or nucleotide sequence over the region being compared. Two sequences are "substantially identical" if they have a specified percentage of the same amino acid residues or nucleotides (i.e., 60% identity over a specified region, or if not specified, over the entire sequence), when compared and aligned for maximum correspondence using any of the following sequence comparison algorithms or over a specified region or a comparison window as measured by manual alignment and visual inspection. Optionally, the identity exists over a region that is at least about 30 nucleotides (or 10 amino acids) in length, or more preferably over a region that is 100-500 or 1000 or more nucleotides (or 20, 50, 200 or more amino acids) in length. Two examples of suitable algorithms for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al., Nuc. Acids Res., 25:3389-3402, 1977, and Altschul et al., J. Mol. Biol., 215:403-410, 1990, respectively.

[0136] In addition to the above sequence identity percentage, another indicator that two nucleic acid sequences or polypeptides are substantially identical is that the polypeptide encoded by the first nucleic acid is immunologically cross-reactive with the antibody generated against the polypeptide encoded by the second nucleic acid. Thus, for example, when two peptides differ only by conservative substitutions, the polypeptide is typically substantially identical to the second polypeptide. Another indicator that two nucleic acid sequences are substantially identical is that the two molecules or their complements hybridize to each other under stringent conditions. Yet another indicator that two nucleic acid sequences are substantially identical is that the same primers can be used to amplify the sequences.

[0137] In this application, the term "nucleic acid" is used interchangeably with the term "polynucleotide" and generally refers to deoxyribonucleotides or ribonucleotides, and polymers thereof, in single- or double-stranded form. The term includes nucleic acids containing known nucleotide analogs or modified backbone residues or linkages, which are synthetic, natural or non-natural, have similar binding properties as the reference nucleic acid, and are metabolized in a manner similar to the reference nucleotide. Examples of such analogs include, but are not limited to, phosphorothioates, phosphoramidates, methyl phosphonates, chiral methyl phosphonates, 2-O-methyl ribonucleotides, peptide nucleic acids (PNAs), and the like.

[0138] As used herein, the term "polypeptide" is used interchangeably with the term "protein" to refer to a polymer of amino acid residues. These terms apply to amino acid polymers in which one or more amino acid residues are artificial chemical mimetics of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymers. Unless otherwise specified, a particular polypeptide sequence also implicitly includes conservatively modified variants thereof.

[0139] In this application, the term "immunoconjugate" as used herein generally refers to the conjugation of an antibody or an antigen-binding fragment thereof with another agent, such as a payload, drug moiety, chemotherapeutic agent, toxin, immunotherapeutic agent, imaging probe, etc. The conjugation may be a covalent bond or a non-covalent interaction through electrostatic forces. Various linkers known in the art may be used to form the immunoconjugate. Furthermore, the immunoconjugate may be provided in the form of a fusion protein, which may be expressed from a polynucleotide encoding the immunoconjugate. As used herein, "fusion protein" refers to a protein produced by the linkage of two or more genes or gene fragments that originally encoded separate proteins (including peptides and polypeptides). Translation of the fusion gene results in a single protein with functional properties derived from each of the original proteins.

[0140] The term "active moiety" or "payload" as used herein generally refers to the portion of a conjugate compound that constitutes an active agent and mediates a pharmacological effect, including but not limited to a prophylactic, therapeutic and / or diagnostic effect, e.g., anti-cancer, anti-inflammatory, anti-infective (e.g., anti-fungal, anti-bacterial, anti-parasitic, anti-viral) or anesthetic. Methods for attaching each of these to antibody-compatible linkers and the methods of the present disclosure are known in the art. See, for example, Singh et al., (2009) Therapeutic Antibodies: Methods and Protocols, vol. 525, 445-457. Additionally, the "active moiety" or "payload" may be a biophysical probe, a fluorophore, a spin label, an infrared probe, an affinity probe, a chelator, a spectroscopic probe, a radioactive probe, a lipid molecule, a polyethylene glycol, a polymer, DNA, RNA, a protein, a peptide, a surface, an antibody, an antibody fragment, a nanoparticle, a quantum dot, a liposome, a PLGA particle, a saccharide or a polysaccharide.

[0141] As used herein, the term "drug moiety" or "D" generally refers to any compound having a desired biological activity and a reactive functional group available for incorporating a drug into the conjugates of the present disclosure. In some embodiments, the drug moiety represents a cytotoxic drug useful in cancer treatment, a protein or polypeptide having a desired biological activity, a toxin such as abrin, ricin A, pseudomonas exotoxin, diphtheria toxin, other suitable proteins include tumor necrosis factor, α-interferon, β-interferon, nerve growth factor, platelet-derived growth factor, tissue plasminogen activator, and biological response modifiers such as lymphokines, interleukin-1 (IL-1), interleukin-2 (IL-2), interleukin-6 (IL-6), granulocyte macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), or other growth factors. In some embodiments, the term "drug moiety" may be a chemical moiety. In certain embodiments, the drug moiety is selected from V-type ATPase inhibitors, HSP90 inhibitors, IAP inhibitors, mTor inhibitors, microtubule stabilizers, microtubule destabilizers, auristatins, dolastatins, maytansinoids, MetAP (methionine aminopeptidase), inhibitors of nuclear export by protein CRM1, DPPIV inhibitors, inhibitors of mitochondrial phosphorylation transfer reactions, protein synthesis inhibitors, kinase inhibitors, CDK2 inhibitors, CDK9 inhibitors, proteasome inhibitors, kinesin inhibitors, HDAC inhibitors, DNA damaging agents, DNA alkylating agents, DNA intercalators, DNA minor groove binders, and DHFR inhibitors.

[0142] In one embodiment, the drug moiety may be a microtubule inhibitor such as an auristatin, e.g., monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF), auristatin F (AF). In another embodiment, the drug moiety may be a microtubule inhibitor such as a maytansinoid, e.g., DM1, DM3, DM4. In another embodiment, the drug moiety may be a DNA damaging agent such as a calicheamicin, duocarmycin, SN-38, pyrrolo[2,1-c][1,4]benzodiazepine (PBD). In yet other embodiments, the drug moiety is selected from the group consisting of amanitin, anthracyclines, baccatin, camptothecin, cemadotin, colchicine, colcemid, combretastatin, cryptophycin, discodermolide, docetaxel, doxorubicin, and the like. rubicin, echinomycin, eleutherobin, epothilone, estramustine, lexitropsin, maytansine, methotrexate, netropsin, puromycin, rhizoxin, taxane, tubulysin, or vinca alkaloid.

[0143] In this application, the term "topoisomerase inhibitor" generally refers to compounds that inhibit topoisomerase activity. Compounds known as topoisomerase I inhibitors have activity against topoisomerase I, while topoisomerase II inhibitors have activity against topoisomerase II. Some compounds have activity against both topoisomerase I and topoisomerase II and are known as topoisomerase I / II inhibitors. Preferred topoisomerase I inhibitors for use in the present invention are camptothecin and camptothecin analogs. Camptothecin is a pentacyclic alkaloid that was originally isolated from the wood and bark of the camptothecium campanulatum tree native to China (Wall, ME et al., J. Am. Chem. Soc, 94:388 (1966)). Camptothecin exerts its pharmacological effect by irreversibly inhibiting topoisomerase I. Methods for the synthesis of camptothecin and camptothecin analogs or derivatives are known and are summarized and described in US Pat. No. 5,244,903, which is incorporated herein by reference in its entirety.

[0144] As used herein, the term "camptothecin" generally includes camptothecin and camptothecin derivatives, including irinotecan, topotecan, lurtotecan, silatecan, etirinotecan pegol, TAS 103, 9-aminocamptothecin, 7-ethylcamptothecin, 10-hydroxycamptothecin, 9-nitrocamptothecin, 10,11-methylenedioxycamptothecin, 9-amino-10,11-methylenedioxycamptothecin, 9-chloro-10,11-methylenedioxycamptothecin camptothecin, 7-(4-methylpiperazinomethylene)-10,11-ethylenedioxy-20(S)-camptothecin, 7-(4-methylpiperazinomethylene)-10,11-methylenedioxy-20(S)-camptothecin, 7-(2-(N-isopropylamino)ethyl)-(20S)-camptothecin, and their stereoisomers, salts, and esters.

[0145] The drugs in question are not limited to the above categories, but include all those that can be used in ADCs.

[0146] In this application, the term "linker" described in this disclosure includes cleavable linkers or non-cleavable linkers. Cleavable linkers may be chemically labile linkers or enzyme-labile linkers. Due to their high plasma stability and good intracellular cleavage selectivity and efficiency, enzyme-labile linkers are widely chosen as candidates for cleavable linkers in ADCs. In some embodiments, the enzyme-labile linker may comprise a peptide unit (-AA-) selected from the group consisting of -valine-citrulline-(-Val-Cit-), -valine-lysine-(-Val-Lys-), -valine-arginine-(-Val-Arg-), -phenylalanine-citrulline-(-Phe-Cit-), -phenylalanine-lysine-(-Phe-Lys-), -phenylalanine-arginine-(-Phe-Arg-). Exemplary enzyme-labile linkers include -Val-Cit- and -Phe-Lys-, which can be recognized by cathepsin B. In some embodiments, the non-cleavable linker can be a linker that can increase the hydrophilicity of the final ADC. In one embodiment, the non-cleavable linker can include one or more poly(ethylene glycols) (PEGs). In other embodiments, the non-cleavable linker can be PEG, PEG-diamine (NH2-PEG-NH2), amine-PEG-hydroxy group (NH2-PEG-OH), amine-PEG-COOH (NH2-PEG-COOH), diethylenetriamine, or combinations thereof. In some embodiments, PEG can be represented as -(CH2CHO)x-, where x can be an integer from 1 to 20.

[0147] As used herein, the terms "toxin," "cytotoxin," or "cytotoxic agent" generally refer to any agent that is detrimental to the growth and proliferation of cells and acts to reduce, inhibit, or destroy cells or malignancies.

[0148] In this application, the term "anti-tumor agent" or "anti-tumor drug" as used herein generally refers to any agent that can be used to treat cell proliferative disorders such as cancer, including, but not limited to, cytotoxic drugs, chemotherapeutic agents, radiotherapy and radiotherapeutic agents, targeted anti-cancer agents, and immunotherapeutic agents.

[0149] As used herein, the term "tumor" or "cancer" generally refers to the growth and proliferation of neoplastic cells, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues.

[0150] In this application, the term "anti-tumor activity" refers to a decrease in the proliferation rate, survival rate, or metastatic activity of tumor cells. Methods for demonstrating anti-tumor activity may include showing a reduction in the growth rate of tumor cells, stasis of tumor size, or a decrease in tumor size. Such activity may be evaluated using accepted in vitro or in vivo tumor models, including but not limited to xenograft models, allograft models, MMTV models, and other known models known in the art for studying anti-tumor activity.

[0151] In the present application, the term "cadherin 6" or "CDH6" generally refers to a single-pass transmembrane protein consisting of 790 amino acids, classified into the type II cadherin family, and this protein has an N-terminal extracellular domain and a C-terminal intracellular domain. The human CDH6 gene was first cloned in 1995, and its sequence may be referred to, for example, under accession numbers NM_004932 and NP_004923 (NCBI). In addition, the term "CDH6" also includes proteins consisting of an amino acid sequence in which one or more amino acids are substituted, deleted, and / or added in the amino acid sequence of CDH6 described above, and having biological activity equivalent to that of the CDH6 protein.

[0152] As used herein, the term "epitope" is used generally to mean a peptide or a portion of the three-dimensional structure of CDH6 to which a specific anti-CDH6 antibody binds.

[0153] The term "CDH6-expressing tumor" or "CDH6-positive tumor" generally refers to a tumor that expresses CDH6 and / or a mutated form of CDH6 on the surface of the tumor cells.

[0154] As used herein, the term "subject" includes humans and non-human animals. Non-human animals include all vertebrates, e.g., mammals and non-mammals (e.g., non-human primates, sheep, dogs, cows, chickens, amphibians, reptiles, etc.). Unless otherwise noted, the terms "patient" and "subject" are used interchangeably herein.

[0155] In this application, the term "pharmaceutical acceptable" generally refers to one or more non-toxic substances that do not interfere with the effectiveness of the biological activity of the active ingredient. Such formulations may generally include salts, buffers, preservatives, compatible carriers, and optionally other therapeutic agents. Such pharmaceutical acceptable formulations may also generally include compatible solid or liquid fillers, diluents, or encapsulating materials suitable for administration to humans. When used pharmaceutical, the salts should be pharmaceutical acceptable salts, but pharmaceutical unacceptable salts may also be conveniently used to prepare pharmaceutical acceptable salts and cannot be excluded from the scope of the present invention. Such pharmacologically and pharmaceutical acceptable salts include, but are not limited to, salts prepared from acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, maleic acid, acetic acid, salicylic acid, citric acid, boric acid, formic acid, malonic acid, succinic acid, and the like. Pharmaceutically acceptable salts may be prepared as alkali metal salts or alkaline earth metal salts, such as sodium salts, potassium salts, or calcium salts. The term "solvate" is used herein in the conventional sense to refer to a complex of a solute (e.g., active compound, salt of active compound) and a solvent. A solvate generally does not significantly alter the physiological activity or toxicity of a compound, and therefore can function as a pharmacological equivalent. When the solvent is water, the solvate may be conveniently referred to as a hydrate, such as, for example, a monohydrate, a dihydrate, a trihydrate, and the like.

[0156] As used herein, the term "treatment" ("treat," "treating," or "treatment") of any disease or disorder generally refers, in one aspect, to ameliorating the disease or disorder (i.e., slowing, arresting, or alleviating the progression of the disease or at least one of its clinical symptoms). In another aspect, "treatment" refers to alleviating or improving at least one physical parameter, including those that may not be discernible by the patient. In yet another aspect, "treatment" refers to modulating the disease or disorder physically (e.g., stabilization of discernible symptoms), physiologically (e.g., stabilization of physical parameters), or both. In yet another aspect, "treatment" refers to preventing or slowing the onset, development, or progression of the disease or disorder.

[0157] In this application, the terms "therapeutically acceptable amount" or "therapeutically effective dose" are used interchangeably to refer to an amount sufficient to produce the desired result (i.e., reduction in tumor size, inhibition of tumor growth, prevention of metastasis, inhibition or prevention of viral, bacterial, fungal or parasitic infection). In some embodiments, a therapeutically acceptable amount does not induce or cause undesirable side effects. A therapeutically acceptable amount may be determined by administering a low dose initially and then gradually increasing the dose until the desired effect is achieved. A "prophylactically effective dose" and a "therapeutically effective dose" of a molecule of the present disclosure can prevent the onset or reduce the severity, respectively, of symptoms of a disease, including symptoms associated with cancer.

[0158] As used herein, the term "co-administration" generally refers to the simultaneous presence of two active agents in the blood of an individual. Co-administered active agents may be delivered simultaneously or sequentially.

[0159] In this application, the terms "including," "including," "containing," "having," and the like, unless otherwise indicated, shall be interpreted as "including, but not limited to,". In the context of describing the present invention, and particularly in the context of the appended claims, the terms "a," "an," "another," "the," and similar referents shall be interpreted to include both the singular and the plural, unless otherwise indicated. The use of any examples or exemplary language (such as, for example, etc.) is intended merely to illustrate aspects or embodiments of the invention, and should not be interpreted as limiting the scope of the invention, unless specifically claimed.

[0160] In this application, the term "about" when referring to a measurable value, such as an amount, a temporal duration, and the like, is meant to encompass variations of ±20%, in some cases ±10%, in some cases ±5%, in some cases ±1%, and in some cases ±0.1% from the specified value, as appropriate for carrying out the disclosed methods.

[0161] (anti-CDH6 antibody) While various embodiments of the present invention have been shown and described herein, it will be apparent to those skilled in the art that such embodiments are provided by way of example only. Numerous changes, modifications, and substitutions will occur to those skilled in the art without departing from the invention. It is understood that various alternatives to the embodiments of the invention described herein may be used.

[0162] The anti-CDH6 antibody of the present invention may be derived from any species. Preferred species include human, monkey, rat, mouse, rabbit, etc. When the anti-CDH6 antibody of the present invention is derived from a species other than human, it is preferable to chimerize or humanize the anti-CDH6 antibody by well-known techniques. The antibody of the present invention may be a polyclonal antibody or a monoclonal antibody, preferably a monoclonal antibody.

[0163] The anti-CDH6 antibody of the present invention is an antibody that can target tumor cells. Specifically, the anti-CDH6 antibody of the present invention has the property of recognizing tumor cells, the property of binding to tumor cells, and / or the property of being internalized by tumor cells through cellular uptake. Therefore, the anti-CDH6 antibody of the present invention can be bound to an active site via a linker to prepare an immune complex (for example, the anti-CDH6 antibody of the present invention can be bound to a compound having antitumor activity via a linker to prepare an antibody-drug complex).

[0164] The anti-CDH6 antibody may be obtained by immunizing an animal with an antigenic polypeptide by a method commonly used in the art, and collecting and purifying the antibody produced in the body. The origin of the antigen is not limited to human, and the animal may be immunized with an antigen derived from an animal other than human, such as mouse or rat. In this case, the cross-reactivity of the obtained antibody that binds to the heterologous antigen with the human antigen may be examined to select an antibody applicable to a human disease.

[0165] Furthermore, antibody-producing cells that produce antibodies against the antigen may be fused with myeloma cells according to known methods (e.g., Kohler and Milstein, Nature (1975), 256:495-497; Kennet, R. ed., Monoclonal Antibodies, 365-367, Plenum Press, NY (1980)) to establish hybridomas and obtain monoclonal antibodies.

[0166] The anti-CDH6 antibody used in the present invention is not particularly limited. For example, an antibody specified by the amino acid sequence set forth in the sequence listing of the present application can be suitably used. The anti-CDH6 antibody used in the present invention is preferably an antibody having the properties of (a) specifically binding to CDH6, and (b) having the activity of being internalized into CDH6-expressing cells by binding to CDH6. Here, CDH6 may be human CDH6.

[0167] A method for obtaining an antibody against CDH6 will be specifically described below.

[0168] (a) The extracellular domain of CDH6 (Ser 54-Ala 615) is used as an immunogen (ACRO Biosystems, CA6-H5229) and the antigen is directly administered to an animal to be immunized (e.g., a rat or mouse). The antigen may be administered once or multiple times, preferably multiple times, if necessary, to increase the antibody titer. (b) A tissue (eg, lymph node) containing antibody-producing cells is harvested from the aforementioned animal in which an immune response has been induced. (c) Myeloma cells (hereinafter referred to as "myeloma") (for example, mouse myeloma SP2 / 0-ag14 cells) are prepared. (d) fusing the antibody-producing cells with myeloma cells; (e) Selecting a group of hybridomas that produce the desired antibody. (f) Division into single cell clones (cloning). (g) optionally culturing hybridomas or breeding animals inoculated with hybridomas for the large-scale production of monoclonal antibodies; and / or (h) To study the biological activity (internalization activity) and binding specificity of the monoclonal antibodies thus produced or to characterize the antibodies as labeling reagents.

[0169] Examples of methods for measuring the titer of an antibody used in the present invention include, but are not limited to, flow cytometry, Cell-ELISA, and the like.

[0170] The specific CDR sequences defined herein are generally based on the IMGT definitions, although when reference is made to a particular antibody heavy chain CDR or CDRs and / or light chain CDR or CDRs, it is understood to encompass all CDR definitions known to those skilled in the art.

[0171] In some embodiments, the anti-CDH6 antibodies or antigen-binding fragments provided herein comprise one, two, three, four, five, and / or six of the CDRs of any one of the antibodies described herein. In some embodiments, the anti-CDH6 antibodies or antigen-binding fragments provided herein comprise a VL that comprises one, two, and / or three VL CDRs in Table 1. In some embodiments, the anti-CDH6 antibodies or antigen-binding fragments provided herein comprise a VH that comprises one, two, and / or three VH CDRs in Table 1. In some embodiments, the anti-CDH6 antibodies or antigen-binding fragments provided herein comprise one, two, and / or three VL CDRs in Table 1 and one, two, and / or three VH CDRs in Table 1.

[0172] In some embodiments, the anti-CDH6 antibody or antigen-binding fragment thereof comprises a VL CDR1, a VL CDR2, a VL CDR3, a VH CDR1, a VH CDR2 and / or a VH CDR3 from an antibody or antigen-binding fragment described herein. In some embodiments, the anti-CDH6 antibody or antigen-binding fragment thereof comprises a variant of the anti-CDH6 antibody or antigen-binding fragment described herein. In some embodiments, the variant of the anti-CDH6 antibody or antigen-binding fragment comprises a substitution, addition and / or deletion of 1-30 amino acids in the anti-CDH6 antibody or antigen-binding fragment. In some embodiments, the variant of the anti-CDH6 antibody or antigen-binding fragment comprises a substitution, addition and / or deletion of 1-25 amino acids in the anti-CDH6 antibody or antigen-binding fragment. In some embodiments, the variant of the anti-CDH6 antibody or antigen-binding fragment comprises a substitution, addition and / or deletion of 1-20 amino acids in the anti-CDH6 antibody or antigen-binding fragment. In some embodiments, the variant of the anti-CDH6 antibody or antigen-binding fragment comprises 1-15 amino acid substitutions, additions, and / or deletions in the anti-CDH6 antibody or antigen-binding fragment. In some embodiments, the variant of the anti-CDH6 antibody or antigen-binding fragment comprises 1-10 amino acid substitutions, additions, and / or deletions in the anti-CDH6 antibody or antigen-binding fragment. In some embodiments, the variant of the anti-CDH6 antibody or antigen-binding fragment comprises 1-5 amino acid substitutions, additions, and / or deletions in the anti-CDH6 antibody or antigen-binding fragment. In some embodiments, the variant of the anti-CDH6 antibody or antigen-binding fragment comprises 1-3 amino acid substitutions, additions, and / or deletions in the anti-CDH6 antibody or antigen-binding fragment. In some embodiments, the amino acid substitutions, additions, and / or deletions are conservative amino acid substitutions. In some embodiments, the conservative amino acid substitutions are in the CDRs of the antibody or antigen-binding fragment. In some embodiments, the conservative amino acid substitutions are not in the CDRs of the antibody or antigen-binding fragment. In some embodiments, the conservative amino acid substitutions are in the framework regions of the antibody or antigen-binding fragment.

[0173] In some embodiments, the present disclosure provides: a) a heavy chain variable region (VH) comprising (1) a heavy chain CDR1 (HCDR1) having the amino acid sequence of SEQ ID NO:2, (2) a heavy chain CDR2 (HCDR2) having the amino acid sequence of SEQ ID NO:3, or (3) a heavy chain CDR3 (HCDR3) having the amino acid sequence of SEQ ID NO:4, or a variant thereof having up to about 3, up to about 5, up to about 8, up to about 10, up to about 12, or up to about 15 amino acid substitutions, additions, and / or deletions in the HCDR; and / or b) a light chain variable region (VL) comprising (1) a light chain CDR1 (LCDR1) having the amino acid sequence of SEQ ID NO:5, (2) a light chain CDR2 (LCDR2) having the amino acid sequence of SEQ ID NO:6, or (3) a light chain CDR3 (LCDR3) having the amino acid sequence of SEQ ID NO:7, or a variant thereof having up to about 3, up to about 5, up to about 8, up to about 10, up to about 12, or up to about 15 amino acid substitutions, additions, and / or deletions in the LCDR, or an antibody or antigen-binding fragment thereof that specifically binds to CDH6 (e.g., human CDH6).

[0174] In some embodiments, the variant has up to about 5 amino acid substitutions, additions and / or deletions in the HCDR, and / or the variant has up to about 5 amino acid substitutions, additions or deletions in the LCDR.

[0175] In some embodiments, provided herein are antibodies or antigen-binding fragments thereof that specifically bind to CDH6 (e.g., human CDH6), comprising: a) a VH having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 18; and / or b) a VL having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:23.

[0176] In some embodiments, the present disclosure provides: a) a heavy chain variable region (VH) comprising (1) a heavy chain CDR1 (HCDR1) having the amino acid sequence of SEQ ID NO: 8, (2) a heavy chain CDR2 (HCDR2) having the amino acid sequence of SEQ ID NO: 9, or (3) a heavy chain CDR3 (HCDR3) having the amino acid sequence of SEQ ID NO: 10, or a variant thereof having up to about 3, up to about 5, up to about 8, up to about 10, up to about 12, or up to about 15 amino acid substitutions, additions, and / or deletions in the HCDR; and / or b) an antibody or antigen-binding fragment thereof that specifically binds to CDH6 (e.g., human CDH6), comprising a light chain variable region (VL) comprising (1) a light chain CDR1 (LCDR1) having the amino acid sequence of SEQ ID NO: 11, (2) a light chain CDR2 (LCDR2) having the amino acid sequence of SEQ ID NO: 12, or (3) a light chain CDR3 (LCDR3) having the amino acid sequence of SEQ ID NO: 13, or a variant thereof having up to about 3, up to about 5, up to about 8, up to about 10, up to about 12, or up to about 15 amino acid substitutions, additions, and / or deletions in the LCDR.

[0177] In some embodiments, the variant has up to about 5 amino acid substitutions, additions and / or deletions in the HCDR, and / or the variant has up to about 5 amino acid substitutions, additions or deletions in the LCDR.

[0178] In some embodiments, provided herein are antibodies or antigen-binding fragments thereof that specifically bind to CDH6 (e.g., human CDH6), comprising: a) a VH having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:41; and / or b) a VL having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:46.

[0179] In some embodiments, the present disclosure provides: a) a heavy chain variable region (VH) comprising (1) a heavy chain CDR1 (HCDR1) having the amino acid sequence of SEQ ID NO: 89, (2) a heavy chain CDR2 (HCDR2) having the amino acid sequence of SEQ ID NO: 90, or (3) a heavy chain CDR3 (HCDR3) having the amino acid sequence of SEQ ID NO: 91, or a variant thereof having up to about 3, up to about 5, up to about 8, up to about 10, up to about 12, or up to about 15 amino acid substitutions, additions, and / or deletions in the HCDR; and / or b) a light chain variable region (VL) comprising (1) a light chain CDR1 (LCDR1) having the amino acid sequence of SEQ ID NO: 92, (2) a light chain CDR2 (LCDR2) having the amino acid sequence of SEQ ID NO: 93, or (3) a light chain CDR3 (LCDR3) having the amino acid sequence of SEQ ID NO: 94, or a variant thereof having up to about 3, up to about 5, up to about 8, up to about 10, up to about 12, or up to about 15 amino acid substitutions, additions, and / or deletions in the LCDR, or an antibody or antigen-binding fragment thereof that specifically binds to CDH6 (e.g., human CDH6).

[0180] In some embodiments, the variant has up to about 5 amino acid substitutions, additions and / or deletions in the HCDR, and / or the variant has up to about 5 amino acid substitutions, additions or deletions in the LCDR.

[0181] In some embodiments, provided herein are antibodies or antigen-binding fragments thereof that specifically bind to CDH6 (e.g., human CDH6), comprising: a) a VH having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:95; and / or b) a VL having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:96.

[0182] In some embodiments, the present disclosure provides: a) a heavy chain variable region (VH) comprising (1) a heavy chain CDR1 (HCDR1) having the amino acid sequence of SEQ ID NO: 97, (2) a heavy chain CDR2 (HCDR2) having the amino acid sequence of SEQ ID NO: 98, or (3) a heavy chain CDR3 (HCDR3) having the amino acid sequence of SEQ ID NO: 99, or a variant thereof having up to about 3, up to about 5, up to about 8, up to about 10, up to about 12, or up to about 15 amino acid substitutions, additions, and / or deletions in the HCDR; and / or b) an antibody or antigen-binding fragment thereof that specifically binds to CDH6 (e.g., human CDH6), comprising a light chain variable region (VL) comprising (1) a light chain CDR1 (LCDR1) having the amino acid sequence of SEQ ID NO: 100, (2) a light chain CDR2 (LCDR2) having the amino acid sequence of SEQ ID NO: 101, or (3) a light chain CDR3 (LCDR3) having the amino acid sequence of SEQ ID NO: 102, or a variant thereof having up to about 3, up to about 5, up to about 8, up to about 10, up to about 12, or up to about 15 amino acid substitutions, additions, and / or deletions in the LCDR.

[0183] In some embodiments, the variant has up to about 5 amino acid substitutions, additions and / or deletions in the HCDR, and / or the variant has up to about 5 amino acid substitutions, additions or deletions in the LCDR.

[0184] In some embodiments, provided herein are antibodies or antigen-binding fragments thereof that specifically bind to CDH6 (e.g., human CDH6), comprising: a) a VH having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 103; and / or b) a VL having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 104.

[0185] Hybridoma strains established in this manner include anti-CDH6 antibody-producing hybridomas 707 and 463. In this specification, the antibody produced by the anti-CDH6 antibody-producing hybridoma 707 is referred to as the "707 antibody" or simply "707", the antibody produced by the hybridoma 463 is referred to as the "463 antibody" or simply "463", the antibody produced by the hybridoma 066 is referred to as the "066 antibody" or simply "066", and the antibody produced by the hybridoma 439 is referred to as the "439 antibody" or simply "439".

[0186] The heavy chain variable region of the 707 antibody has HCDR1 consisting of the amino acid sequence shown in SEQ ID NO: 2, HCDR2 consisting of the amino acid sequence shown in SEQ ID NO: 3, and HCDR3 consisting of the amino acid sequence shown in SEQ ID NO: 4. The light chain variable region of the 707 antibody has LCDR1 comprising the amino acid sequence shown in SEQ ID NO: 5, LCDR2 comprising the amino acid sequence shown in SEQ ID NO: 6, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO: 7.

[0187] Furthermore, the heavy chain variable region of the 707 antibody consists of the amino acid sequence shown in SEQ ID NO: 18. The light chain variable region of the 707 antibody consists of the amino acid sequence shown in SEQ ID NO:23.

[0188] The heavy chain variable region of the 463 antibody has HCDR1 consisting of the amino acid sequence shown in SEQ ID NO: 8, HCDR2 consisting of the amino acid sequence shown in SEQ ID NO: 9, and HCDR3 consisting of the amino acid sequence shown in SEQ ID NO: 10. The light chain variable region of the 463 antibody has LCDR1 comprising the amino acid sequence shown in SEQ ID NO: 11, LCDR2 comprising the amino acid sequence shown in SEQ ID NO: 12, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO: 13.

[0189] Furthermore, the heavy chain variable region of the 463 antibody consists of the amino acid sequence shown in SEQ ID NO: 41. The light chain variable region of the 463 antibody consists of the amino acid sequence shown in SEQ ID NO:46.

[0190] The heavy chain variable region of the 066 antibody has HCDR1 consisting of the amino acid sequence shown in SEQ ID NO: 89, HCDR2 consisting of the amino acid sequence shown in SEQ ID NO: 90, and HCDR3 consisting of the amino acid sequence shown in SEQ ID NO: 91. The light chain variable region of the 066 antibody has LCDR1 comprising the amino acid sequence shown in SEQ ID NO: 92, LCDR2 comprising the amino acid sequence shown in SEQ ID NO: 93, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO: 94.

[0191] Furthermore, the heavy chain variable region of the 066 antibody consists of the amino acid sequence shown in SEQ ID NO: 95. The light chain variable region of the 066 antibody consists of the amino acid sequence shown in SEQ ID NO: 96.

[0192] The heavy chain variable region of the 439 antibody has HCDR1 consisting of the amino acid sequence shown in SEQ ID NO: 97, HCDR2 consisting of the amino acid sequence shown in SEQ ID NO: 98, and HCDR3 consisting of the amino acid sequence shown in SEQ ID NO: 99. The light chain variable region of the 439 antibody has LCDR1 comprising the amino acid sequence shown in SEQ ID NO: 100, LCDR2 comprising the amino acid sequence shown in SEQ ID NO: 101, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO: 102.

[0193] Furthermore, the heavy chain variable region of the 439 antibody consists of the amino acid sequence shown in SEQ ID NO: 103. The light chain variable region of the 439 antibody consists of the amino acid sequence shown in SEQ ID NO: 104.

[0194] (Other antibodies) The antibodies of the present invention include not only the above-mentioned monoclonal antibodies against CDH6, but also genetically modified antibodies, such as chimeric antibodies, humanized antibodies, and human antibodies, that have been artificially modified for the purpose of reducing heterologous antigenicity against humans, and these antibodies may be produced by known methods.

[0195] In some embodiments, the anti-CDH6 antibody or antigen-binding fragment is a human antibody or antigen-binding fragment. Human antibodies may be produced using a variety of techniques known in the art. In some embodiments, human antibodies are produced from immortalized human B lymphocytes immunized in vitro. In some embodiments, human antibodies are produced from lymphocytes isolated from an immunized individual. In either case, cells producing antibodies against the target antigen can be produced and isolated. In some embodiments, human antibodies are selected from phage libraries expressing human antibodies. Alternatively, phage display technology may be used to generate human antibodies and antibody fragments in vitro from immunoglobulin variable region gene repertoires from unimmunized donors. Techniques for the production and use of antibody phage libraries are well known in the art. Once antibodies are identified, affinity maturation strategies known in the art, including but not limited to chain shuffling and site-directed mutagenesis, can be used to generate higher affinity human antibodies. In some embodiments, human antibodies are generated in transgenic mice containing human immunoglobulin loci. These mice are capable of producing a full repertoire of human antibodies upon immunization, in the absence of endogenous immunoglobulin production.

[0196] Examples of chimeric antibodies include antibodies whose variable and constant regions are heterologous to each other, such as chimeric antibodies in which the variable region of an antibody derived from a mouse or rat is linked to a constant region derived from a human (see Proc. Natl. Acad. Sci. USA, 81:6851-6855, 1984).

[0197] Examples of chimeric antibodies derived from mouse anti-human CDH6 antibodies include antibodies consisting of a light chain comprising the light chain variable region and a human-derived constant region of each mouse anti-human CDH6 antibody described herein (e.g., 707 antibody or 463 antibody), and a heavy chain comprising a heavy chain variable region and a human-derived constant region.

[0198] Other examples of chimeric antibodies derived from mouse anti-human CDH6 antibodies include antibodies consisting of a light chain comprising a light chain variable region in which one to several, one to three, one or two, preferably one amino acid residue in the light chain variable region of each mouse anti-human CDH6 antibody described herein (e.g., 707 antibody or 463 antibody) has been substituted with another amino acid residue, and a heavy chain comprising a heavy chain variable region in which one to several, one to three, one or two, preferably one amino acid residue in the heavy chain variable region has been substituted with another amino acid residue. The antibody may have any predetermined human-derived constant region.

[0199] Other examples of chimeric antibodies derived from mouse anti-human CDH6 antibodies include antibodies consisting of a light chain comprising a light chain variable region in which one or two amino acid residues, preferably one residue, in any one to three CDRs in the light chain variable region of each of the mouse anti-human CDH6 antibodies described herein (e.g., 707 antibody or 463 antibody) have been substituted with other amino acid residues, and a heavy chain comprising a heavy chain variable region in which one or two amino acid residues, preferably one residue, in any one to three CDRs in the heavy chain variable region have been substituted with other amino acid residues. Such antibodies may have any predetermined human-derived constant region.

[0200] It is known in the art that the constant region of an antibody mediates several effector functions, and these effector functions vary depending on the antibody isotype. In some embodiments, the anti-CDH6 antibodies or antigen-binding fragments described herein comprise at least one constant region of a human IgA antibody. In some embodiments, the anti-CDH6 antibodies or antigen-binding fragments described herein comprise at least one constant region of a human IgD antibody. In some embodiments, the anti-CDH6 antibodies or antigen-binding fragments described herein comprise at least one constant region of a human IgE antibody. In some embodiments, the anti-CDH6 antibodies or antigen-binding fragments described herein comprise at least one constant region of a human IgG antibody. In some embodiments, the anti-CDH6 antibodies or antigen-binding fragments described herein comprise at least one constant region of a human IgM antibody. In some embodiments, the anti-CDH6 antibodies or antigen-binding fragments described herein comprise at least one constant region of a human IgG1 antibody. In some embodiments, the anti-CDH6 antibodies or antigen-binding fragments described herein comprise at least one constant region of a human IgG2 antibody. In some embodiments, the anti-CDH6 antibodies or antigen-binding fragments described herein comprise at least one constant region of a human IgG3 antibody. In some embodiments, the anti-CDH6 antibodies or antigen-binding fragments described herein comprise at least one constant region of a human IgG4 antibody. In some embodiments, the Fc region is fused via a hinge. The hinge may be an IgG1 hinge, an IgG2 hinge, or an IgG3 hinge. The amino acid sequences of the Fc regions of human IgG1, IgG2, IgG3, and IgG4 are known to those skilled in the art. In some cases, Fc regions with amino acid mutations have been identified in natural antibodies.

[0201] An example of a chimeric antibody derived from the 707 antibody is an antibody consisting of a heavy chain comprising a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 18 and a light chain comprising a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 23. The antibody may have any given human-derived constant region. Optionally, the heavy chain constant region may be a human IgG1 constant region and the light chain constant region may be a human Igκ constant region.

[0202] In one embodiment, the heavy chain may comprise the amino acid sequence set forth in SEQ ID NO: 72, the light chain may comprise the amino acid sequence set forth in SEQ ID NO: 73, and the chimeric antibody is designated Ch069707.

[0203] An example of a chimeric antibody derived from the 463 antibody is an antibody consisting of a heavy chain comprising a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 41 and a light chain comprising a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 46. The antibody may have any given human-derived constant region. Optionally, the heavy chain constant region may be a human IgG1 constant region (SEQ ID NO: 70) and the light chain constant region may be a human Igκ constant region (SEQ ID NO: 71).

[0204] In one embodiment, the heavy chain may comprise the amino acid sequence set forth in SEQ ID NO: 80, the light chain may comprise the amino acid sequence set forth in SEQ ID NO: 81, and the chimeric antibody is designated Ch069463.

[0205] Examples of such humanized antibodies include antibodies obtained by incorporating only the complementarity determining regions (CDRs) into a human-derived antibody (see Nature (1986), 321, p. 522-525), antibodies obtained by incorporating some framework amino acid residues and CDR sequences into a human antibody by CDR grafting techniques (International Publication No. WO90 / 07861), and antibodies obtained by modifying some of the amino acid sequences of the CDRs while maintaining the antigen-binding ability.

[0206] In the present specification, the humanized antibody derived from the 707 antibody, Ch069707 antibody, 463 antibody, or Ch069463 antibody is not limited to a specific humanized antibody as long as it retains all six CDR sequences specific to the 707 antibody, Ch069707 antibody, 463 antibody, or Ch069463 antibody and has internalization activity. The amino acid sequence of a part of the CDR of the humanized antibody may be further modified as long as it has internalization activity.

[0207] Specific examples of the humanized antibody of the Ch069707 antibody include any combination of a heavy chain including a heavy chain variable region consisting of any amino acid sequence selected from the group consisting of (1) the amino acid sequence shown in SEQ ID NO: 66, (2) an amino acid sequence having at least 95% or more identity to the amino acid sequence (1) (preferably, an amino acid sequence having at least 95% or more sequence identity to the framework region sequence other than each CDR sequence), and (3) an amino acid sequence having one or several amino acid deletions, substitutions, or additions in the amino acid sequence (1), and (4) an amino acid sequence shown in SEQ ID NO: 68, (5) an amino acid sequence having at least 95% or more identity to the amino acid sequence (4) (preferably, an amino acid sequence having at least 95% or more sequence identity to the framework region sequence other than each CDR sequence), and (6) an amino acid sequence having one or several amino acid deletions, substitutions, or additions in the amino acid sequence (4). Optionally, the heavy chain constant region may be a human IgG1 constant region (SEQ ID NO: 70) and the light chain constant region may be a human Igκ constant region (SEQ ID NO: 71), and particular humanized antibodies are designated CL069707-H1L1, CL069707-H1L2, CL069707-H2L1, and CL069707-H2L2, respectively, as further described below.

[0208] In some embodiments, the heavy chain may comprise an amino acid sequence set forth in SEQ ID NO:85, or an amino acid sequence having at least 95% or greater identity to SEQ ID NO:85, and the light chain may comprise an amino acid sequence set forth in SEQ ID NO:86, or an amino acid sequence having at least 95% or greater identity to SEQ ID NO:86.

[0209] In some embodiments, the humanized antibody of the Ch069707 antibody may comprise any combination of a heavy chain comprising a heavy chain variable region consisting of any amino acid sequence selected from the group consisting of the amino acid sequences shown in SEQ ID NOs: 27 and 29, and a light chain comprising a light chain variable region consisting of any amino acid sequence selected from the group consisting of the amino acid sequences shown in SEQ ID NOs: 34 and 36.

[0210] In one embodiment, the heavy chain may comprise the amino acid sequence set forth in SEQ ID NO: 74, the light chain may comprise the amino acid sequence set forth in SEQ ID NO: 76, and the humanized antibody is designated CL069707-H1L1.

[0211] In one embodiment, the heavy chain may comprise the amino acid sequence set forth in SEQ ID NO: 74, the light chain may comprise the amino acid sequence set forth in SEQ ID NO: 77, and the humanized antibody is designated CL069707-H1L2.

[0212] In one embodiment, the heavy chain may comprise the amino acid sequence set forth in SEQ ID NO: 75, the light chain may comprise the amino acid sequence set forth in SEQ ID NO: 76, and the humanized antibody is designated CL069707-H2L1.

[0213] In one embodiment, the heavy chain may comprise the amino acid sequence set forth in SEQ ID NO: 75, the light chain may comprise the amino acid sequence set forth in SEQ ID NO: 77, and the humanized antibody is designated CL069707-H2L2.

[0214] Specific examples of the humanized antibody of the Ch069463 antibody include any combination of a heavy chain including a heavy chain variable region consisting of any amino acid sequence selected from the group consisting of (1) the amino acid sequence shown in SEQ ID NO: 67, (2) an amino acid sequence having at least 95% or more identity to the amino acid sequence (1) (preferably, an amino acid sequence having at least 95% or more sequence identity to the framework region sequence other than each CDR sequence), and (3) an amino acid sequence having one or more amino acid deletions, substitutions, or additions in the amino acid sequence (1), and (4) an amino acid sequence shown in SEQ ID NO: 69, (5) an amino acid sequence having at least 95% or more identity to the amino acid sequence (4) (preferably, an amino acid sequence having at least 95% or more sequence identity to the framework region sequence other than each CDR sequence), and (6) an amino acid sequence having one or more amino acid deletions, substitutions, or additions in the amino acid sequence (4). Optionally, the heavy chain constant region may be a human IgG1 constant region (SEQ ID NO: 70) and the light chain constant region may be a human Igκ constant region (SEQ ID NO: 71), and the humanized antibodies are designated CL069463-H1L1, CL069463-H1L2, CL069463-H1L3, CL069463-H2L1, CL069463-H2L2, and CL069463-H2L3.

[0215] In some embodiments, the humanized antibody of the Ch069463 antibody may comprise any combination of a heavy chain comprising a heavy chain variable region consisting of any amino acid sequence selected from the group consisting of the amino acid sequences shown in SEQ ID NOs: 51 and 54, and a light chain comprising a light chain variable region consisting of any amino acid sequence selected from the group consisting of the amino acid sequences shown in SEQ ID NOs: 58, 63, and 65.

[0216] In some embodiments, the heavy chain may comprise an amino acid sequence set forth in SEQ ID NO:87, or an amino acid sequence having at least 95% or greater identity to SEQ ID NO:87, and the light chain may comprise an amino acid sequence set forth in SEQ ID NO:88, or an amino acid sequence having at least 95% or greater identity to SEQ ID NO:88.

[0217] In one embodiment, the heavy chain may comprise the amino acid sequence set forth in SEQ ID NO: 78, the light chain may comprise the amino acid sequence set forth in SEQ ID NO: 82, and the humanized antibody is designated CL069463-H1L1.

[0218] In one embodiment, the heavy chain may comprise the amino acid sequence set forth in SEQ ID NO: 78, the light chain may comprise the amino acid sequence set forth in SEQ ID NO: 83, and the humanized antibody is designated CL069463-H1L2.

[0219] In one embodiment, the heavy chain may comprise the amino acid sequence set forth in SEQ ID NO: 78, the light chain may comprise the amino acid sequence set forth in SEQ ID NO: 84, and the humanized antibody is designated CL069463-H1L3.

[0220] In one embodiment, the heavy chain may comprise the amino acid sequence set forth in SEQ ID NO: 79, the light chain may comprise the amino acid sequence set forth in SEQ ID NO: 82, and the humanized antibody is designated CL069463-H2L1.

[0221] In one embodiment, the heavy chain may comprise the amino acid sequence set forth in SEQ ID NO: 79, the light chain may comprise the amino acid sequence set forth in SEQ ID NO: 83, and the humanized antibody is designated CL069463-H2L2.

[0222] In one embodiment, the heavy chain may comprise the amino acid sequence set forth in SEQ ID NO: 79, the light chain may comprise the amino acid sequence set forth in SEQ ID NO: 84, and the humanized antibody is designated CL069463-H2L3. [Table 2-1] [Table 2-2] [Table 2-3] [Table 2-4] [Table 2-5] [Table 2-6] [Table 2-7] [Table 2-8]

[0223] The amino acid substitutions herein are preferably conservative amino acid substitutions. The conservative amino acid substitutions are substitutions that occur within a group of amino acids related to the particular amino acid side chain. The preferred amino acid groups are as follows: acidic group=aspartic acid and glutamic acid, basic group=lysine, arginine and histidine, non-polar group=alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine and tryptophan, and uncharged polar family=glycine, asparagine, glutamine, cysteine, serine, threonine and tyrosine. Other preferred amino acid groups are as follows: aliphatic hydroxy group=serine and threonine, amide-containing group=asparagine and glutamine, aliphatic group=alanine, valine, leucine and isoleucine, and aromatic group=phenylalanine, tryptophan and tyrosine. The amino acid substitutions are preferably made without impairing the properties of the substance having the original amino acid sequence.

[0224] By combining sequences that show high identity to the above heavy chain and light chain amino acid sequences, it is possible to select an antibody having biological activity equivalent to each of the above antibodies. Such identity is generally 80% or more, preferably 90% or more, more preferably 95% or more, and most preferably 99% or more. It is also possible to select an antibody having biological activity equivalent to each of the above antibodies by combining heavy and light chain amino acid sequences that contain substitutions, deletions, or additions of one or several amino acid residues with respect to the heavy or light chain amino acid sequence.

[0225] The anti-CDH6 human antibody may be obtained by transforming eukaryotic cells with cDNAs, or preferably vectors containing cDNAs, encoding the heavy and light chains of such human antibodies, by recombinant gene technology, then culturing the transformed cells that produce the genetically modified human monoclonal antibody and obtaining the antibody from the culture supernatant. In this case, eukaryotic cells, preferably mammalian cells such as CHO cells, lymphocytes, or myelomas, may be used, for example, as hosts.

[0226] Furthermore, methods for obtaining phage display-derived human antibodies selected from human antibody libraries are also known (see, for example, Wormstone, I. M. et al., Investigative Ophthalmology & Visual Science (2002), 43(7): p. 2301-2308; Carmen, S. et al., Briefings in Functional Genomics and Proteomics (2002), 1(2): p. 189-203; Siriwardena, D. et al., Ophthalmology (2002), 109(3): p. 427-431).

[0227] (immune complex) The anti-CDH6 antibodies of the present application can be conjugated to an active moiety, which may include a drug moiety and / or a label.

[0228] In some embodiments, the drug moiety is selected from the group consisting of cytotoxic drugs, cytokines, nucleic acids, nucleic acid-associated molecules, radionuclides, chemokines, immune (co)stimulatory molecules, immunosuppressive molecules, death ligands, apoptosis-inducing proteins, kinases, prodrug converting enzymes, ribonucleases, agonist antibodies or antibody fragments, antagonist antibodies or antibody fragments, growth factors, hormones, clotting factors, fibrinolytic proteins, peptide mimetics thereof, and fragments, fusion proteins, or derivatives thereof.

[0229] In some embodiments, the label is selected from the group consisting of a radiolabel, a fluorophore, a chromophore, an imaging agent, and a metal ion.

[0230] In some embodiments, the cytotoxic agent comprises a microtubule inhibitor and / or a DNA damaging agent.

[0231] In some embodiments, the cytotoxic drug is selected from the group consisting of paclitaxel; cytochalasin B; short bacteriocin D; ethidium bromide; emetine; mitomycin; etoposide; onychothioside; thienoside; vincristine; colchicine; doxorubicin; erythromycin; dihydroxycarbamycin dione; tubulin inhibitors; mitoxantrone; actinomycin D. D);1-dehydrotestosterone;glucocorticoids;procaine;bupivacaine;lidocaine;propranolol;puromycin;kallikrein or its analogues or derivatives;antimetobotics;alkylating agents;antibiotics;mitotic inhibitors;Diphtheria toxin and related molecules, their active fragments, and heterodimeric molecules, ricin toxin, cholera toxin, shiga-like toxin, LT toxin, C3 toxin, shiga toxin, pertussis toxin, tetanus toxin, soybean Bowman-Birk protease inhibitor, Pseudomonas exotoxin, alorin, fucoside, capsidin, geranin, phaseolus toxin chain A, capsidin chain A A), alpha-bromotoxin, oleuropein, staphylin protein, American commercial protein, bitter melon inhibitor, jatropha toxin, croton toxin, soapwort inhibitor, white tree toxin, mitogellin, limiting trichothecene, phenomycin and enoxycin toxin; ribonuclease (RNase); DNAse I (DNase I), staphylococcal endotoxin A; American commercial land antiviral protein; diphtheria toxin; and Pseudomonas endotoxin.

[0232] In some embodiments, the tubulin inhibitor may be medensin I or an analog or derivative thereof, the antimetabolite is aminopterin, 6-mercaptopurine, 6-thioguanine, cytarabine, fludarabine, 5-fluorouracil, dacarbazine, hydroxyurea, asparaginase, gemcitabine, or cladribine, and the alkylating agent is azacitidine, thiophan, azacitidine benzoate, or azacitidine benzoate. benzoate, melphalan, carazacitidine (BSNU), lomustine (CCNU), cyclophosphamide, leucovorin, dibromomannan, streptozotocin, dacarbazine (DTIC), procarbazine, mitomycin C, cis-molybdenum, carbomolybdenum, duocarmycin A, duocarmycin SASA, rachelmycin, CC-1065 or analogues or derivatives thereof, the antibiotic is bleomycin, adriamycin, idarubicin (or mitomycin, mitoxantrone, puccamycin, antrixin (AMC)), the mitotic inhibitor is monomethyl auristatin E or F, the diphtheria toxin-related molecule is diphtheria toxin A chain, the ricin toxin is ricin A or deglycosylated ricin A chain toxin, the shiga-like toxin is SLT I, SLT II and SLT IIV, and the commercial proteins from the United States are PAPI, PAPII, and PAP S.

[0233] In some embodiments, the radionuclide is At 211 , I 131 , I 125 , I 123 , Y 90 , Re 186 , Re 188 , Sm 153 , Bi 212 , P 32 , Pb 212 , Tc 99 , S 35 , F 19 , N 15 , C 14 , C 13 Or H 3 Optionally, the radionuclide may be attached to the antibody by a chelating agent.

[0234] In some embodiments, the cytokine comprises IL-2, IL-4, IL-6, IL-7, IL-10, IL-12, IL-13, IL-15, IL-18, IL-23, IL-24, IL-27, IL_28a, IL_28b, IL-29, KGF IFNα, IFNβ, IFNγ, GM-CSF, CD40L, Flt3 ligand, stem cell factor, anisidine, or TNFα.

[0235] (Anti-CDH6 antibody-drug conjugate) The anti-CDH6 antibody-drug conjugate may be produced by binding the anti-CDH6 antibody of the present application to a drug via a linker structure moiety. The drug is not particularly limited as long as it has a substituent or a partial structure that can be linked to the linker structure. The anti-CDH6 antibody-drug conjugate may be used for various purposes depending on the drug bound to it. Examples of such drugs include substances having antitumor activity, substances effective for blood diseases, substances effective for autoimmune diseases, anti-inflammatory substances, antibacterial substances, antifungal substances, antiparasitic substances, antiviral substances, and antianesthetic substances.

[0236] (Cytotoxic drugs) Hereinafter, an example will be described in which a cytotoxic drug is used as a compound to be bound to the anti-CDH6 antibody-drug conjugate of the present invention. The cytotoxic drug is not particularly limited as long as it has an antitumor effect and has a substituent or partial structure that can be linked to a linker structure. When a part or all of the linker is cleaved in a tumor cell, the cytotoxic drug is released, and the cytotoxic drug exerts an antitumor effect. Since the linker is cleaved at the linking position with the drug, the cytotoxic drug is released with its original structure intact, and exerts its original antitumor effect.

[0237] In some embodiments, the cytotoxic agent comprises a tubulin inhibitor and / or a topoisomerase inhibitor. For example, the cytotoxic agent may comprise monomethylauristatin E (MMAE), monomethylauristatin F (MMAF), medensin I, pyrrolobenzodiazepines (PBDs), camptothecin, nemorubicin, PNU-159682, anthracyclines, betacamycin, perillyl alkaloids, paclitaxel, montelukast, elinafide, kallikrein, duocarmycin, rachelmycin (CC-1065), or analogs, derivatives, or prodrugs thereof.

[0238] In some embodiments, the cytotoxic agent comprises a topoisomerase I inhibitor. For example, the cytotoxic agent may comprise camptothecin (CPT) or a derivative thereof.

[0239] By way of non-limiting example, the camptothecin may include camptothecin and camptothecin derivatives, such as irinotecan, topotecan, lurtotecan, silatecan, etirinotecan pegol, TAS 103, 9-aminocamptothecin, 7-ethylcamptothecin, 10-hydroxycamptothecin, 9-nitrocamptothecin, 10,11-methylenedioxycamptothecin, 9-amino-10,11-methylenedioxycamptothecin, 9-chloro-10,11-methylenedioxycamptothecin Camptothecin, 7-(4-methylpiperazinomethylene)-10,11-ethylenedioxy-20(S)-camptothecin, 7-(4-methylpiperazinomethylene)-10,11-methylenedioxy-20(S)-camptothecin, 7-(2-(N-isopropylamino)ethyl)-(20S)-camptothecin, and stereoisomers, salts, and esters thereof.

[0240] As an example of a cytotoxic drug used in the present invention, the camptothecin derivative exatecan ((1S,9S)-1-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13(9H,15H)-dione, represented by the following formula) may be preferably used. [ka] Formula II

[0241] Exatecan can be readily obtained, for example, by the methods described in U.S. Patent Publication No. US2016 / 0297890 or other known methods, and the amino group at position 1 may be preferably utilized as a linking position to a linker structure.

[0242] Since exatecan has a camptothecin structure, it is known that the equilibrium shifts to a structure in which the lactone ring is formed (closed ring) in an acidic aqueous medium (e.g., about pH 3), and to a structure in which the lactone ring is opened (open ring) in a basic aqueous medium (e.g., about pH 10). Formula II discussed herein includes their tautomers, mesomers, racemates, enantiomers, or diastereomers, or mixtures thereof, or pharma- ceutically acceptable salts or solvates thereof. Drug conjugates in which exatecan residues corresponding to such closed ring structures and / or open ring structures are introduced are also expected to have the same antitumor effect, and it goes without saying that all such drug conjugates are within the scope of the present invention.

[0243] Other examples of the cytotoxic drug include cytotoxic drugs described in the literature (Pharmacological Reviews, 68:3-19, 2016). Specific examples include auristatins such as doxorubicin, calicheamicin, dolastatin 10, monomethyl auristatin E (MMAE), and monomethyl auristatin F (MMAF), maytansinoids such as DM1 and DM4, pyrrolobenzodiazepine dimer SG2000 (SJG-136), camptothecin derivative SN-38, and duocarmycins such as CC1065, amanitin, daunorubicin, and mitomycin C. C), bleomycin, cyclocytidine, vincristine, vinblastine, methotrexate, platinum-based antitumor agents (cisplatin and its derivatives), paclitaxel (Taxo) and its derivatives.

[0244] In the antibody-drug conjugate, the number of drug molecules bound per antibody molecule is an important factor affecting its efficacy and safety. The antibody-drug conjugate is produced so that the number of drug molecules bound is constant by specifying the reaction conditions such as the amount of starting materials and reagents used in the reaction. This is different from chemical reactions of low molecular weight compounds, which generally result in mixtures containing different numbers of drug molecules bound. The number of drug molecules bound per antibody molecule is defined and indicated as an average value, i.e., the average number of drug molecules bound. Unless otherwise specified, that is, except when expressing an antibody-drug conjugate having a specific number of drug molecules contained in an antibody-drug conjugate mixture having different numbers of drug molecules bound, the number of drug molecules bound according to the present invention also means an average value in principle. The number of exatecan molecules bound to an antibody molecule is controllable, and about 1 to 10 exatecan molecules may be bound as the average number of drug molecules bound per antibody. The number of exatecan molecules is preferably 2 to 8, 3 to 8, 4 to 8, 5 to 8, 6 to 8, or 7 to 8, more preferably 5 to 8, even more preferably 7 to 8, and even more preferably 8. Furthermore, based on the description of the examples in this application, a person skilled in the art can design a reaction for binding the required number of drug molecules to an antibody molecule, and can obtain an antibody-drug conjugate in which the number of bound exatecan molecules is controlled.

[0245] (Linker structure) In the anti-CDH6 antibody-drug conjugate of the present invention, the linker structure that binds the drug moiety to the anti-CDH6 antibody will be described. In the antibody-drug conjugate of the present application, the linker structure that binds the drug moiety to the anti-CDH6 antibody is not particularly limited as long as the resulting antibody-drug conjugate can be used. The linker structure may be appropriately selected and used depending on the purpose of use. As an example of the linker structure, it may include a linker described in a known document (Pharmacol Rev, 68: 3-19, 2016.1, Protein Cell DOI 10.1007 / s13238-016-0323-0, etc.).

[0246] Any of the linker structures shown below is preferably used. The left end of the structure is the linking position to the antibody, and the right end is the linking position to the drug. Furthermore, in the linker structure shown below, VA represents an amino acid sequence consisting of peptide-bonded valine-alanine (VA), and GGFG in the linker structure shown below represents an amino acid sequence consisting of peptide-bonded glycine-glycine-phenylalanine-glycine (GGFG). -(Succinimidyl-3-yl-N)-CH2CH2-C(=O)-GGFG-PABC-, -(Succinimidyl-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-PABC-, -(Succinimidyl-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-PABC-, -(Succinimidyl-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-GGFG-PABC-, -(Succinimidyl-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-GGFG-PABC-, -CH2-C(=O)-NH-CH2CH2-C(=O)-GGFG-PABC-, -C(=O)-CH2CH2CH2CH2CH2CH2-C(=O)-GGFG-PABC-, -(Succinimidyl-3-yl-N)-CH2CH2-C(=O)-GGFG-NH-CH2CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2CH2CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2-O-CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2CH2-O-CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-GGFG-NH-CH2CH2-C(=O)-, -(succinimidyl-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-, -(succinimidyl-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-GGFG-NH-CH2CH2-C(=O)-, -CH2-C(=O)-NH-CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-, -C(=O)-CH2CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2-C(=O)-VA-PABC-, -(Succinimidyl-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-VA-PABC-, -(Succinimidyl-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-VA-NH-PABC-, -(Succinimidyl-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-VA-PABC-, -(Succinimidyl-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2o-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-VA-PABC-, -CH2-C(=O)-NH-CH2CH2-C(=O)-VA-PABC-, -C(=O)-CH2CH2CH2CH2CH2CH2-C(=O)-VA-PABC-, -(Succinimidyl-3-yl-N)-CH2CH2-C(=O)-VA-NH-CH2CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2-C(=O)-VA-NH-CH2CH2CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-VA-NH-CH2CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-VA-NH-CH2CH2CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-VA-NH-CH2CH2CH2CH2CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-VA-NH-CH2-O-CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-VA-NH-CH2CH2-O-CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-VA-NH-CH2CH2CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-VA-NH-CH2CH2-C(=O)-, -(succinimidyl-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-VA-NH-CH2CH2CH2-C(=O)-, -(succinimidyl-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-VA-NH-CH2CH2-C(=O)-, -CH2-C(=O)-NH-CH2CH2-C(=O)-VA-NH-CH2CH2CH2-C(=O)-, and -C(=O)-CH2CH2CH2CH2CH2CH2-C(=O)-VA-NH-CH2CH2CH2-C(=O)-.

[0247] In some embodiments, the spacer comprises a self-immolative spacer. For example, the self-immolative spacer may comprise a p-aminobenzoxycarbonyl group (PABC) or a p-aminobenzyl group (PAB).

[0248] In some embodiments, the cleavable peptide may be spliced ​​directly to the spacer.

[0249] In some embodiments, L may include -Val-Cit-PABC-, -Val-Ala-PABC-, -Glu-Val-Cit-PABC-, -Ala-Ala-Asn-PABC-, -Gly-Val-Cit-PABC-, -Gly-Gly-Gly-PABC-, -Gly-Gly-Phe-Gly-PABC-, -Val-Cit-PAB-, -Val-Ala-PAB-, -Glu-Val-Cit-PAB-, -Ala-Ala-Asn-PAB-, -Gly-Val-Cit-PAB-, -Gly-Gly-Gly-PAB-, or -Gly-Gly-Phe-Gly-PAB-.

[0250] For example, L is [ka] and [ka] It may be selected from the above structures.

[0251] In some embodiments, the p-aminobenzoxycarbonyl group (PABC) or p-aminobenzyl group (PAB) comprises a polysarcosine (poly-N-methylglycine) residue.

[0252] In some embodiments, L is [ka] and [ka] Selected from the above structures, where n 5 represents an integer of 0 to 20, and optionally, 5 may represent an integer of 1 to 15.

[0253] For example, 5 may be 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20.

[0254] For example, 51-20, 1-19, 1-18, 1-17, 1-16, 1-15, 1-14, 1-13, 1-12, 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 2-20, 2-19, 2-18, 2-17, 2-16, 2-15, 2-14, 2-13, 2-12, 2-11, 2-10, 2-9, 2-8, 2-7, 2-6, 2-5, 2-4, 2-3, 3-20, 3 ~19, 3~18, 3~17, 3~16, 3~15, 3~14, 3~13, 3~12, 3~11, 3~10, 3~9, 3~8, 3~7, 3~6, ​​3~5, 3~4, 4~20, 4~19, 4~18, 4~17, 4~16, 4~15, 4~14, 4~13, 4~12, 4~11, 4~10, 4~9, 4~8, 4~7, 4~6, 4~5, 5~20, 5~19, 5~18, 5~17, 5~16, 5~15, 5~14, 5~13, 5~12, 5~11, 5~10, 5~9, 5~8, 5~7, 5~6, 6~20, 6~19, 6~18, 6~17, 6~16, 6~15, 6~14, 6~13, 6~12, 6~11, 6~10, 6~9, 6~8, 6~7, 7~20, 7~19, 7~18, 7~17, 7~16, 7~15, 7~14, 7~13, 7~12, 7~11, 7~10, 7~9, 7~8, 8~20, 8~ It may represent an integer of 19, 8 to 18, 8 to 17, 8 to 16, 8 to 15, 8 to 14, 8 to 13, 8 to 12, 8 to 11, 8 to 10, 8 to 9, 9 to 20, 9 to 19, 9 to 18, 9 to 17, 9 to 16, 9 to 15, 9 to 14, 9 to 13, 9 to 12, 9 to 11, 9 to 10, 10 to 20, 10 to 19, 10 to 18, 10 to 17, 10 to 16, 10 to 15, 10 to 14, 10 to 13, 10 to 12, or 10 to 11.

[0255] For example, 5 may represent an integer of 1 to 7. For example, 5 may represent an integer of 8 to 15.

[0256] For example, L is [ka] and [ka] It may be selected from the above structures.

[0257] The antibody-drug conjugate may be produced by reacting a compound obtained by a known method (e.g., a method described in published patent document US2016 / 297890 (e.g., a method described in paragraphs

[0336] to

[0374] )) with an antibody having a sulfhydryl group. The antibody having a sulfhydryl group may be obtained by a method familiar to those skilled in the art (Hermanson, G. T, Bioconjugate Techniques, pp. 56-136, pp. 456-493, Academic Press (1996)).

[0258] Specific examples of the antibody-drug conjugate of the present invention include antibody-drug conjugates having the structure represented by the following formula: [ka] , [ka] , [ka] and [ka] Here, n may be any number from 1 to 10. For example, n may be 1 to 9.5, 1 to 9, 1 to 8.5, 1 to 8, 1 to 7.5, 1 to 7, 1 to 6.5, 1 to 6, 1 to 5.5, 1 to 5, 1 to 4.5, 1 to 4, 1 to 3.5, 1 to 3, 1 to 2.5, 1 to 2, 1 to 1.5, 1.5 to 9.5, 1.5 to 9, 1.5 to 8.5, 1.5 to 8, 1.5 to 7.5, 1.5 to 7, 1.5 to 6.5, 1.5 to 6, 1.5 to 5.5, 1.5 to 5, 1.5 to 4.5, 1.5 to 4, 1.5 to 3.5, 1.5 to 3, 1.5 to 2.5, 1.5 to 2, 2 to 9.5, 2 to 9, 2 to 8.5, 2 to 8, 2 to 7.5, 2 ~7, 2~6.5, 2~6, 2~5.5, 2~5, 2~4.5, 2~4, 2~3.5, 2~3, 2~2.5, 2.5~9.5, 2.5~9, 2.5~8.5, 2.5~8, 2.5~7.5, 2.5~7, 2.5~6.5, 2.5~6, 2.5~5.5, 2.5~5, 2.5~4.5, 2.5~4, 2.5~3.5, 2.5~3, 3~9.5, 3~9, 3~8.5, 3~8, 3~7.5, 3~7, 3~6.5, 3~6, ​​3~5.5, 3~5, 3~4.5, 3~4, 3~3.5, 3.5~9.5, 3.5~9, 3.5~8.5 , 3.5~8, 3.5~7.5, 3.5~7, 3.5~6.5, 3.5~6, 3.5~5.5, 3.5~5, 3.5~4.5, 3.5~4, 4~9.5, 4~9, 4~8.5, 4~8, 4~7.5, 4~7, 4~6.5, 4~6, 4~5.5, 4~5, 4~4.5, 4.5~9.5, 4.5~9, 4.5~8.5, 4.5~8, 4.5~7.5, 4.5~7, 4.5~6.5, 4.5~6, 4.5~5.5, 4.5~5, 5~9.5, 5~9, 5~8.5, 5~8, 5~7.5, 5~7, 5~6.5, 5~6, 5~5.5 , 5.5 to 9.5, 5.5 to 9, 5.5 to 8.5, 5.5 to 8, 5.5 to 7.5, 5.5 to 7, 5.5 to 6.5, 5.5 to 6, 6 to 9.5, 6 to 9, 6 to 8.5, 6 to 8, 6 to 7.5, 6 to 7, 6 to 6.5, 6.5 to 9.5, 6.5 to 9, 6.5 to 8.5, 6.5 to 8, 6.5 to 7.5, 6.5 to 7, 7 to 9.5, 7 to 9, 7 to 8.5, 7 to 8, 7 to 7.5, 7.5 to 9.5, 7.5 to 9, 7.5 to 8.5, 7.5 to 8, 8 to 9.5, 8 to 9, 8 to 8.5, 8.5 to 9.5, or 8.5 to 9.

[0259] Here, Ab represents the anti-CDH6 antibody disclosed herein, and the antibody is bound to the linker-payload via a sulfhydryl group derived from the antibody. Here, n has the same meaning as the so-called DAR (drug-antibody ratio), and represents the drug-antibody ratio per antibody. Specifically, n represents the number of bound drug molecules per antibody molecule, and is a numerical value defined and indicated as the average value, that is, the average number of bound drug molecules. In the present invention, when measured by the normal procedure F, n may be 2 to 8, preferably 5 to 8, more preferably 7 to 8, and even more preferably 8.

[0260] An example of the antibody-drug conjugate of the present invention is an antibody-drug conjugate having a structure represented by the above formula, in which the antibody represented by Ab includes any antibody selected from the group consisting of the following antibodies (a) to (k), a functional fragment of the antibody, and a pharmacologically acceptable salt of the antibody-drug conjugate. (a) an antibody comprising a heavy chain comprising the amino acid sequence shown in SEQ ID NO: 72 and a light chain comprising the amino acid sequence shown in SEQ ID NO: 73; (b) an antibody comprising a heavy chain comprising the amino acid sequence shown in SEQ ID NO: 74 and a light chain comprising the amino acid sequence shown in SEQ ID NO: 76; (c) an antibody comprising a heavy chain comprising the amino acid sequence shown in SEQ ID NO: 74 and a light chain comprising the amino acid sequence shown in SEQ ID NO: 77; (d) an antibody comprising a heavy chain comprising the amino acid sequence shown in SEQ ID NO: 75 and a light chain comprising the amino acid sequence shown in SEQ ID NO: 76; (e) an antibody comprising a heavy chain comprising the amino acid sequence shown in SEQ ID NO: 75 and a light chain comprising the amino acid sequence shown in SEQ ID NO: 77; (f) an antibody comprising a heavy chain comprising the amino acid sequence shown in SEQ ID NO: 80 and a light chain comprising the amino acid sequence shown in SEQ ID NO: 81; (g) an antibody comprising a heavy chain comprising the amino acid sequence shown in SEQ ID NO: 78 and a light chain comprising the amino acid sequence shown in SEQ ID NO: 82; (h) an antibody comprising a heavy chain comprising the amino acid sequence represented by SEQ ID NO: 78 and a light chain comprising the amino acid sequence represented by SEQ ID NO: 83; (i) an antibody comprising a heavy chain comprising the amino acid sequence shown in SEQ ID NO: 78 and a light chain comprising the amino acid sequence shown in SEQ ID NO: 84; (j) an antibody comprising a heavy chain comprising the amino acid sequence shown in SEQ ID NO: 79 and a light chain comprising the amino acid sequence shown in SEQ ID NO: 82; (k) an antibody comprising a heavy chain comprising the amino acid sequence represented by SEQ ID NO: 79 and a light chain comprising the amino acid sequence represented by SEQ ID NO: 83; (l) an antibody comprising a heavy chain comprising the amino acid sequence represented by SEQ ID NO: 79 and a light chain comprising the amino acid sequence represented by SEQ ID NO: 84; (m) Any antibody selected from the group consisting of antibodies (a) to (j), wherein the heavy or light chain contains one or more modifications selected from the group consisting of N-linked glycosylation, O-linked glycosylation, N-terminal processing, C-terminal processing, deamidation, isomerization of aspartic acid, oxidation of methionine, addition of a methionine residue to the N-terminus, amidation of proline residues, and post-translational modifications represented by conversion of N-terminal glutamine or N-terminal glutamic acid to pyroglutamic acid, and deletion of one or two amino acids at the carboxyl terminus.

[0261] An example of an antibody-drug conjugate of the present invention is an antibody-drug conjugate having a structure represented by the following formula: [ka] , [ka] , [ka] or [ka] where n can be any number from 1 to 10, Here, the antibody represented by Ab comprises a heavy chain variable region (VH) comprising (1) a heavy chain CDR1 (HCDR1) having the amino acid sequence of SEQ ID NO: 2, (2) a heavy chain CDR2 (HCDR2) having the amino acid sequence of SEQ ID NO: 3, (3) a heavy chain CDR3 (HCDR3) having the amino acid sequence of SEQ ID NO: 4, and / or a light chain variable region (VL) comprising (1) a light chain CDR1 (LCDR1) having the amino acid sequence of SEQ ID NO: 5, (2) a light chain CDR2 (LCDR2) having the amino acid sequence of SEQ ID NO: 6, (3) a light chain CDR3 (LCDR3) having the amino acid sequence of SEQ ID NO: 7, where n is a number from 1 to 10 (e.g., 2 to 10, 4 to 10, 5 to 10, 6 to 10, 7 to 10, 8 to 10). In some embodiments, the antibody represented by Ab comprises a heavy chain variable region having the amino acid sequence represented by SEQ ID NO: 18 and a light chain variable region having the amino acid sequence represented by SEQ ID NO: 23. In some embodiments, the antibody designated by Ab comprises a heavy chain variable region having the amino acid sequence set forth in SEQ ID NO: 66 and a light chain variable region having the amino acid sequence set forth in SEQ ID NO: 68. In some embodiments, the antibody designated by Ab comprises CL069707-H1L1, CL069707-H1L2, CL069707-H2L1 or CL069707-H2L2.

[0262] An example of an antibody-drug conjugate of the present invention is an antibody-drug conjugate having a structure represented by the following formula: [ka] , [ka] , [ka] or [ka] where n can be any number from 1 to 10, Here, the antibody represented by Ab comprises a heavy chain variable region (VH) comprising (1) a heavy chain CDR1 (HCDR1) having the amino acid sequence of SEQ ID NO: 8, (2) a heavy chain CDR2 (HCDR2) having the amino acid sequence of SEQ ID NO: 9, (3) a heavy chain CDR3 (HCDR3) having the amino acid sequence of SEQ ID NO: 10, and / or a light chain variable region (VL) comprising (1) a light chain CDR1 (LCDR1) having the amino acid sequence of SEQ ID NO: 11, (2) a light chain CDR2 (LCDR2) having the amino acid sequence of SEQ ID NO: 12, (3) a light chain CDR3 (LCDR3) having the amino acid sequence of SEQ ID NO: 13, where n is a number from 1 to 10 (e.g., 2 to 10, 4 to 10, 5 to 10, 6 to 10, 7 to 10, 8 to 10). In some embodiments, the antibody represented by Ab comprises a heavy chain variable region having the amino acid sequence represented by SEQ ID NO: 41 and a light chain variable region having the amino acid sequence represented by SEQ ID NO: 46. In some embodiments, the antibody designated by Ab comprises a heavy chain variable region having the amino acid sequence set forth in SEQ ID NO: 67 and a light chain variable region having the amino acid sequence set forth in SEQ ID NO: 69. In some embodiments, the antibody designated by Ab comprises CL069463-H1L1, CL069463-H1L2, CL069463-H1L3, CL069463-H2L1, CL069463-H2L2, or CL069463-H2L3.

[0263] An example of an antibody-drug conjugate of the present invention is an antibody-drug conjugate having a structure represented by the following formula: [ka] , [ka] , [ka] or [ka] where n can be any number from 1 to 10, Here, the antibody represented by Ab comprises a heavy chain variable region (VH) comprising (1) a heavy chain CDR1 (HCDR1) having the amino acid sequence of SEQ ID NO: 89, (2) a heavy chain CDR2 (HCDR2) having the amino acid sequence of SEQ ID NO: 90, (3) a heavy chain CDR3 (HCDR3) having the amino acid sequence of SEQ ID NO: 91, and / or a light chain variable region (VL) comprising (1) a light chain CDR1 (LCDR1) having the amino acid sequence of SEQ ID NO: 92, (2) a light chain CDR2 (LCDR2) having the amino acid sequence of SEQ ID NO: 93, (3) a light chain CDR3 (LCDR3) having the amino acid sequence of SEQ ID NO: 94, where n is a number from 1 to 10 (e.g., 2 to 10, 4 to 10, 5 to 10, 6 to 10, 7 to 10, 8 to 10). In some embodiments, the antibody represented by Ab comprises a heavy chain variable region having the amino acid sequence represented by SEQ ID NO: 95 and a light chain variable region having the amino acid sequence represented by SEQ ID NO: 96.

[0264] An example of an antibody-drug conjugate of the present invention is an antibody-drug conjugate having a structure represented by the following formula: [ka] , [ka] , [ka] or [ka] where n can be any number from 1 to 10, Here, the antibody represented by Ab comprises a heavy chain variable region (VH) including (1) a heavy chain CDR1 (HCDR1) having the amino acid sequence of SEQ ID NO: 97, (2) a heavy chain CDR2 (HCDR2) having the amino acid sequence of SEQ ID NO: 98, and (3) a heavy chain CDR3 (HCDR3) having the amino acid sequence of SEQ ID NO: 99, and / or a light chain variable region (VL) including (1) a light chain CDR1 (LCDR1) having the amino acid sequence of SEQ ID NO: 100, (2) a light chain CDR2 (LCDR2) having the amino acid sequence of SEQ ID NO: 101, and (3) a light chain CDR3 (LCDR3) having the amino acid sequence of SEQ ID NO: 102, where n is a number from 1 to 10 (e.g., 2 to 10, 4 to 10, 5 to 10, 6 to 10, 7 to 10, 8 to 10). In some embodiments, the antibody designated Ab comprises a heavy chain variable region having the amino acid sequence set forth in SEQ ID NO:103 and a light chain variable region having the amino acid sequence set forth in SEQ ID NO:104.

[0265] An example of an antibody-drug conjugate of the present invention is an antibody-drug conjugate having a structure represented by the following formula: [ka] where n can be any number from 1 to 10, Here, the antibody represented by Ab comprises a heavy chain variable region (VH) comprising (1) a heavy chain CDR1 (HCDR1) having the amino acid sequence of SEQ ID NO: 2, (2) a heavy chain CDR2 (HCDR2) having the amino acid sequence of SEQ ID NO: 3, (3) a heavy chain CDR3 (HCDR3) having the amino acid sequence of SEQ ID NO: 4, and / or a light chain variable region (VL) comprising (1) a light chain CDR1 (LCDR1) having the amino acid sequence of SEQ ID NO: 5, (2) a light chain CDR2 (LCDR2) having the amino acid sequence of SEQ ID NO: 6, (3) a light chain CDR3 (LCDR3) having the amino acid sequence of SEQ ID NO: 7, where n is a number from 1 to 10 (e.g., 2 to 10, 4 to 10, 5 to 10, 6 to 10, 7 to 10, 8 to 10). In some embodiments, the antibody represented by Ab comprises a heavy chain variable region having the amino acid sequence represented by SEQ ID NO: 18 and a light chain variable region having the amino acid sequence represented by SEQ ID NO: 23. In some embodiments, the antibody designated by Ab comprises a heavy chain variable region having the amino acid sequence set forth in SEQ ID NO: 66 and a light chain variable region having the amino acid sequence set forth in SEQ ID NO: 68. In some embodiments, the antibody designated by Ab comprises CL069707-H1L1.

[0266] (Drugs) The anti-CDH6 antibody-drug conjugate in the examples is a conjugate of an anti-CDH6 antibody and / or a functional fragment of an antibody having internalization activity with a drug having anti-tumor activity such as cytotoxic activity. The anti-CDH6 antibody-drug conjugate exhibits anti-tumor activity against cancer cells expressing CDH6, and can therefore be used as a drug, particularly as a therapeutic and / or preventive agent for cancer.

[0267] The anti-CDH6 antibody-drug conjugate of the present invention may absorb moisture or have adsorbed water and turn into a hydrate, for example, when placed in air or subjected to a recrystallization or purification process. Such water-containing compounds and pharmacologically acceptable salts are also included in the present invention. The present invention may also include an anti-CDH6 antibody-drug conjugate in which one or more atoms constituting the antibody-drug conjugate are replaced with an isotope of the atom. A composition containing such an isotope-labeled antibody-drug conjugate is useful, for example, as a therapeutic agent, a preventive agent, a research reagent, an assay reagent, a diagnostic agent, or an in vivo diagnostic imaging agent.

[0268] The type of cancer to which the anti-CDH6 antibody-drug conjugate of the present invention is applied is not particularly limited as long as the cancer expresses CDH6 in the cancer cells to be treated. Examples of such cancers include renal cell carcinoma (e.g., renal clear cell carcinoma or papillary renal cell carcinoma), ovarian cancer, ovarian serous adenocarcinoma, thyroid cancer, bile duct cancer, lung cancer (e.g., small cell lung cancer or non-small cell lung cancer), glioblastoma, mesothelioma, uterine cancer, pancreatic cancer, Wilms' tumor, and neuroblastoma, but are not limited to these as long as the cancer expresses CDH6. More preferred examples of such cancers include renal cell carcinoma (e.g., renal clear cell carcinoma, papillary renal cell carcinoma) and ovarian cancer.

[0269] The anti-CDH6 antibody-drug conjugates of the present invention may be administered preferably to mammals, more preferably to humans.

[0270] Substances used in the pharmaceutical composition containing the anti-CDH6 antibody-drug conjugate of the present invention may be appropriately selected from pharmaceutical additives commonly used in the art depending on the application amount or application concentration.

[0271] The anti-CDH6 antibody drug conjugate of the present invention may be administered as a pharmaceutical composition containing one or more pharma- ceutical compatible components. For example, the pharmaceutical composition typically contains one or more pharmaceutical carriers (e.g., sterile liquids (e.g., water and oils, including petroleum and oils of animal, vegetable or synthetic origin (e.g., peanut oil, soybean oil, mineral oil, sesame oil)). When the pharmaceutical composition is administered intravenously, water is the more typical carrier. Saline solution, aqueous dextrose, and aqueous glycerol solutions may also be used as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical vehicles are known in the art. If desired, the composition may contain minor amounts of humectants, emulsifiers, or pH buffering agents.

[0272] Various delivery systems are known and may be used to administer the anti-CDH6 antibody-drug conjugate of the present invention. Examples of administration routes include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, and subcutaneous routes. Administration may be, for example, by injection or bolus injection. According to certain preferred embodiments, administration of the antibody-drug conjugate is by injection. Parenteral administration is the preferred administration route.

[0273] This application discloses the following specific embodiments. (Embodiment 1) A peptide that specifically binds to the cadherin-6 (CDH6) epitope, and i) Approximately 3.1 × 10 in ELISA assay -9 Binding to CDH6 protein with a KD value of less than M ii) having the ability to be internalized by CDH6-expressing cells upon binding to CDH6; An immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof comprising an antibody or antigen-binding fragment thereof having one or more of the above properties.

[0274] (Embodiment 2) The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof described in embodiment 1, wherein the CDH6 is a mammalian CDH6 protein.

[0275] (Embodiment 3) The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof described in embodiment 1 or 2, wherein the CDH6 is a human CDH6 protein.

[0276] (Embodiment 4) The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof according to any one of embodiments 1 to 3, wherein the antibody comprises a monoclonal antibody, a polyclonal antibody, a dimer, a multimer, a complete antibody, a human antibody, a humanized antibody, and / or a chimeric antibody.

[0277] (Embodiment 5) The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof according to any one of embodiments 1 to 4, wherein the antigen-binding fragment comprises a Fab, a Fab', an Fv fragment, a F(ab')2, a scFv, a di-scFv, and / or a dAb.

[0278] (Embodiment 6) The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof according to any one of embodiments 1 to 5, wherein the antibody is a monoclonal antibody.

[0279] (Embodiment 7) The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof according to any one of embodiments 1 to 6, wherein the antibody is a chimeric antibody, a humanized antibody and / or a human antibody.

[0280] (Embodiment 8) The immune complex or a pharma- ceutically acceptable salt or solvate thereof according to any one of embodiments 1 to 7, wherein the antibody or antigen-binding fragment comprises at least one CDR (complementarity determining region) of a heavy chain variable region (VH), and the VH comprises an amino acid sequence as set forth in SEQ ID NO: 18, SEQ ID NO: 66, SEQ ID NO: 41, SEQ ID NO: 67, SEQ ID NO: 95, or SEQ ID NO: 103.

[0281] (Embodiment 9) The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof according to any one of embodiments 1 to 8, wherein the antibody or antigen-binding fragment comprises at least one CDR of a light chain variable region (VL), and the VL comprises an amino acid sequence shown in SEQ ID NO: 23, SEQ ID NO: 68, SEQ ID NO: 46, SEQ ID NO: 69, SEQ ID NO: 96, or SEQ ID NO: 104.

[0282] (Embodiment 10) An immune complex or a pharma- ceutically acceptable salt or solvate thereof according to any one of embodiments 1 to 9, comprising a VH, wherein the VH comprises HCDR1, HCDR2, and HCDR3, and the HCDR1 comprises the amino acid sequence shown in SEQ ID NO:1.

[0283] (Embodiment 11) An immune complex or a pharma- ceutically acceptable salt or solvate thereof according to any one of embodiments 1 to 10, comprising a VH, wherein the VH comprises HCDR1, HCDR2, and HCDR3, and the HCDR1 comprises an amino acid sequence shown in SEQ ID NO: 2, SEQ ID NO: 8, SEQ ID NO: 89, or SEQ ID NO: 97.

[0284] (Embodiment 12) An immune complex or a pharma- ceutically acceptable salt or solvate thereof described in any one of embodiments 1 to 11, comprising a VH, wherein the VH comprises HCDR1, HCDR2, and HCDR3, and the HCDR2 comprises the amino acid sequence shown in SEQ ID NO: 3, SEQ ID NO: 9, SEQ ID NO: 90, or SEQ ID NO: 98.

[0285] (Embodiment 13) An immune complex or a pharma- ceutically acceptable salt or solvate thereof according to any one of embodiments 1 to 12, comprising a VH, wherein the VH comprises HCDR1, HCDR2, and HCDR3, and the HCDR3 comprises an amino acid sequence as shown in SEQ ID NO: 4, SEQ ID NO: 10, SEQ ID NO: 91, or SEQ ID NO: 99.

[0286] (Embodiment 14) An immune complex or a pharma- ceutically acceptable salt or solvate thereof according to any one of embodiments 1 to 13, comprising a VH, wherein the VH comprises HCDR1, HCDR2, and HCDR3, wherein the HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 1, the HCDR2 comprises the amino acid sequence shown in SEQ ID NO: 3 or SEQ ID NO: 9, and the HCDR3 comprises the amino acid sequence shown in SEQ ID NO: 4 or SEQ ID NO: 10.

[0287] (Embodiment 15) A VH, wherein the VH comprises HCDR1, HCDR2, and HCDR3, wherein the HCDR1 comprises the amino acid sequence set forth in SEQ ID NO:2, the HCDR2 comprises the amino acid sequence set forth in SEQ ID NO:3, and the HCDR3 comprises the amino acid sequence set forth in SEQ ID NO:4; or wherein said HCDR1 comprises the amino acid sequence shown in SEQ ID NO:8, said HCDR2 comprises the amino acid sequence shown in SEQ ID NO:9, and said HCDR3 comprises the amino acid sequence shown in SEQ ID NO:10; or wherein said HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 89, said HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 90, and said HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 91; or The immune complex or a pharma- ceutically acceptable salt or solvate thereof according to any one of embodiments 1 to 14, wherein the HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 97, the HCDR2 comprises the amino acid sequence shown in SEQ ID NO: 98, and the HCDR3 comprises the amino acid sequence shown in SEQ ID NO: 99.

[0288] (Embodiment 16) The immune complex or a pharma- ceutically acceptable salt or solvate thereof according to any one of embodiments 1 to 15, comprising a VH, wherein the VH comprises an amino acid sequence shown in SEQ ID NO: 18, SEQ ID NO: 66, SEQ ID NO: 41, SEQ ID NO: 67, SEQ ID NO: 95, or SEQ ID NO: 103.

[0289] (Embodiment 17) The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof according to any one of embodiments 1 to 16, comprising an antibody heavy chain constant region.

[0290] (Embodiment 18) The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof described in embodiment 17, wherein the antibody heavy chain constant region comprises a constant region derived from human IgG.

[0291] (Embodiment 19) The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof described in embodiment 17 or 18, wherein the antibody heavy chain constant region comprises the amino acid sequence set forth in SEQ ID NO: 70.

[0292] (Embodiment 20) The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof according to any one of embodiments 1 to 16, comprising an antibody heavy chain, the antibody heavy chain comprising the amino acid sequence shown in SEQ ID NO: 72, SEQ ID NO: 85, SEQ ID NO: 80, or SEQ ID NO: 87.

[0293] (Embodiment 21) An immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof described in any one of embodiments 1 to 20, comprising a VL, wherein the VL comprises LCDR1, LCDR2, and LCDR3, and the LCDR1 comprises an amino acid sequence represented by SEQ ID NO: 5, SEQ ID NO: 11, SEQ ID NO: 92, or SEQ ID NO: 100.

[0294] (Embodiment 22) An immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof described in any one of embodiments 1 to 21, comprising a VL, wherein the VL comprises LCDR1, LCDR2, and LCDR3, and the LCDR2 comprises the amino acid sequence shown in SEQ ID NO: 6, SEQ ID NO: 12, SEQ ID NO: 93, or SEQ ID NO: 101.

[0295] (Embodiment 23) An immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof described in any one of embodiments 1 to 22, comprising a VL, wherein the VL comprises LCDR1, LCDR2, and LCDR3, and the LCDR3 comprises an amino acid sequence represented by SEQ ID NO: 7, SEQ ID NO: 13, SEQ ID NO: 94, or SEQ ID NO: 102.

[0296] (Embodiment 24) A VL, wherein the VL comprises LCDR1, LCDR2, and LCDR3, wherein the LCDR1 comprises the amino acid sequence set forth in SEQ ID NO:5, the LCDR2 comprises the amino acid sequence set forth in SEQ ID NO:6, and the LCDR3 comprises the amino acid sequence set forth in SEQ ID NO:7; or wherein the LCDR1 comprises the amino acid sequence shown in SEQ ID NO: 11, the LCDR2 comprises the amino acid sequence shown in SEQ ID NO: 12, and the LCDR3 comprises the amino acid sequence shown in SEQ ID NO: 13; or wherein the LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 92, the LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 93, and the LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 94; or The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof according to any one of embodiments 1 to 23, wherein the LCDR1 comprises the amino acid sequence shown in SEQ ID NO: 100, the LCDR2 comprises the amino acid sequence shown in SEQ ID NO: 101, and the LCDR3 comprises the amino acid sequence shown in SEQ ID NO: 102.

[0297] (Embodiment 25) A peptide comprising a VH and a VL, wherein the VH comprises HCDR1, HCDR2, and HCDR3, and the VL comprises LCDR1, LCDR2, and LCDR3, wherein the HCDR1 comprises the amino acid sequence set forth in SEQ ID NO:1, the HCDR2 comprises the amino acid sequence set forth in SEQ ID NO:3, the HCDR3 comprises the amino acid sequence set forth in SEQ ID NO:4, the LCDR1 comprises the amino acid sequence set forth in SEQ ID NO:5, the LCDR2 comprises the amino acid sequence set forth in SEQ ID NO:6, and the LCDR3 comprises the amino acid sequence set forth in SEQ ID NO:7, or The immune complex or a pharma- ceutically acceptable salt or solvate thereof according to any one of embodiments 1 to 24, wherein the HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 1, the HCDR2 comprises the amino acid sequence shown in SEQ ID NO: 9, the HCDR3 comprises the amino acid sequence shown in SEQ ID NO: 10, the LCDR1 comprises the amino acid sequence shown in SEQ ID NO: 11, the LCDR2 comprises the amino acid sequence shown in SEQ ID NO: 12, and the LCDR3 comprises the amino acid sequence shown in SEQ ID NO: 13.

[0298] (Embodiment 26) A peptide comprising a VH and a VL, wherein the VH comprises HCDR1, HCDR2, and HCDR3, and the VL comprises LCDR1, LCDR2, and LCDR3, wherein the HCDR1 comprises the amino acid sequence set forth in SEQ ID NO:2, the HCDR2 comprises the amino acid sequence set forth in SEQ ID NO:3, the HCDR3 comprises the amino acid sequence set forth in SEQ ID NO:4, the LCDR1 comprises the amino acid sequence set forth in SEQ ID NO:5, the LCDR2 comprises the amino acid sequence set forth in SEQ ID NO:6, and the LCDR3 comprises the amino acid sequence set forth in SEQ ID NO:7, or wherein the HCDR1 comprises the amino acid sequence shown in SEQ ID NO:8, the HCDR2 comprises the amino acid sequence shown in SEQ ID NO:9, the HCDR3 comprises the amino acid sequence shown in SEQ ID NO:10, the LCDR1 comprises the amino acid sequence shown in SEQ ID NO:11, the LCDR2 comprises the amino acid sequence shown in SEQ ID NO:12, and the LCDR3 comprises the amino acid sequence shown in SEQ ID NO:13, or wherein the HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 89, the HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 90, the HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 91, the LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 92, the LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 93, and the LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 94, or The immune complex or a pharma- ceutically acceptable salt or solvate thereof according to any one of embodiments 1 to 25, wherein the HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 97, the HCDR2 comprises the amino acid sequence shown in SEQ ID NO: 98, the HCDR3 comprises the amino acid sequence shown in SEQ ID NO: 99, the LCDR1 comprises the amino acid sequence shown in SEQ ID NO: 100, the LCDR2 comprises the amino acid sequence shown in SEQ ID NO: 101, and the LCDR3 comprises the amino acid sequence shown in SEQ ID NO: 102.

[0299] (Embodiment 27) The immune complex or a pharma- ceutically acceptable salt or solvate thereof according to any one of embodiments 1 to 26, comprising a VL, wherein the VL comprises an amino acid sequence as set forth in SEQ ID NO: 23, SEQ ID NO: 68, SEQ ID NO: 46, SEQ ID NO: 69, SEQ ID NO: 96, or SEQ ID NO: 104.

[0300] (Embodiment 28) A VH and a VL, wherein the VH comprises the amino acid sequence set forth in SEQ ID NO: 18 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 23; or wherein the VH comprises the amino acid sequence set forth in SEQ ID NO: 41 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 46; or wherein the VH comprises the amino acid sequence set forth in SEQ ID NO: 66 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 68; or wherein the VH comprises the amino acid sequence set forth in SEQ ID NO:67 and the VL comprises the amino acid sequence set forth in SEQ ID NO:69; or wherein the VH comprises the amino acid sequence set forth in SEQ ID NO: 95 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 96; or wherein the VH comprises the amino acid sequence shown in SEQ ID NO: 103, and the VL comprises the amino acid sequence shown in SEQ ID NO: 104. The immune complex or a pharma- ceutically acceptable salt or solvate thereof according to any one of embodiments 1 to 27.

[0301] (Embodiment 29) The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof according to any one of embodiments 1 to 28, comprising an antibody light chain constant region.

[0302] (Embodiment 30) The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof according to any one of embodiments 1 to 29, wherein the antibody light chain constant region comprises the amino acid sequence shown in SEQ ID NO: 71.

[0303] (Embodiment 31) The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof according to any one of embodiments 1 to 30, comprising an antibody heavy chain, wherein the antibody heavy chain comprises the amino acid sequence shown in SEQ ID NO: 73, SEQ ID NO: 86, SEQ ID NO: 81, or SEQ ID NO: 88.

[0304] (Embodiment 32) An antibody comprising an antibody heavy chain and an antibody light chain, wherein the antibody heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 72 and the antibody light chain comprises the amino acid sequence set forth in SEQ ID NO: 73; or wherein the antibody heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 85 and the antibody light chain comprises the amino acid sequence set forth in SEQ ID NO: 86; or wherein the antibody heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 80 and the antibody light chain comprises the amino acid sequence set forth in SEQ ID NO: 81; or The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof according to any one of embodiments 1 to 31, wherein the antibody heavy chain comprises the amino acid sequence shown in SEQ ID NO: 87 and the antibody light chain comprises the amino acid sequence shown in SEQ ID NO: 88.

[0305] (Embodiment 33) An immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof according to any one of embodiments 1 to 32, further comprising an active moiety bound to the antibody or antigen-binding fragment thereof.

[0306] (Embodiment 34) The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof described in embodiment 33, wherein the active moiety comprises a drug moiety and / or a label.

[0307] (Embodiment 35) The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof described in embodiment 34, wherein the drug moiety is selected from the group consisting of cytotoxic drugs, cytokines, nucleic acids, nucleic acid-associated molecules, radionuclides, chemokines, immune (co)stimulatory molecules, immunosuppressive molecules, death ligands, apoptosis-inducing proteins, kinases, prodrug-converting enzymes, ribonucleases, agonistic antibodies or antibody fragments, antagonistic antibodies or antibody fragments, growth factors, hormones, coagulation factors, fibrinolytic proteins, peptides mimicking these, and fragments, fusion proteins or derivatives thereof.

[0308] (Embodiment 36) The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof described in embodiment 34, wherein the label is selected from the group consisting of a radioactive label, a fluorophore, a chromophore, an imaging agent, and a metal ion.

[0309] (Embodiment 37) The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof described in embodiment 35 or 36, wherein the cytotoxic agent comprises a microtubule inhibitor and / or a DNA damaging agent.

[0310] (Embodiment 38) The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof according to any one of embodiments 35 to 37, wherein the cytotoxic drug comprises a tubulin inhibitor and / or a topoisomerase inhibitor.

[0311] (Embodiment 39) The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof described in any one of embodiments 35 to 38, wherein the cytotoxic drug comprises a topoisomerase I inhibitor.

[0312] (Embodiment 40) The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof according to any one of embodiments 35 to 39, wherein the cytotoxic drug comprises camptothecin or a derivative thereof.

[0313] (Embodiment 41) The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof described in any one of embodiments 35 to 40, wherein the cytotoxic drug comprises the structure of formula II: [ka] (II)

[0314] (Embodiment 42) An antibody-drug conjugate (ADC) comprising formula (I), Ab-(L-(D) m ) n (I) wherein Ab is an antibody or antigen-binding protein according to any one of embodiments 1 to 41; L is a linker, D is a drug moiety; m is an integer from 1 to 8; and The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof according to any one of embodiments 1 to 41, wherein n is any number from 1 to 10.

[0315] (Embodiment 43) The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof of embodiment 42, wherein L is selected from a cleavable linker and a non-cleavable linker.

[0316] (Embodiment 44) The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof described in embodiment 42 or 43, wherein L comprises a cleavable peptide.

[0317] (Embodiment 45) The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof described in embodiment 44, wherein the cleavable peptide is cleavable by an enzyme.

[0318] (Embodiment 46) The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof described in embodiment 45, wherein the enzyme comprises cathepsin B.

[0319] (Embodiment 47) The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof according to any one of embodiments 44 to 46, wherein the cleavable peptide or L comprises an amino acid unit.

[0320] (Embodiment 48) The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof described in embodiment 47, wherein the amino acid unit comprises a dipeptide, tripeptide, tetrapeptide or pentapeptide.

[0321] (Embodiment 49) The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof described in embodiment 47 or 48, wherein the amino acid unit is selected from Val-Cit, Val-Ala, Glu-Val-Cit, Ala-Ala-Asn, Gly-Val-Cit, Gly-Gly-Gly and Gly-Gly-Phe-Gly.

[0322] (Embodiment 50) The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof according to any one of embodiments 42 to 49, wherein L comprises a spacer.

[0323] (Embodiment 51) The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof described in embodiment 50, wherein the spacer comprises a self-immolative spacer.

[0324] (Embodiment 52) ​​The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof described in embodiment 51, wherein the self-immolative spacer comprises a p-aminobenzoxycarbonyl group (PABC) or a p-aminobenzyl group (PAB).

[0325] (Embodiment 53) The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof according to any one of embodiments 44 to 52, wherein the cleavable peptide is spliced ​​directly to the spacer.

[0326] (Embodiment 54) The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof according to any one of embodiments 42 to 53, wherein L comprises -Val-Cit-PABC-, -Val-Ala-PABC-, -Glu-Val-Cit-PABC-, -Ala-Ala-Asn-PABC-, -Gly-Val-Cit-PABC-, -Gly-Gly-Gly-PABC-, -Gly-Gly-Phe-Gly-PABC-, -Val-Cit-PAB-, -Val-Ala-PAB-, -Glu-Val-Cit-PAB-, -Ala-Ala-Asn-PAB-, -Gly-Val-Cit-PAB-, -Gly-Gly-Gly-PAB-, or -Gly-Gly-Phe-Gly-PAB-.

[0327] (Embodiment 55) The spacer is -NH-(CH2)n 1 -La-Lb-Lc-, where La represents -O- or a single bond, and Lb represents -CR 2 (-CR 3 )- or a single bond, where R 2 and R 3 are each independently a C1 to C6 alkyl group, -(CH2)n a -NH2, -(CH2)n b -COOH or -(CH2)n c -OH, n 1 represents an integer from 0 to 6, and n a , n b and n c each independently represents an integer of 1 to 4, provided that n a When is 0, R 2 and R 3 and Lc represents -C(=O)-.

[0328] (Embodiment 56) The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof described in embodiment 55, wherein the spacer comprises -NH-(CH2)3-C(=O)-, -NH-CH2-O-CH2-C(=O)-, or -NH-(CH2)2-O-CH2-C(=O)-.

[0329] (Embodiment 57) The L comprises the structure -L1-L2-L3-, where L1 is -(succinimidyl-3-yl-N)-(CH2)n 2 -C(=O)-, -CH2-C(=O)-NH-(CH2)n 3 -C(=O)- or -C(=O)-(CH2)n 4 -C(=O)-, where n 2 represents an integer from 2 to 8, and n 3 represents an integer from 1 to 8, and n 4 The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof according to any one of embodiments 42 to 56, wherein L represents an integer of 1 to 8, L2 represents an amino acid unit, and L3 represents a self-degrading spacer.

[0330] (Embodiment 58) The L is -(Succinimidyl-3-yl-N)-CH2CH2-C(=O)-GGFG-PABC-, -(Succinimidyl-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-PABC-, -(Succinimidyl-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-PABC-, -(Succinimidyl-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-GGFG-PABC-, -(Succinimidyl-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-GGFG-PABC-, -CH2-C(=O)-NH-CH2CH2-C(=O)-GGFG-PABC-, -C(=O)-CH2CH2CH2CH2CH2CH2-C(=O)-GGFG-PABC-, -(Succinimidyl-3-yl-N)-CH2CH2-C(=O)-GGFG-NH-CH2CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2CH2CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2-O-CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2CH2-O-CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-GGFG-NH-CH2CH2-C(=O)-, -(succinimidyl-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-, -(succinimidyl-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-GGFG-NH-CH2CH2-C(=O)-, -CH2-C(=O)-NH-CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-, -C(=O)-CH2CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2-C(=O)-VA-PABC-, -(Succinimidyl-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-VA-PABC-, -(Succinimidyl-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-VA-NH-PABC-, -(Succinimidyl-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-VA-PABC-, -(Succinimidyl-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2o-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-VA-PABC-, -CH2-C(=O)-NH-CH2CH2-C(=O)-VA-PABC-, -C(=O)-CH2CH2CH2CH2CH2CH2-C(=O)-VA-PABC-, -(Succinimidyl-3-yl-N)-CH2CH2-C(=O)-VA-NH-CH2CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2-C(=O)-VA-NH-CH2CH2CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-VA-NH-CH2CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-VA-NH-CH2CH2CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-VA-NH-CH2CH2CH2CH2CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-VA-NH-CH2-O-CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-VA-NH-CH2CH2-O-CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-VA-NH-CH2CH2CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-VA-NH-CH2CH2-C(=O)-, -(succinimidyl-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-VA-NH-CH2CH2CH2-C(=O)-, -(succinimidyl-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-VA-NH-CH2CH2-C(=O)-, -CH2-C(=O)-NH-CH2CH2-C(=O)-VA-NH-CH2CH2CH2-C(=O)-, and -C(=O)-CH2CH2CH2CH2CH2CH2-C(=O)-VA-NH-CH2CH2CH2-C(=O)- The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof according to any one of embodiments 42 to 57, selected from:

[0331] (Embodiment 59) An immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof according to any one of embodiments 52 to 58, wherein the p-aminobenzoxycarbonyl group (PABC) or p-aminobenzyl group (PAB) comprises a polysarcosine (poly-N-methylglycine) residue.

[0332] (Embodiment 60) The L is [ka] and [ka] Selected from the above structures, where n 5 The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof according to any one of embodiments 42 to 59, wherein represents an integer of 0 to 20.

[0333] (Embodiment 61) 5 The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof according to embodiment 60, wherein represents an integer between 8 and 15.

[0334] (Embodiment 62) The L is [ka] , [ka] [ka] and [ka] The immunoconjugate according to any one of embodiments 42 to 61, or a pharma- ceutically acceptable salt or solvate thereof, selected from the structures above.

[0335] (Embodiment 63) The antibody-drug conjugate, [ka] , [ka] , [ka] and [ka] Selected from the above structures, The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof according to any one of embodiments 42 to 62, wherein n is any number from 1 to 10.

[0336] (Embodiment 64) The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof described in embodiment 63, wherein n is any number from 2 to 8.

[0337] (Embodiment 65) A method for producing an immune complex or a pharma- ceutically acceptable salt or solvate thereof described in any one of embodiments 1 to 64, comprising a step of reacting an antibody or an antigen-binding fragment thereof described in any one of embodiments 1 to 64 with a drug-linker intermediate compound.

[0338] (Embodiment 66) A pharmaceutical composition comprising the immunoconjugate according to any one of embodiments 1 to 64 or a pharma- ceutically acceptable salt or solvate thereof.

[0339] (Embodiment 67) The pharmaceutical composition described in embodiment 66, further comprising a pharma- ceutically acceptable carrier or excipient.

[0340] (Embodiment 68) Use of an immunoconjugate according to any one of embodiments 1 to 64 or a pharma- ceutically acceptable salt or solvate thereof, or a pharmaceutical composition according to embodiment 66 or 67, in the manufacture of a medicament for treating a tumor.

[0341] (Embodiment 69) The use described in embodiment 68, wherein the tumor is a CDH6-expressing tumor.

[0342] (Embodiment 70) The use described in embodiment 68 or 69, wherein the tumor comprises renal cell carcinoma, renal clear cell carcinoma, papillary renal cell carcinoma, ovarian cancer, ovarian serous adenocarcinoma, thyroid cancer, cholangiocarcinoma, lung cancer, small cell lung carcinoma, glioblastoma, mesothelioma, uterine cancer, pancreatic cancer, Wilms' tumor or neuroblastoma.

[0343] (Embodiment 71) A method for treating a tumor, comprising administering to a subject an immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof described in any one of embodiments 1 to 64.

[0344] (Embodiment 72) The method of embodiment 71, wherein the tumor is a CDH6-expressing tumor.

[0345] (Embodiment 73) The method described in embodiment 71 or 72, wherein the tumor comprises renal cell carcinoma, renal clear cell carcinoma, papillary renal cell carcinoma, ovarian cancer, ovarian serous adenocarcinoma, thyroid cancer, cholangiocarcinoma, lung cancer, small cell lung carcinoma, glioblastoma, mesothelioma, uterine cancer, pancreatic cancer, Wilms tumor or neuroblastoma.

[0346] (Embodiment 74) A method for treating a tumor, comprising simultaneously, separately or sequentially administering to a subject a pharmaceutical composition comprising at least one component selected from the immunoconjugate or a pharma-ceutically acceptable salt or solvate thereof described in any one of embodiments 1 to 64, and at least one antitumor drug.

[0347] (Example) The following examples are provided to fully disclose and describe to one of ordinary skill in the art how to make and use the present invention, and are not intended to limit the scope of what the inventors regard as their invention, nor are they intended to represent all or the only experiments performed. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperature, etc.), but some experimental error and deviation should be accounted for. Unless otherwise indicated, parts are parts by weight, molecular weight is weight average molecular weight, temperature is in degrees Celsius, and pressure is at or near atmospheric. Standard abbreviations may be used. For example, bp = base pairs, kb = kilobases, pl = picoliters, s or sec = seconds, min = minutes, h or hr = hours, aa = amino acids, nt = nucleotides, im = intramuscular (also adverb), ip = intraperitoneal (also adverb), sc = subcutaneous (also adverb), etc.

[0348] Example 1: Linker-Payload Preparation 1.1 Preparation of compound LP-1 Step 1: Synthesis of intermediate 11-1 To a solution of compound 11-1A (Mc-Val-Ala-OH, purchased from MedChemExpress Shanghai, 2.4 g, 6.29 mmol) and 11-1B (3.18 g, 6.29 mmol) in a mixture of DCM:MeOH (v:v=2:1, 90 mL) at room temperature, EEDQ (1.86 g, 7.55 mmol) was added. The reaction was stirred at room temperature for 24 h, the solvent was removed under vacuum, and the crude residue was further purified by flash chromatography to give compound 11-1 (3.9 g, 71%). LC-MS (ESI, m / z): 868.49 (M+H).

[0349] Step 2: Synthesis of intermediate 11-2 Compound 11-1 (2 g, 2.3 mmol) was dissolved in anhydrous THF (50 mL), and hydrogen fluoride-pyridine (4.6 g, 46 mmol) was added at 0° C. under argon atmosphere, and then the reaction mixture was stirred at 0° C. for 2 h. Water was added to quench the reaction, and it was extracted with DCM, and the organic phase was dried and concentrated. The residue was purified by silica gel chromatography to give compound 11-2 (1.1 g, 76%). LC-MS (ESI, m / z): 630.31 (M+H).

[0350] Step 3: Synthesis of intermediate 11-3 Compound 11-2 (700 mg, 1.11 mmol) was dissolved in anhydrous DMF (4 mL), and DIPEA (0.39 mL, 2.23 mmol) and bis(4-nitrophenyl)carbonate (406 mg, 1.33 mmol) were added at room temperature under argon atmosphere, and the reaction mixture was stirred at room temperature overnight. The solvent was removed by concentration, and the product was precipitated from MTBE, and the yellow solid was collected by filtration, washed with diethyl ether, and dried to give compound 11-3, which was used directly in the next step. LC-MS (ESI, m / z): 795.41 (M+H).

[0351] Step 4: Synthesis of intermediate 11-4 Compound 11-3 (300 mg, 0.44 mmol) was dissolved in anhydrous DMF (4 mL) and dry pyridine (1 mL) was added, followed by exatecan mesylate (purchased from MedChemExpress Shanghai, 234 mg, 0.44 mmol) and HOBt (60 mg, 0.44 mmol). The reaction mixture was stirred at room temperature under argon overnight. The product was purified by preparative HPLC to give intermediate 11-4 (230 mg, 48%). LC-MS (ESI, m / z): 1091.53 (M+H).

[0352] Step 5: Synthesis of intermediate 11-5 Compound 11-4 (200 mg, 0.183 mmol) was dissolved in 1 mL of anhydrous DCM, 300 μL of TFA was added at 0 °C, and the reaction mixture was stirred at room temperature for 30 min and concentrated to remove the solvent to give intermediate 11-5 as a TFA salt, which was used in the next step without further purification. LC-MS (ESI, m / z): 991.47 (M+H).

[0353] Step 6: Synthesis of compound LP-1 Compound 11-5 (120 mg, 0.109 mmol) was dissolved in 1 mL of anhydrous DMF, Ac-Sar10-COOH (84 mg, 0.109 mmol) was added, followed by HATU (50 mg, 0.130 mmol) and DIPEA (38 μL, 0.22 mmol), the reaction mixture was stirred at room temperature overnight, concentrated to remove the solvent, and the crude product was purified by preparative HPLC to give compound LP-1 (74 mg, 38%). LC-MS (ESI, m / z): 1743.85 (M+H). [ka]

[0354] 1.2 Preparation of compound LP-2 [ka] LP-2 The synthesis of compound LP-2 was carried out according to the procedure of compound LP-1, replacing starting material 11-1A with Mc-GGFG-OH (purchased from MedChemExpress Shanghai) to obtain compound LP-2 as a beige amorphous solid. LC-MS (ESI, m / z): 1891.90 (M+H).

[0355] Example 2: Generation and screening of humanized anti-CDH6 antibodies The murine anti-CDH6 antibody CL069707 was humanized by CDR grafting (Proc. Nal. Acad. Sci. USA, 86:10029-10033(1989)). The CDR regions of CL069707 were grafted to the most similar human germline sequences. Some of the important key residues were backmutated based on the criteria presented, for example, by Queen et al. (Proc. Nal. Acad. Sci. USA, 86:10029-10033(1989)).

[0356] The two humanized heavy chain variants were named CL069707-H1 and CL069707-H2. The amino acid sequence of the CL069707-H1 heavy chain is shown in SEQ ID NO: 74. The amino acid sequence of the CL069707-H2 heavy chain is shown in SEQ ID NO: 75. The two humanized light chain variants were named CL069707-L1 and CL069707-L2. The amino acid sequence of the CL069707-L1 light chain is shown in SEQ ID NO: 76. The amino acid sequence of the CL069707-L2 light chain is shown in SEQ ID NO: 77.

[0357] DNA sequences encoding the full-length amino acid sequences of CL069707-H1, CL069707-H2, CL069707-L1, and CL069707-L2 were synthesized and inserted into the pCDNA3.1 expression vector. Antibodies CL069707-H1L1, CL069707-H1L2, CL069707-H2L1, and CL069707-H2L2 were generated by combining the heavy and light chains in 293 cells.

[0358] EC of humanized antibody binding to tumor cells 50was measured as follows: Cell cultures of the human ovarian cancer cell line OVCAR-3 (purchased from the National Collection of Authenticated Cell Cultures) were maintained in vitro as independent monolayer cultures at 37° C. in an atmosphere of 5% CO2. Cells were harvested by trypsin-EDTA partial digestion followed by centrifugation at 1000 rpm for 5 min. Cells were resuspended in cold PBS and serial dilutions of Ch069707 and CL069707-H1L1, CL069707-H1L2, CL069707-H2L1 and CL069707-H2L2 antibodies were added. The Ch069707 antibody was a chimeric antibody. The variable region was the same as that of CL069707 and the constant region was the same as the human IgG1 constant region (SEQ ID NO: 70 and SEQ ID NO: 71). The cell solutions were mixed, incubated at 4° C. and washed with cold PBS before adding the second antibody conjugate (for detection). After incubation at 4°C, the cells were washed with PBS and then subjected to flow cytometry (FACS) analysis. Figure 1A shows that CL069707-H1L1, CL069707-H1L2, CL069707-H2L1 and CL069707-H2L2 had similar EC 50 Figure 1B shows that EC of CL069707-H1L1 on OVCAR-3 cells was 50 was slightly lower than that of Ch069707.

[0359] The mouse anti-CDH6 antibody CL069463 was humanized in a similar manner. The results are shown in Figure 2. CL069463-H1L1, CL069463-H2L2, and CL069463-H2L3 had similar EC values ​​to Ch069463 on OVCAR-3 cells. 50 The Ch069463 antibody was a chimeric antibody. The variable regions were the same as those of CL069463, and the constant regions were the same as the human IgG1 constant regions (SEQ ID NO: 70 and SEQ ID NO: 71).

[0360] Example 3: In vitro evaluation of humanized CL069707-H1L1 3.1 Analysis of CL069707-H1L1 binding to human CDH6, CDH9, and CDH10 CDH9 and CDH10 are the family members most closely related to CDH6. Binding of CL069707-H1L1 to human CDH6, CDH9 and CDH10 ECD domains was analyzed by ELISA binding assay. Human CDH6-EC6D-His, CDH9-ECD-His and CDH10-ECD-His antigens were obtained from Acro Biosystems, Inc. 100 μL of 1 μg / mL antigen diluted in PBS was added to a 96-well plate and incubated overnight at 4°C. The plate was washed three times with 300 μL of wash buffer. 1% BSA blocking reagent was then added to the plate at 100 μL / well and incubated at 37°C for 1 hour, after which the blocking reagent was discarded. Three-fold serial dilutions of CL069707-H1L1 were added to the plate and incubated at 37°C for 1 hour. The plate was then washed three times with 300 μL of wash buffer. 100 μL / well of HRP-conjugated anti-human antibody diluted in 1% BSA was added to the plate and then incubated at 37° C. for 1 hour. The plate was washed three times with 300 μL of wash buffer. 100 μL / well of TMB substrate was added to the plate and incubated at room temperature for about 10 minutes. The reaction was then stopped with 100 μL / well of stop solution. The OD450 was read on a plate reader and the data was processed. The results are shown in FIG. 3. CL069707-H1L1 binds EC to human CDH6-ECD-His. 50 Binds at 0.1 nM and CL069707-H1L1 does not bind to CDH9-ECD-His or CDH10-ECD-His proteins.

[0361] 3.2 ELISA binding EC of CL069707-H1L1 to human, cynomolgus monkey, mouse and rat CDH6 antigen 50 Evaluation The binding of CL069707-H1L1 to human, cynomolgus monkey, mouse, or rat CDH6 antigen was analyzed by ELISA. Human, cynomolgus monkey, mouse, and rat CDH6-ECD-His antigens were obtained from Acro Biosystems, Inc. ELISA was performed in the same manner as in Example 3.1. The results are shown in Figure 4. CL069707-H1L1 had similar EC 50 It binds to human, cynomolgus monkey, mouse and rat CDH6-ECD-His antigens.

[0362] 3.3 Evaluation of the binding constants of CL069707-H1L1 and Ch069707 to human and cynomolgus monkey CDH6 antigens The binding affinity of CL069707-H1L1 and Ch069707 was measured using the Octet® system based on Biolayer Interference (BLI) technology. The antibodies were loaded onto AHC (anti-hIgG Fc capture) at a concentration of 100 nM. Then, 3.13 nM, 6.25 nM, 12.5 nM, 25 nM, 50 nM and 100 nM of human CDH6-ECD-His or cynomolgus monkey CDH6-ECD-His antigens were incubated with the antibody-bound biosensor chip, and the binding of the antigen and antibody was measured. From six different binding curves obtained from each antigen concentration, the binding constant (KD) was calculated based on a 1:1 binding model. The results are shown in Table 2. CL069707-H1L1 and Ch069707 bind to the human CDH6-ECD-His antigen with similar affinity. CL069707-H1L1 binds to human CDH6-ECD-His and cynomolgus CDH6-ECD-His antigens with similar affinity. [Table 3]

[0363] Example 4: Preparation of antibody-drug conjugates General methods for producing antibody-drug conjugates The antibody that can be used in the antibody-drug conjugate of the present invention is not particularly limited, so long as it is an anti-CDH6 antibody having internalization activity or a functional fragment of the antibody.

[0364] Next, a typical method for producing the antibody-drug conjugate of the present invention will be described. In the following description, the "compound number" shown in each reaction scheme is used to represent the compound. Specifically, each compound will be referred to as "compound of formula (1)", "compound (1)", etc. The same applies to other compound numbers.

[0365] An antibody-drug conjugate represented by the following formula (1), in which an anti-CDH6 antibody is linked to a linker structure via a thioether, may be produced by reacting an antibody having a sulfhydryl group converted from a disulfide bond by reduction of the anti-CDH6 antibody with compound (2). The antibody-drug conjugate may be produced, for example, by the following method. [ka] where Ab represents an antibody having a sulfhydryl group, and L 1 has the structure represented by -(succinimidyl-3-yl-N)-, and L 1’ represents a maleimidyl group represented by the following formula: [ka] Here, (NH-DX) has the structure represented by the following formula: [ka] -L 1 -L x - has a structure represented by any of the following formulas: -(Succinimidyl-3-yl-N)-CH2CH2-C(=O)-GGFG-PABC-, -(Succinimidyl-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-PABC-, -(Succinimidyl-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-PABC-, -(Succinimidyl-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-GGFG-PABC-, -(Succinimidyl-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-GGFG-PABC-, -CH2-C(=O)-NH-CH2CH2-C(=O)-GGFG-PABC-, -C(=O)-CH2CH2CH2CH2CH2CH2-C(=O)-GGFG-PABC-, -(Succinimidyl-3-yl-N)-CH2CH2-C(=O)-GGFG-NH-CH2CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2CH2CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2-O-CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2CH2-O-CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-GGFG-NH-CH2CH2-C(=O)-, -(succinimidyl-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-, -(succinimidyl-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-GGFG-NH-CH2CH2-C(=O)-, -CH2-C(=O)-NH-CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-, -C(=O)-CH2CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2-C(=O)-VA-PABC-, -(Succinimidyl-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-VA-PABC-, -(Succinimidyl-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-VA-NH-PABC-, -(Succinimidyl-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-VA-PABC-, -(Succinimidyl-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2o-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-VA-PABC-, -CH2-C(=O)-NH-CH2CH2-C(=O)-VA-PABC-, -C(=O)-CH2CH2CH2CH2CH2CH2-C(=O)-VA-PABC-, -(Succinimidyl-3-yl-N)-CH2CH2-C(=O)-VA-NH-CH2CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2-C(=O)-VA-NH-CH2CH2CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-VA-NH-CH2CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-VA-NH-CH2CH2CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-VA-NH-CH2CH2CH2CH2CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-VA-NH-CH2-O-CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-VA-NH-CH2CH2-O-CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-VA-NH-CH2CH2CH2-C(=O)-, -(Succinimidyl-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-VA-NH-CH2CH2-C(=O)-, -(succinimidyl-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-VA-NH-CH2CH2CH2-C(=O)-, -(succinimidyl-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-VA-NH-CH2CH2-C(=O)-, -CH2-C(=O)-NH-CH2CH2-C(=O)-VA-NH-CH2CH2CH2-C(=O)-, and -C(=O)-CH2CH2CH2CH2CH2CH2-C(=O)-VA-NH-CH2CH2CH2-C(=O)-.

[0366] In the above reaction scheme, the antibody-drug conjugate (1) is understood to have a structure in which one structural portion from the drug to the linker end is linked to one antibody. However, this description is given for convenience, and in reality, multiple structural portions as described above are often linked to one antibody molecule. The same applies to the interpretation of the production method described below.

[0367] An antibody having a sulfhydryl group may be obtained by a method familiar to those skilled in the art (Hermanson, G. T, Bioconjugate Techniques, pp. 56-136, pp. 456-493, Academic Press (1996)). Examples of the method include, but are not limited to, reacting the amino group of an antibody with Traut's reagent, reacting the amino group of an antibody with N-succinimidyl S-acetylthioalkanoate and then with hydroxylamine, reacting the antibody with N-succinimidyl 3-(pyridyldithio)propionate and then with a reducing agent, or reacting the antibody with a reducing agent such as dithiothreitol, 2-mercaptoethanol, or tris(2-carboxyethyl)phosphine hydrochloride (TCEP) to reduce interchain disulfide bonds in the antibody to form sulfhydryl groups.

[0368] Specifically, an antibody in which the interchain disulfide bonds have been partially or completely reduced can be obtained by using 0.3 to 3 molar equivalents of TCEP per interchain disulfide bond in the antibody as a reducing agent and reacting the antibody in a buffer solution containing a chelating agent. Examples of the chelating agent include ethylenediaminetetraacetic acid (EDTA) and diethylenetriaminepentaacetic acid (DTPA). The chelating agent may be used at a concentration of 1 to 20 mM. The buffer solution may be a solution of sodium phosphate, sodium borate, sodium acetate, or the like.

[0369] Furthermore, the drug-linker moiety can be linked via a thioether bond by addition reaction of a sulfhydryl group to the drug-linker moiety.

[0370] Next, an antibody-drug conjugate (1) in which 2 to 8 drug molecules are bound to each antibody can be produced using 2 to 20 molar equivalents of compound (2) per antibody having a sulfhydryl group. Specifically, a solution in which compound (2) is dissolved may be added to a buffer solution containing an antibody having a sulfhydryl group to cause the reaction. In this case, a sodium acetate solution, sodium phosphate, sodium borate, or the like may be used as the buffer solution. The pH of the reaction is 5 to 9, and more preferably, the reaction may be performed at about pH 7. As a solvent for dissolving compound (2), an organic solvent such as dimethyl sulfoxide (DMSO), dimethylformamide (DMF), dimethylacetamide (DMA), or N-methyl-2-pyrrolidone (NMP) may be used. The reaction may be performed by adding a solution in which compound (2) is dissolved in an organic solvent at 1 to 20% v / v to a buffer solution containing an antibody having a sulfhydryl group. The reaction temperature is 0 to 37°C, more preferably 10 to 25°C, and the reaction time is 0.5 to 2 hours. The reaction may be terminated by inactivating the reactivity of unreacted compound (2) with a thiol-containing reagent. Examples of the thiol-containing reagent include cysteine ​​or N-acetyl-L-cysteine ​​(NAC). More specifically, the reaction may be terminated by adding 1 to 2 molar equivalents of NAC to the compound (2) used, and incubating the resulting mixture at room temperature for 10 to 30 minutes.

[0371] (Identification of antibody-drug conjugates) The produced antibody-drug conjugate (1) may be subjected to concentration, buffer exchange, purification, measurement of antibody concentration and average number of bound drug molecules per antibody molecule to identify the antibody-drug conjugate (1) according to the general procedures described below.

[0372] General Procedure A: Concentration of an Aqueous Solution of Antibody or Antibody-Drug Conjugate The antibody or antibody-drug conjugate solution was added to an Amicon Ultra (50,000 MWCO, Millipore Corporation) container, and the antibody or antibody-drug conjugate solution was concentrated by centrifugation (centrifugation at 2,000 to 3,800 G for 5 to 20 minutes).

[0373] Routine Procedure B: Measurement of antibody concentration The absorbance of the antibodies was measured using a microplate reader (Multiskan GO, Thermo Fisher Scientific Inc.) according to the method specified by the manufacturer. In this case, the extinction coefficient at 280 nm, which differs for each antibody (1.3 to 1.8 mL mg -1 cm -1 ) was used.

[0374] Standard Procedure C: Buffer Exchange of Antibodies Zeba™ Desalting Spin Columns (5mL, 40k MWCO, Thermo Scientific™) were equilibrated with phosphate buffer (50mM, pH 7.0) containing sodium chloride (50mM) and EDTA (2mM) (referred to herein as PBS7.0 / EDTA) according to the method specified by the manufacturer. The aqueous solution of the antibody was loaded in an amount of 2mL per Zeba™ (5mL) column, and the desalting column was then centrifuged (1000G for 4 minutes) to collect fractions (approximately 2mL). The fractions may be concentrated by standard procedure A. The antibody concentration was measured using standard procedure B, and then adjusted to >10mg / mL using PBS7.0 / EDTA.

[0375] Routine Procedure D: Purification of Antibody-Drug Conjugates A Zeba™ desalting spin column (5 mL, 40k MWCO, Thermo Scientific™) was equilibrated with any available formulation buffer solution, such as histidine-acetate buffer (20 mM histidine, pH 5.5) containing sodium chloride (150 mM) or phosphate buffer (50 mM, pH 7.0) containing sodium chloride (50 mM). The aqueous reaction solution of the antibody drug conjugate (approximately 2 mL) was loaded onto the Zeba™ column (5 mL), and the desalting column was then centrifuged (centrifuged at 1000 G for 4 minutes) to collect the antibody fraction (approximately 2 mL). The collected fractions were loaded again onto a Zeba™ desalting column and the gel filtration purification process, eluted by centrifugation, was repeated a total of two times to obtain the antibody-drug conjugate free of unbound linker-payload and low molecular weight compounds (tris(2-carboxyethyl)phosphine hydrochloride (TCEP), N-acetyl-L-cysteine ​​(NAC), dimethylsulfoxide).

[0376] Routine Procedure E: Determination of antibody concentration in antibody-drug conjugates and average number of drug molecules bound per antibody molecule The bound drug concentration in the antibody-drug conjugate may be calculated by measuring the UV absorbance of an aqueous solution of the antibody-drug conjugate at two wavelengths, 280 nm and 370 nm, and then performing the calculation shown below.

[0377] The total absorbance at any given wavelength is equal to the sum of the absorbances of all light-absorbing species present in the system (additivity of absorbance). Therefore, based on the hypothesis that the molar extinction coefficients of the antibody and drug do not change before and after antibody-drug binding, the antibody and drug concentrations in the antibody-drug complex are expressed by the following formula: A 280 =A D,280 +A A,280 =ε D,280 C D +ε A,280 C A Formula (1) A 370 =A D,370 +A A,370 =ε D,370 C D +ε A,370 C A Formula (2)

[0378] In this case, A 280 represents the absorbance at 280 nm of an aqueous solution of the antibody-drug conjugate, and A 370 represents the absorbance at 370 nm of an aqueous solution of the antibody-drug conjugate, and A A,280 represents the absorbance of the antibody at 280 nm, and A A,370 represents the absorbance of the antibody at 370 nm, and A D,280 represents the absorbance at 280 nm of the complex precursor, and A D,370 represents the absorbance at 370 nm of the complex precursor, and ε A,280 represents the molar extinction coefficient of the antibody at 280 nm, and ε A,370 represents the molar extinction coefficient of the antibody at 370 nm, and ε D,280 represents the molar extinction coefficient at 280 nm of the complex precursor, and ε D,370 represents the molar extinction coefficient at 370 nm of the complex precursor, and C A represents the antibody concentration in the antibody-drug conjugate, and C D represents the drug concentration in the antibody-drug complex.

[0379] In this case, ε A,280 , ε A,370 , ε D,280 , and ε D,370 For , a value prepared in advance (an estimated value by calculation or a measured value by UV measurement of the compound) is used. For example, ε A,280 may be estimated from the amino acid sequence of the antibody by known computational methods (Protein Science, 1995, vol. 4:2411-2423). A,370 is generally zero. D,280 and ε D,370 may be obtained by measuring the absorbance of a solution in which the complex precursor used is dissolved at a specific molar concentration, according to the Beer-Lambert law (absorbance molar concentration × molar extinction coefficient × cell path length). A and C D is the A of the aqueous solution of the antibody-drug conjugate 280 and A 370 and then solving the simultaneous equations of Equation (1) and Equation (2) by substituting those values. D CA The average number of drug molecules bound per antibody may be determined by dividing by the number of

[0380] Routine Procedure F: Determination of the average number of drug molecules bound per antibody molecule - (2) In addition to the above "General Procedure E", the average number of bound drug molecules per antibody molecule in the antibody-drug conjugate may be measured by liquid chromatography-mass spectrometry (LC-MS) analysis using the following method. The following describes a method for measuring the average number of bound drug molecules by LC-MS when the antibody is bound to the linker-payload by a disulfide bond. Those skilled in the art can refer to this method to appropriately measure the average number of bound drug molecules by LC-MS depending on the mode of linkage between the antibody and the linker-payload.

[0381] Preparation of samples for LC-MS analysis (reduction of antibody-drug conjugate) The antibody-drug conjugate solution (approximately 5 mg / mL, 6 μL) was mixed with an aqueous solution of dithiothreitol (DTT) (100 mM, 3 μL) and 21 μL of water. The disulfide bond between the light and heavy chains of the antibody-drug conjugate was cleaved by incubating the mixture at 37 °C for 30 min. The obtained sample was used for LC-MS analysis.

[0382] (HPLC parameters) Column: Agilent PLRP-S, 1000Å, 50×2.1mm, 8μm Detection wavelength: 280nm Bandwidth: 4nm Column oven temperature: 80℃ Autosampler thermostat: 5℃ Flow rate: 0.5mL / min Injection volume: 5μL Mobile phase A: 0.05% TFA, HO Mobile phase B: 0.05% TFA, ACN Gradient program (B%): 25%-34% (0-0.7 min), 34%-45% (0.7-5 min), 45%-90% (5-6 min), 90% (6-7 min), 90%-25% (7-7.10 min), 25% (7.10-10 min) (MS parameters) Gas temperature: 350℃ Drying gas: 13L / min Nebulizer pressure: 45psig Capillary voltage: 5000V Fragmenter voltage: 350V Mass range: 500-8000m / z Acquisition speed: 1 spectrum / sec

[0383] (Data Analysis) The ESI scangram allows detection of the light chain bound to the drug molecule (light chain Li bound to the i-drug molecule) and the heavy chain bound to the drug molecule (heavy chain Hi bound to the i-drug molecule).

[0384] The peak area ratio (%) of each strand is calculated based on the total corrected peak area according to the following formula: i Peak area ratio of light chain bound to drug molecule = 100% × A Li / (A L0 +A L1 ) i Peak area ratio of heavy chain bound to drug molecule = 100% × A Hi / (A H0 +A H1 +A H2 +A H3 )

[0385] The average number of bound drug molecules per antibody molecule in an antibody-drug conjugate is calculated according to the following formula: Average number of bound drug molecules = (L0 peak area ratio x 0 + L1 peak area ratio x 1 + H0 peak area ratio x 0 + H1 peak area ratio x 1 + H2 peak area ratio x 2 + H3 peak area ratio x 3) x 2

[0386] Routine Procedure G: Measurement of antibody aggregation in antibody-drug conjugates Aggregation in antibody drug conjugates may be determined by size exclusion chromatography (SEC) in high performance liquid chromatography (HPLC) analysis using the following method.

[0387] HPLC system: Agilent 1260 Infinity II HPLC system (Agilent Technologies, Inc.) Detector: UV absorption spectrometer (measurement wavelength: 280 nm) SEC-column: TOSOH TSKgel G3000SWXL (7.8 x 300 mm, 5 μm) Mobile phase: 200 mmol / L KHPO4, 150 mmol / L NaCl, 15% (v / v) isopropanol, pH 7.0 Flow rate: 0.75mL / min Isocratic work: 18 minutes Column temperature: room temperature Sample injection amount: 50μg

[0388] (Data Analysis) The SEC chromatogram of the quality control (QC, CL069707-H1L1) is shown in Figure 5A, which confirms that the molecular weight of the main QC product is approximately 150 kDa, with a monomer retention time of approximately 9.5–10.5 min, and that the retention time of the aggregates is earlier than that of the monomer.

[0389] Conventional Procedure H: Comparing the hydrophilicity of antibodies in antibody-drug conjugates The hydrophilicity of an antibody drug conjugate may be determined by hydrophobic interaction chromatography (HIC) in a high performance liquid chromatography (HPLC) analysis using the following method.

[0390] HPLC system: Agilent 1260 Infinity II HPLC system (Agilent Technologies, Inc.) Detector: UV absorption spectrometer (measurement wavelength: 280 nm) HIC-column: TOSOH TSKgel Butyl-NPR (inner diameter 4.6 mm x 3.5 cm, 2.5 μm) Mobile phase A: 1.5 mol / L (NH4)2SO4, 50 mmol / L KHPO4, pH 7.0 Mobile phase B: 50 mmol / L KHPO4, 25% (v / v) isopropanol, pH 7.0 Isocratic work: 25 minutes Column temperature: room temperature Gradient program (B%): 0%-25% (0-1 min), 25% (1-3 min), 25%-80% (3-13 min), 80% (13-17 min), 80%-0% (17-17.10 min), 0% (17.10-25 min) Sample injection volume: 10 μL

[0391] (Data Analysis) The HIC chromatogram of the quality control (QC, CL069707-H1L1) is shown in Figure 5B. Compared with the unconjugated antibody, the antibody-drug conjugate exhibits higher hydrophobicity and therefore has a longer retention time. It is confirmed that the shorter the retention time, the better the hydrophilicity of the sample.

[0392] 4.1 Preparation of CL069707-H1L1-drug conjugates 4.1.1 Preparation of Antibody Drug Conjugate CL069707-H1L1-LP1 Step 1: Antibody-drug conjugate Reduction of the antibody. CL069707-H1L1 was reduced using the standard procedure B (1.423 mL mg -1 cm -1 Using the absorbance coefficient at 280 nm (where is used as the absorbance coefficient) and C, the antibody was adjusted to 9 mg / mL with PBS7.0 / EDTA. To this solution (1.099 mL) was added an aqueous solution of 5 mM TCEP (0.101 mL, 7.0 equivalents per antibody molecule). After confirming that the pH of the solution was within 7.0±0.1, the solution was incubated at 37° C. for 2 hours to reduce the interchain disulfide bonds of the antibody.

[0393] For conjugation of the antibody and the linker-payload, the above solution was incubated for 10 minutes at 4° C. Then, a 10 mM solution of LP1 in dimethylacetamide (0.108 mL, 15 equivalents per antibody molecule) was added, and the resulting mixture was incubated for 30 minutes at 22° C. to allow conjugation of the linker-payload to the antibody.

[0394] Purification: The above solution was purified by the normal procedure D described in the manufacturing method to obtain 1.2 mL of a solution containing the title antibody drug conjugate "CL069707-H1L1-LP1".

[0395] Characterization is performed according to the usual procedure E(ε D,280 = 6384, ε D,370 = 16180), Procedure F, Procedure G and Procedure H were used to obtain the following characteristic values:

[0396] Antibody concentration: 7.82 mg / mL, average number of bound drug molecules (n) per antibody molecule measured by routine procedure E: 8.55. Average number of bound drug molecules (n) per antibody molecule measured by routine procedure F: 7.65. Aggregation of antibody-drug conjugate measured by routine procedure G: 2.83% (Figure 6A). Retention time of antibody-drug conjugate measured by routine procedure H: 7.505 min (Figure 6B).

[0397] 4.1.2 Preparation of Antibody Drug Conjugate CL069707-H1L1-LP2 Step 1: Antibody-drug conjugate Reduction of the antibody. CL069707-H1L1 was reduced using the standard procedure B (1.423 mL mg -1 cm -1 Using the absorbance coefficient at 280 nm (where is used as the absorbance coefficient) and C, the antibody was adjusted to 9 mg / mL with PBS7.0 / EDTA. To this solution (1.099 mL) was added an aqueous solution of 5 mM TCEP (0.101 mL, 7.0 equivalents per antibody molecule). After confirming that the pH of the solution was within 7.0±0.1, the solution was incubated at 37° C. for 2 hours to reduce the interchain disulfide bonds of the antibody.

[0398] For conjugation of the antibody and the linker-payload, the above solution was incubated for 10 minutes at 4° C. Then, a 10 mM solution of LP2 in dimethylacetamide (0.108 mL, 15 equivalents per antibody molecule) was added, and the resulting mixture was incubated at 22° C. for 30 minutes to allow the linker-payload to be conjugated to the antibody.

[0399] Purification: The above solution was purified by the normal procedure D described in the manufacturing method to obtain 1.2 mL of a solution containing the title antibody drug conjugate "CL069707-H1L1-LP2".

[0400] Characterization is performed according to the usual procedure E(ε D,280 =5814, ε D,370 = 14742), Procedure F, Procedure G and Procedure H were used to obtain the following characteristic values:

[0401] Antibody concentration: 7.37 mg / mL, average number of bound drug molecules (n) per antibody molecule measured by routine procedure E: 9.27. Average number of bound drug molecules (n) per antibody molecule measured by routine procedure F: 7.72. Aggregation of antibody-drug conjugate measured by routine procedure G: 2.96% (Figure 7A). Retention time of antibody-drug conjugate measured by routine procedure H: 7.820 min (Figure 7B).

[0402] 4.1.3 Preparation of Antibody Drug Conjugate CL069707-H1L1-GGFG-DXd Step 1: Antibody-drug conjugate Reduction of the antibody. CL069707-H1L1 was reduced using the standard procedure B (1.423 mL mg -1 cm -1 Using the absorbance coefficient at 280 nm (where is used as the absorbance coefficient) and C, the antibody was adjusted to 9 mg / mL with PBS7.0 / EDTA. To this solution (0.275 mL) was added an aqueous solution of 5 mM TCEP (0.025 mL, 7.0 equivalents per antibody molecule). After confirming that the pH of the solution was within 7.0±0.1, the solution was incubated at 37° C. for 2 hours to reduce the interchain disulfide bonds of the antibody.

[0403] Conjugation of the antibody and the linker-payload: the above solution was incubated for 10 minutes at 4° C. Then, a 10 mM solution (0.027 mL, 15 equivalents per antibody molecule) of GGFG-DXd (purchased from DC Chemicals, DC7556) in dimethylacetamide was added, and the resulting mixture was incubated at 22° C. for 30 minutes to allow the linker-payload to be conjugated to the antibody.

[0404] Purification: The above solution was purified by the normal procedure D described in the manufacturing method to obtain 0.3 mL of a solution containing the title antibody drug conjugate "CL069707-H1L1-GGFG-DXd".

[0405] Characterization is performed according to the usual procedure E(ε D,280 =5178, ε D,370 = 20217), procedure G and procedure H were used to obtain the following characteristic values:

[0406] Antibody concentration: 6.78 mg / mL, average number of bound drug molecules per antibody molecule (n): 6.88, measured by routine procedure E. Aggregation of antibody-drug conjugates: 0.92%, measured by routine procedure G (Figure 8A). Retention time of antibody-drug conjugates: 8.802 min, measured by routine procedure H (Figure 8B).

[0407] 4.1.4 Preparation of Antibody Drug Conjugate DS-6000a (Herein Referred to as Reference ADC) Step 1: Antibody-drug conjugate The sequence of DS-6000a mAb (referred to herein as the reference antibody) was disclosed in US2020 / 0390900A1 (antibody H01L02). The sequence of the heavy chain variable region of the reference antibody is set forth in SEQ ID NO: 105. The sequence of the light chain variable region of the reference antibody is set forth in SEQ ID NO: 106. The sequences of the heavy and light chain constant regions of the reference antibody are set forth in SEQ ID NO: 70 and SEQ ID NO: 71, respectively. EVQLVQSGAEVKKPGASVKVSCKASGYTFTRNFMHWVRQAPGQGLEWMGWIYPGDGETEYAQKFQGRVTITADTSTSTAYMELSSLRSEDTAVYYCARGVYGGFAGGYFDFWGQGTLVTVSS (SEQ ID NO: 109) DIQMTQSPSSLSASVGDRVTITCKASQNIYKNLAWYQQKPGKAPKLLIYDANTLQTGVPSRFSGSGSGSDFTLTISSLQPEDFATYFCQQYYSGWAFGQGTKVEIK (SEQ ID NO: 110)

[0408] Reduction of the antibody. The reference antibody was reduced using the normal procedure B (1.678 mL mg -1 cm -1 Using the absorbance coefficient at 280 nm (where is used as the absorbance coefficient) and C, the antibody was adjusted to 14.8 mg / mL with PBS7.0 / EDTA. To this solution (0.659 mL) was added an aqueous solution of 5 mM TCEP (0.130 mL, 10.0 equivalents per antibody molecule). After confirming that the pH of the solution was within 7.0±0.1, the solution was incubated at 37° C. for 2 hours to reduce the interchain disulfide bonds of the antibody.

[0409] Conjugation of the antibody to the linker-payload: the above solution was incubated for 10 minutes at 4° C. Then, a 10 mM solution of GGFG-DXd in dimethylacetamide (0.098 mL, 15 equivalents per antibody molecule) was added, and the resulting mixture was incubated at 22° C. for 30 minutes to allow the linker-payload to be conjugated to the antibody.

[0410] Purification: The above solution was purified by the general procedure D described in the manufacturing method to obtain 1.4 mL of a solution containing the title antibody drug conjugate "Reference ADC".

[0411] Characterization is performed according to the usual procedure E(ε D,280 =5178, ε D,370 = 20217), procedure G and procedure H were used to obtain the following characteristic values:

[0412] Antibody concentration: 4.46 mg / mL, average number of bound drug molecules per antibody molecule (n): 7.02, measured by routine procedure E. Aggregation of antibody-drug conjugates: 2.68%, measured by routine procedure G (Figure 9A). Retention time of antibody-drug conjugates: 7.672 min, measured by routine procedure H (Figure 9B).

[0413] 4.1.5 Preparation of Antibody Drug Conjugate Reference Antibody-LP1 Step 1: Antibody-drug conjugate Reduction of the antibody. The reference antibody was reduced using the normal procedure B (1.678 mL mg -1 cm -1 Using the absorbance coefficient at 280 nm (where is used as the absorbance coefficient) and C, the antibody was adjusted to 12.7 mg / mL with PBS7.0 / EDTA. To this solution (0.106 mL) was added an aqueous solution of 5 mM TCEP (12.6 μL, 7 equivalents per antibody molecule). After confirming that the pH of the solution was within 7.0 ± 0.1, the solution was incubated at 37°C for 2 hours to reduce the interchain disulfide bonds of the antibody.

[0414] For conjugation of the antibody and the linker-payload, the above solution was incubated for 10 minutes at 4° C. Then, a 10 mM solution of LP1 in dimethylacetamide (13.5 μL, 15 equivalents per antibody molecule) was added, and the resulting mixture was incubated for 30 minutes at 22° C. to allow conjugation of the linker-payload to the antibody.

[0415] Purification: The above solution was purified by the normal procedure D described in the manufacturing method to obtain 200 μL of a solution containing the title antibody drug conjugate "Reference antibody-LP1".

[0416] Characterization is performed according to the usual procedure E(ε D,280 = 6384, ε D,370 = 16180), procedure G and procedure H were used to obtain the following characteristic values:

[0417] Antibody concentration: 8.07 mg / mL, average number of bound drug molecules per antibody molecule (n): 7.11, measured by routine procedure E. Aggregation of antibody-drug conjugate measured by routine procedure G: 0.89% (Figure 10A). Retention time of antibody-drug conjugate measured by routine procedure H: 6.422 min (Figure 10B).

[0418] 4.1.6 Production of Antibody-Drug Conjugate Human IgG-LP1 Step 1: Antibody-drug conjugate Reduction of the antibody. Human IgG (purchased from Solarbio) was reduced using the standard procedure B (1.35 mL mg -1 cm -1 Using the absorbance coefficient at 280 nm (where is used as the absorbance coefficient) and C, the antibody was adjusted to 10 mg / mL with PBS7.0 / EDTA. To this solution (1.33 mL) was added an aqueous solution of 5 mM TCEP (0.267 mL, 10 equivalents per antibody molecule). After confirming that the pH of the solution was within 7.0 ± 0.1, the solution was incubated at 37°C for 2 hours to reduce the interchain disulfide bonds of the antibody.

[0419] For conjugation of the antibody and the linker-payload, the above solution was incubated for 10 minutes at 4° C. Then, a 10 mM solution of LP1 in dimethylacetamide (0.2 mL, 15 equivalents per antibody molecule) was added, and the resulting mixture was incubated for 30 minutes at 22° C. to allow conjugation of the linker-payload to the antibody.

[0420] Purification: The above solution was purified by the normal procedure D described in the manufacturing method to obtain 2 mL of a solution containing the title antibody-drug conjugate "human IgG-LP1".

[0421] Characterization is performed according to the usual procedure E(ε D,280 = 6384, ε D,370 = 16180), procedure G and procedure H were used to obtain the following characteristic values:

[0422] Antibody concentration: 11.08 mg / mL, average number of bound drug molecules per antibody molecule (n): 9.15, measured by routine procedure E. Aggregation of antibody-drug conjugate measured by routine procedure G: 4.38% (Figure 11A). Retention time of antibody-drug conjugate measured by routine procedure H: 6.213 min (Figure 11B).

[0423] 4.1.7 Production of Antibody-Drug Conjugate Human IgG-LP2 Step 1: Antibody-drug conjugate Reduction of the antibody. Human IgG (purchased from Solarbio) was reduced using the standard procedure B (1.35 mL mg -1 cm -1 Using the absorbance coefficient at 280 nm (where is used as the absorbance coefficient) and C, the antibody was adjusted to 10 mg / mL with PBS7.0 / EDTA. To this solution (0.467 mL) was added an aqueous solution of 5 mM TCEP (0.093 mL, 10 equivalents per antibody molecule). After confirming that the pH of the solution was within 7.0±0.1, the solution was incubated at 37° C. for 2 hours to reduce the interchain disulfide bonds of the antibody.

[0424] For conjugation of the antibody and the linker-payload, the above solution was incubated for 10 minutes at 4° C. Then, a 10 mM solution of LP2 in dimethylacetamide (0.07 mL, 15 equivalents per antibody molecule) was added, and the resulting mixture was incubated at 22° C. for 30 minutes to allow the linker-payload to be conjugated to the antibody.

[0425] Purification: The above solution was purified by the normal procedure D described in the manufacturing method to obtain 1 mL of a solution containing the title antibody-drug conjugate "human IgG-LP2".

[0426] Characterization is performed according to the usual procedure E(ε D,280 =5814, ε D,370 = 14742), procedure G and procedure H were used to obtain the following characteristic values:

[0427] Antibody concentration: 4.68 mg / mL, average number of bound drug molecules per antibody molecule (n): 9.18, measured by routine procedure E. Aggregation of antibody drug conjugate measured by routine procedure G: 2.92% (Figure 12A). Retention time of antibody drug conjugate measured by routine procedure H: 6.506 min (Figure 12B).

[0428] 4.1.8 Production of Antibody-Drug Conjugate Human IgG-GGFG-DXd Step 1: Antibody-drug conjugate Reduction of the antibody. Human IgG (purchased from Solarbio) was reduced using the standard procedure B (1.35 mL mg -1 cm -1 Using the absorbance coefficient at 280 nm (where is used as the absorbance coefficient) and C, the antibody was adjusted to 10 mg / mL with PBS7.0 / EDTA. To this solution (2.45 mL) was added an aqueous solution of 5 mM TCEP (0.327 mL, 10 equivalents per antibody molecule). After confirming that the pH of the solution was within 7.0±0.1, the solution was incubated at 37° C. for 2 hours to reduce the interchain disulfide bonds of the antibody.

[0429] Conjugation of the antibody to the linker-payload: the above solution was incubated for 10 minutes at 4° C. Then, a 10 mM solution of GGFG-DXd in dimethylacetamide (0.294 mL, 18 equivalents per antibody molecule) was added, and the resulting mixture was incubated for 30 minutes at 22° C. to allow the linker-payload to be conjugated to the antibody.

[0430] Purification: The above solution was purified by the normal procedure D described in the manufacturing method to obtain 1 mL of a solution containing the title antibody-drug conjugate "human IgG-GGFG-DXd."

[0431] Characterization is performed according to the usual procedure E(ε D,280 =5178, ε D,370 = 20217), procedure G and procedure H were used to obtain the following characteristic values:

[0432] Antibody concentration: 8.20 mg / mL, average number of bound drug molecules per antibody molecule (n): 7.08, measured by routine procedure E. Aggregation of antibody drug conjugates: 4.25%, measured by routine procedure G (Figure 13A). Retention time of antibody drug conjugates: 8.222 min, measured by routine procedure H (Figure 13B).

[0433] The preparation of the other antibody drug conjugates "CL069707-MMAE", "CL069707-DXd", "CL069066-MMAE", "CL069066-DXd", "CL069439-MMAE" and "CL069439-DXd" was the same as the above samples.

[0434] Example 5: In vitro evaluation of antibody drug conjugates 5.1 Internalization activity of antibody-drug conjugates Human ovarian cancer cell line PA-1 (purchased from Zhejiang Meisen Cell Technology Co., Ltd.), OVCAR-3 (purchased from National Collection of Authenticated Cell Cultures) and human renal cancer cell line 786-O (purchased from Shanghai Xunqing Biotechnology Co., Ltd.) cell cultures were maintained in vitro as independent monolayer cultures at 37°C in an atmosphere of 5% CO2. Cells were harvested by trypsin-EDTA partial digestion, followed by centrifugation at 1000 rpm for 5 min. Cells were resuspended in cold PBS and 50 μg / mL CL069707-H1L1-LP1 was added. After the cell solution was mixed and incubated at 4°C for 30 min, the cells were washed with PBS, divided into 5 equal portions, and incubated at 37°C for 0 h, 0.5 h, 1 h, 2 h, and 4 h. Samples were taken at each time point and washed with cold PBS before adding the second antibody conjugate (for detection). After incubation at 4° C., the cells were washed with PBS and then subjected to flow cytometry (FACS) analysis. The results are shown in Figure 14. CL069707-H1L1-LP1 was internalized by PA-1, OVCAR-3, and 786-O in a time-dependent manner.

[0435] 5.2 In vitro tumor growth inhibition activity of antibody-drug conjugates CDH6-positive human ovarian cancer cell lines OVCAR-3 (purchased from National Collection of Authenticated Cell Cultures) and PA-1 (purchased from Zhejiang Meisen Cell Technology Co., Ltd.) were seeded in medium in a 96-well plate at 2000 cells / 100 μL / well, and then the cells were cultured overnight. The next day, each conjugate was added to the cells to a final concentration of 0.01-100 nM. After 5 days of culture, the medium was removed from the cells and a CCK-8 (Cell Counting Kit-8) viability assay was performed according to the manufacturer's instructions. Cell viability was calculated as a % of the control wells containing only tumor cells. Figures 15A-D show the concentration-dependent cell growth inhibitory activity of each antibody-drug conjugate when added to CDH6-positive OVCAR-3 and PA-1 cells. In Figure 15A and Figure 15B, all humanized CL069707-GGFG-DXd (H1L1, H1L2, H2L1 and H2L2) showed similar excellent tumor cell growth inhibitory activity against OVCAR-3 cells and PA-1 cells. In Figure 15C and Figure 15D, both of the two positive antibody-drug conjugates showed excellent tumor cell growth inhibitory activity, among which CL069707-H1L1-LP1 showed the most significant inhibitory activity against OVCAR-3 cells, followed by CL069707-H1L1-LP2, of which CL069707-H1L1-LP1 and CL069707-H1L1-LP2 showed the same inhibitory activity against PA-1 cells.

[0436] Example 6: In vitro cytotoxic activity of murine anti-CDH6 antibodies CL069707, CL069439, CL069066 conjugated to vc-MMAE or GGFG-DXd CDH6-positive human ovarian cancer cell line OVCAR-3 (purchased from the National Collection of Authenticated Cell Cultures) was seeded at 2000 cells / 100 μL / well in medium in a 96-well plate, and then the cells were cultured overnight. The next day, CL069707-vc-MMAE, CL069439-vc-MMAE, and CL069066-vc-MMAE were added to the cells to a final concentration of 0.005–30 nM, respectively, and CL069707-GGFG-DXd, CL069439-GGFG-DXd, and CL069066-GGFG-DXd were added to the cells to a final concentration of 0.05–300 nM, respectively. After 5 days of culture, the medium was removed from the cells and a CCK-8 (Cell Counting Kit-8) viability assay was performed according to the manufacturer's instructions. Cell viability was calculated as % of control wells containing only tumor cells. Figure 16A shows that all three conjugates had concentration-dependent cell growth inhibitory activity against OVCAR-3 cells. Furthermore, CL069707-vc-MMAE showed stronger cytotoxic activity than CL069439-vc-MMAE and CL069066-vc-MMAE. Figure 16B shows that all three conjugates had concentration-dependent cell growth inhibitory activity against OVCAR-3 cells. Furthermore, CL069707-GGFG-DXd showed stronger cytotoxic activity than CL069439-GGFG-DXd and CL069066-GGFG-DXd.

[0437] Example 7: In vivo antitumor efficacy of antibody drug conjugates in PA-1 xenograft model Six-week-old female Balb / c mice were purchased from JSJ Laboratory (Shanghai, China). Human ovarian cancer cell line PA-1 (purchased from Zhejiang Meisen Cell Technology Co., Ltd.) cells were mixed with Matrigel and then subcutaneously implanted at 10 million cells per animal. 15 days after PA-1 cell implantation (average tumor size was approximately 150 mm 3) Mice were intravenously injected with one of IgG-LP2, CL069707-H1L1-LP1, CL069707-H1L1-LP2 or CL069707-H1L1-GGFG-DXd at 10 mg / kg. Tumor volumes were measured twice a week from the start of treatment using calipers, and TV = (width x length). 2 The tumor volume was calculated from the formula: ##EQU1## The results are shown in Figures 17A and 17B. All antibody-drug conjugates significantly reduced tumor volume after single-dose administration without significantly affecting the body weight of the mice.

[0438] Example 8: In vivo antitumor efficacy of antibody drug conjugates in PA-1 xenograft model Six-week-old female Balb / c mice were purchased from JSJ Laboratory (Shanghai, China). Human ovarian cancer cell line PA-1 (purchased from Zhejiang Meisen Cell Technology Co., Ltd.) cells were mixed with Matrigel and then subcutaneously implanted at 10 million cells per animal. Fourteen days after PA-1 cell implantation (average tumor size was approximately 150 mm 3 Mice were intravenously injected with PBS, CL069707-H1L1-LP1 (2.5 mg / kg and 5 mg / kg), CL069707-H1L1-LP2 (2.5 mg / kg and 5 mg / kg), or CL069707-H1L1-GGFG-DXd (5 mg / kg). Tumor volumes were measured twice a week from the start of treatment using calipers, and TV = (width x length). 2 The tumor volume was calculated from the ratio of 0.01 to 0.01 / 2. The results are shown in Figures 18A and 18B. All antibody-drug conjugates dose-dependently reduced tumor volume after single-dose administration without significant effect on mouse body weight. In particular, CL067707-H1L1-LP1 at 5 mg / kg had a better tumor-inhibiting effect than CL069707-H1L1-LP2 and CL067707-H1L1-GGFG-DXd.

[0439] Example 9: In vivo antitumor efficacy of antibody-drug conjugates in the OVCAR-3 xenograft model Balb / c mice aged 6 to 8 weeks were purchased from Shanghai Lingchang Biotechnology Co., Ltd. (Shanghai, China). Human ovarian cancer cell line OVCAR-3 (ATCC-HTB-161) cells were mixed with Matrigel and then subcutaneously implanted at 10 million cells per animal. Thirty-five days after OVCAR-3 cell implantation (average tumor size was approximately 150 mm 3 ) Mice were intravenously injected with either PBS or 10 mg / kg CL069707-H1L1-LP1. Tumor volumes were measured twice a week from the start of treatment using calipers, and TV = (width x length). 2 The results are shown in Figures 19A and 19B. A single dose of CL069707-H1L1-LP1 significantly reduced the tumor volume without affecting the body weight of the mice.

[0440] Example 10: In vivo antitumor efficacy of antibody drug conjugates in the 786-O xenograft model Six-week-old NCG mice were purchased from gempharmatech (Suzhou, China). Human renal cancer cell line 786-O (purchased from Shanghai Xunqing Biotechnology Co., Ltd.) cells were resuspended in serum-free medium and then subcutaneously implanted at 6.5 million cells per animal. 15 days after 786-O cell implantation (average tumor size was approximately 150 mm 3 On days 10 and 13, mice were intravenously injected with PBS, 10 mg / kg IgG-LP1, or 10 mg / kg CL069707-H1L1-LP1. Tumor volumes were measured twice a week from the start of treatment using calipers, and TV = (width x length). 2 The results were calculated from the formula: ##EQU1## The results are shown in Figures 20A and 20B. CL069707-H1L1-LP1 significantly reduced the tumor volume without affecting the body weight of the mice, when compared to IgG-LP1.

[0441] Example 11: In vivo antitumor efficacy of antibody-drug conjugates in renal cancer patient-derived xenograft (PDX) models Six to eight week old Nu / Nu mice were purchased from Zhejiang Charles River Co., Ltd. The tumors were sliced ​​into pieces of 3 mm × 3 mm × 3 mm (approximately 50 to 90 mg) and subcutaneously implanted into the right flank of the mice. The tumor growth and body weight of the animals were then checked daily. The average tumor volume was approximately 150 mm 3 When the tumor volume reached 100 mg / kg, the mice were randomly divided into 5 groups. The day of grouping was considered as day 0. Then, the mice were intravenously injected with 10 mg / kg of IgG-LP1, CL069707-H1L1-LP1, IgG-GGFG-DXd, reference ADC, and reference antibody-LP1. The tumor volume was measured with a caliper twice a week from the start of treatment, and TV=(width × length). 2 The ratio was calculated from the mean tumor growth rate (Tg / 2) of the mice treated with IgG-LP1 and IgG-GGFG-DXd, respectively. The results are shown in Figures 21A and 21B. CL069707-H1L1-LP1 significantly reduced tumor volume without affecting the body weight of the mice when compared to IgG-LP1, followed by the reference antibody-LP1. The reference ADC did not show tumor growth suppression activity when compared to IgG-GGFG-DXd.

[0442] Example 12: Preparation of mouse monoclonal antibody hybridoma cells of CDH6 protein 12.1 Antigen Preparation The CDH6 extracellular domain (Ser 54-Ala 615) was used as the immunogen, and the antigen was purchased from ACRO Biosystems with catalog number CA6-H5229.

[0443] 12.2 Immunization of mice Each antigen group was used to immunize 12 Balb / c mice (8-12 weeks old), and the serum titers of the immunized mice were monitored to determine the optimal number of immunizations. The optimized adjuvant and immunization method could generate antibodies (IgG subtype) with high affinity to most antigen polypeptides. After the first immunization, 3-4 boost immunizations were performed, and mouse serum was collected after boost immunization to detect the titer (recombinant protein was used as antigen coating). Mice with serum with a competent titer were boosted for fusion, and mice with serum with an incompetent titer continued with 1-2 boosts until they reached the highest titer before fusion.

[0444] 12.3 Serological detection and screening Blood was collected from the orbit of the immunized mice and serum titers were detected by ELISA (recombinant protein was used as antigen coating). The serum titers had to be above 10K, otherwise the boost immunization was continued.

[0445] 12.4 Fusion and Screening The entire spleen and half of the lymph node were harvested and fused with the myeloma SP2 / 0 cell line. The process was an optimized PEG fusion. The fused cells were plated in four 384-well plates (10 per well). 2 ~10 4 The cells were seeded in 100 wells (1000 cells) and cultured. The supernatants from all wells were collected and the positive cell lines were screened by ELISA to detect the response of the cell supernatants to the CDH6 recombinant protein, and the mirrored wells of the cells were transferred to a 96-well plate for further culture. After several days of growth, the supernatants from all wells were collected and the reactivity with the CDH6 recombinant protein was detected by ELISA. For further affinity ranking, the binding ability of the cell supernatants to the CDH6 recombinant protein at various dilutions was detected for the positive wells, and 120 parent clones with the highest affinity were selected for subcloning.

[0446] 12.5 Subcloning and Screening Subcloning was performed by limiting dilution and ELISA screening to obtain monoclonal hybridoma cells. The cells were seeded in a 96-well plate and cultured to cover about 1 / 6 of the bottom of the plate. The response of the supernatant of each well to CDH6 recombinant protein was detected by ELISA, and two wells with high OD values ​​and good cell conditions were used for the next subcloning. The above steps were repeated until the positive rate of the cell line in the well was 100%. Then, a monoclonal cell line was obtained. After the last subcloning round, all positive cells were immediately expanded, some were frozen for later use, and the other part was prepared as ascites.

[0447] 12.6 Ascites preparation and antibody purification Finally, 13 monoclonal cell lines were obtained and injected into the abdomen of F1 mice for antibody production, and the generated ascites was purified with protein A / G and used for subsequent detection.

[0448] Example 13: Antigen-binding activity of antibodies Recombinant protein CDH6 was coated on an ELISA plate at 1 μg / mL and kept at 4 °C overnight. After washing with PBST, 10% fetal bovine serum was added to the plate, and the mixture was blocked at 37 °C for 1 h. CDH6 monoclonal antibody was added at 13 different dilutions (0.1-100 ng / mL) to the plate, and the mixture was reacted at 37 °C for 1 h. After washing with PBST, horseradish peroxidase-labeled goat anti-human IgG secondary antibody (goat anti-mouse (HRP), Thermo Fisher Scientific) was added to the plate, and the mixture was reacted at 37 °C for 30 min. After washing the plate repeatedly with PBST five times, the droplets remaining on the absorbent paper were tapped as lightly as possible. 100 μL of TMB (eBioscience) was added to each well of the plate, and the plate was placed in the dark at room temperature (20 ± 5 °C) for 1.5 min. The substrate reaction was stopped by adding 100 μL of 2N H2SO4 stop buffer to each well of the plate, and the OD value at 450 nm was read using a microplate reader to analyze the binding ability of the antibodies to the target antigen CDH6. As shown in Table 1 and Figure 23, the sensitivity of the anti-CDH6 antibodies and CDH6 recombinant proteins of the present application was 12.5 ng / mL or less, of which No. 13 (CL069463 antibody) was 3.125 ng / mL or less, No. 23 (CL069707 antibody) was 1.56 ng / mL or less, No. 4 (CL069066 antibody) was 6.3 ng / mL or less, and No. 16 (CL069439 antibody) was 1.0 ng / mL or less. [Table 4]

[0449] Example 14: Specific recognition of cell surface expressed CDH6 antigen by antibodies The binding of 13 CDH6 monoclonal antibodies to CDH6 on the cell surface was analyzed by flow cytometry (FCM) using OVCAR-3 cells (human ovarian cancer cells) as positive cells and HepG2 cells (human liver cancer cells) as negative cells. Logarithmic growth phase cells were harvested and 5 × 10 6The cells were adjusted to a cell density of 100 cells / mL and pre-cooled on ice. Thirteen CDH6 monoclonal antibodies were diluted to 20 μg / mL in pre-cooled saline containing 2% FBS. 100 μL of cells were taken and an equal amount of the diluted CDH6 monoclonal antibodies was added, and the mixture was reacted in the dark at 4°C for 30 minutes. After the reaction was completed, the cells were washed twice with pre-cooled saline containing 2% FBS (6000 rpm, 45 seconds). The secondary antibody PE anti-mouse IgG (BD Pharmingen) was diluted 1:500 in pre-cooled saline containing 2% FBS, and each washed cell was resuspended in 100 μL of the diluted secondary antibody and reacted in the dark at 4°C for 30 minutes. After the reaction was completed, the cells were washed twice with pre-cooled saline containing 2% FBS (6000 rpm, 45 seconds). The cells were resuspended in 400 μL of saline. The ability of antibodies to bind to cell surface antigens was analyzed using a flow cytometer (BD Calibur).

[0450] The results are shown in Figure 24. The results showed that 11 antibodies, including CL069463 and CL069707, were able to specifically recognize OVCAR-3 cells (human ovarian cancer cells) (Figure 24), but no binding was observed to negative cells, HepG2 cells (human liver cancer cells).

[0451] While preferred embodiments of the present invention have been shown and described herein, it will be apparent to those skilled in the art that such embodiments are provided by way of example only. The present invention is not intended to be limited by the specific examples provided herein. Although the present invention has been described with reference to the above specification, the description and illustration of the embodiments herein should not be construed in a limiting sense. Numerous changes, modifications, and substitutions will occur to those skilled in the art without departing from the present invention. Furthermore, it should be understood that all aspects of the present invention are not limited to the specific descriptions, configurations, or relative proportions set forth herein, which depend upon a variety of conditions and variables.

[0452] While preferred embodiments of the present invention have been shown and described herein, it will be apparent to those skilled in the art that such embodiments are provided by way of example only. The present invention is not intended to be limited by the specific examples provided herein. Although the present invention has been described with reference to the above specification, the description and illustration of the embodiments herein should not be construed in a limiting sense. Numerous changes, modifications, and substitutions will occur to those skilled in the art without departing from the present invention. Furthermore, it should be understood that all aspects of the present invention are not limited to the specific descriptions, configurations, or relative proportions set forth herein, which depend upon a variety of conditions and variables.

[0453] It is understood that various alternative forms of the embodiments of the invention described herein may be used in practicing the invention. It is therefore contemplated that the invention will cover such alternatives, modifications, variations, or equivalents. It is intended that the following claims define the scope of the invention, and that methods, structures, and equivalents thereof that fall within the scope of these claims will be covered thereby.

[0454] (References) (1) Wheelock, MJ and Johnson, KR (2003) Annu Rev Cell Dev Biol 19,207-35. (2) Christofori, G. (2003) EMBO J 22, 2318-23. (3)Hazan,RB et al.(2004) Ann NY Acad Sci 1014,155-63. (4) Bryant, DM and Stow, JL (2004) Trends Cell Biol 14,427-34. (5)Rabascio, C. et al. (2004) Cancer Res 64,4373-7. (6) Yamaoka-Tojo, M. et al. (2006) Arterioscler Thromb Vasc Biol 26,1991-7. (7)Patel, IS et al. (2003) Int J Cancer 106,172-7. (8) Sanders, DS et al. (2000) J Pathol 190,526-30. (9)Goeppert,B. et al. (2016) Epigenetics 11,780-790. (10)Zhao,L. et al.(2016) Clin Endocrinol(Oxf)84,748-55. (11)Sancisi,V. et al. (2013) PLoS One 8,e75489. (12)Gugnoni,M. et al. (2017) Oncogene 36,667-677. (13)Bialucha, CU et al. (2017) Cancer Discov 7,1030-1045.

Claims

1. i) capable of binding to CDH6 protein with a sensitivity of less than 12.5 ng / mL in an ELISA assay; ii) Approximately 3.1 x 10 in ELISA assays -9 It is capable of binding to CDH6 protein with a K value of less than M; and iii) having an activity of being internalized into CDH6-expressing cells by binding to CDH6; An antigen binding protein having one or more of the above properties.

2. 2. The antigen binding protein of claim 1, wherein the CDH6 is a mammalian CDH6 protein.

3. 3. The antigen-binding protein of claim 1 or 2, wherein the CDH6 is a human CDH6 protein.

4. Competes with a reference antibody for binding to the CDH6 protein, said reference antibody comprising a light chain variable region (VL) and a heavy chain variable region (VH), wherein: The VH comprises the amino acid sequence set forth in SEQ ID NO: 18, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 23; or The antigen-binding protein of any one of claims 1 to 3, wherein the VH comprises the amino acid sequence shown in SEQ ID NO: 41 and the VL comprises the amino acid sequence shown in SEQ ID NO:

46.

5. 5. The antigen-binding protein of any one of claims 1 to 4, comprising an antibody or an antigen-binding fragment thereof.

6. 6. The antigen-binding protein of claim 5, wherein the antibody or antigen-binding fragment thereof comprises a monoclonal antibody, a polyclonal antibody, a dimer, a polymer, a multispecific antibody, a complete antibody, a human antibody, a humanized antibody or a chimeric antibody.

7. The antigen-binding fragment may be a Fab, Fab', Fv fragment, F(ab') 2 7. The antigen-binding protein of claim 5 or 6, comprising a FcFv, a scFv, a di-scFv and / or a dAb.

8. The antigen-binding protein of any one of claims 5 to 7, wherein the antibody comprises a chimeric antibody, a humanized antibody and / or a human antibody.

9. The antigen-binding protein of any one of claims 5 to 8, wherein the antibody is a monoclonal antibody.

10. 10. The antigen binding protein of any one of claims 1 to 9, comprising at least one CDR of a heavy chain variable region (VH), wherein said VH comprises the amino acid sequence set forth in SEQ ID NO:18, SEQ ID NO:66, SEQ ID NO:41, SEQ ID NO:67, SEQ ID NO:95 or SEQ ID NO:

103.

11. 11. The antigen binding protein of any one of claims 1 to 10, comprising at least one CDR of a light chain variable region (VL), wherein said VL comprises the amino acid sequence set forth in SEQ ID NO:23, SEQ ID NO:68, SEQ ID NO:46, SEQ ID NO:69, SEQ ID NO:96 or SEQ ID NO:

104.

12. 12. The antigen binding protein of any one of claims 1 to 11, comprising a VH, wherein the VH comprises HCDR1, HCDR2 and HCDR3, and the HCDR1 comprises the amino acid sequence shown in SEQ ID NO:

1.

13. 13. The antigen binding protein of any one of claims 1 to 12, comprising a VH, wherein said VH comprises HCDR1, HCDR2 and HCDR3, and said HCDR1 comprises the amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:8, SEQ ID NO:89 or SEQ ID NO:

97.

14. 14. The antigen binding protein of any one of claims 1 to 13, comprising a VH, wherein said VH comprises HCDR1, HCDR2 and HCDR3, and said HCDR2 comprises the amino acid sequence set forth in SEQ ID NO:3, SEQ ID NO:9, SEQ ID NO:90 or SEQ ID NO:

98.

15. 15. The antigen binding protein of any one of claims 1 to 14, comprising a VH, wherein said VH comprises HCDR1, HCDR2 and HCDR3, and said HCDR3 comprises the amino acid sequence set forth in SEQ ID NO:4, SEQ ID NO:10, SEQ ID NO:91 or SEQ ID NO:

99.

16. 16. The antigen binding protein of any one of claims 1 to 15, comprising a VH, wherein the VH comprises HCDR1, HCDR2 and HCDR3, wherein the HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 1, the HCDR2 comprises the amino acid sequence shown in SEQ ID NO: 3 or SEQ ID NO: 9, and the HCDR3 comprises the amino acid sequence shown in SEQ ID NO: 4 or SEQ ID NO:

10.

17. a VH, wherein the VH comprises HCDR1, HCDR2 and HCDR3, wherein the HCDR1 comprises the amino acid sequence set forth in SEQ ID NO:1, the HCDR2 comprises the amino acid sequence set forth in SEQ ID NO:3, and the HCDR3 comprises the amino acid sequence set forth in SEQ ID NO:4; or The antigen-binding protein of any one of claims 1 to 16, wherein the HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 1, the HCDR2 comprises the amino acid sequence shown in SEQ ID NO: 9, and the HCDR3 comprises the amino acid sequence shown in SEQ ID NO:

10.

18. VH, wherein the VH comprises HCDR1, HCDR2 and HCDR3, wherein the HCDR1 comprises the amino acid sequence set forth in SEQ ID NO:2, the HCDR2 comprises the amino acid sequence set forth in SEQ ID NO:3, and the HCDR3 comprises the amino acid sequence set forth in SEQ ID NO:4; or The HCDR1 comprises the amino acid sequence represented by SEQ ID NO: 8, the HCDR2 comprises the amino acid sequence represented by SEQ ID NO: 9, and the HCDR3 comprises the amino acid sequence represented by SEQ ID NO: 10; wherein the HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 89, the HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 90, and the HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 91; or wherein the HCDR1 comprises the amino acid sequence shown in SEQ ID NO:97, the HCDR2 comprises the amino acid sequence shown in SEQ ID NO:98, and the HCDR3 comprises the amino acid sequence shown in SEQ ID NO:

99. The antigen-binding protein of any one of claims 1 to 17.

19. 19. The antigen binding protein of any one of claims 1 to 18, comprising a VH, wherein the VH comprises a framework region HFR1, the C-terminus of the HFR1 is directly or indirectly linked to the N-terminus of the HCDR1, and the HFR1 comprises the amino acid sequence shown in SEQ ID NO: 14, SEQ ID NO: 24, SEQ ID NO: 37, SEQ ID NO: 47 or SEQ ID NO:

52.

20. 20. The antigen binding protein of any one of claims 1 to 19, comprising a VH, wherein said VH comprises a framework region HFR2, said HFR2 being located between said HCDR1 and said HCDR2, and said HFR2 comprising the amino acid sequence set forth in SEQ ID NO: 15, SEQ ID NO: 28, SEQ ID NO: 38 or SEQ ID NO:

48.

21. 21. The antigen binding protein of any one of claims 1 to 20, comprising a VH, wherein said VH comprises a framework region HFR3, said HFR3 being located between said HCDR2 and said HCDR3, and said HFR3 comprising the amino acid sequence set forth in SEQ ID NO: 16, SEQ ID NO: 25, SEQ ID NO: 39, SEQ ID NO: 49 or SEQ ID NO:

53.

22. 22. The antigen binding protein of any one of claims 1 to 21, comprising a VH, wherein said VH comprises a framework region HFR4, the N-terminus of said HFR4 is directly or indirectly linked to the C-terminus of said HCDR3, and said HFR4 comprises the amino acid sequence set forth in SEQ ID NO: 17, SEQ ID NO: 26, SEQ ID NO: 40 or SEQ ID NO:

50.

23. a VH, wherein the VH comprises framework regions HFR1, HFR2, HFR3 and HFR4, the C-terminus of the HFR1 is directly or indirectly linked to the N-terminus of the HCDR1, the HFR2 is located between the HCDR1 and the HCDR2, the HFR3 is located between the HCDR2 and the HCDR3, and the N-terminus of the HFR4 is directly or indirectly linked to the C-terminus of the HCDR3, wherein the HFR1 comprises the amino acid sequence set forth in SEQ ID NO: 14, the HFR2 comprises the amino acid sequence set forth in SEQ ID NO: 15, the HFR3 comprises the amino acid sequence set forth in SEQ ID NO: 16, and the HFR4 comprises the amino acid sequence set forth in SEQ ID NO: 17; or the HFR1 comprises the amino acid sequence set forth in SEQ ID NO:24, the HFR2 comprises the amino acid sequence set forth in SEQ ID NO:15, the HFR3 comprises the amino acid sequence set forth in SEQ ID NO:25, and the HFR4 comprises the amino acid sequence set forth in SEQ ID NO:26; or the HFR1 comprises the amino acid sequence set forth in SEQ ID NO:24, the HFR2 comprises the amino acid sequence set forth in SEQ ID NO:28, the HFR3 comprises the amino acid sequence set forth in SEQ ID NO:25, and the HFR4 comprises the amino acid sequence set forth in SEQ ID NO:26; or the HFR1 comprises the amino acid sequence set forth in SEQ ID NO:37, the HFR2 comprises the amino acid sequence set forth in SEQ ID NO:38, the HFR3 comprises the amino acid sequence set forth in SEQ ID NO:39, and the HFR4 comprises the amino acid sequence set forth in SEQ ID NO:40; or the HFR1 comprises the amino acid sequence set forth in SEQ ID NO:47, the HFR2 comprises the amino acid sequence set forth in SEQ ID NO:48, the HFR3 comprises the amino acid sequence set forth in SEQ ID NO:49, and the HFR4 comprises the amino acid sequence set forth in SEQ ID NO:50; or The antigen-binding protein of claims 1 to 22, wherein the HFR1 comprises the amino acid sequence shown in SEQ ID NO:52, the HFR2 comprises the amino acid sequence shown in SEQ ID NO:38, the HFR3 comprises the amino acid sequence shown in SEQ ID NO:53, and the HFR4 comprises the amino acid sequence shown in SEQ ID NO:

26.

24. 24. The antigen binding protein of any one of claims 1 to 23, comprising a VH, wherein said VH comprises the amino acid sequence set forth in SEQ ID NO:18, SEQ ID NO:66, SEQ ID NO:41, SEQ ID NO:67, SEQ ID NO:95 or SEQ ID NO:

103.

25. 25. An antigen-binding protein according to any one of claims 1 to 24, comprising an antibody heavy chain constant region.

26. 26. The antigen binding protein of claim 25, wherein the antibody heavy chain constant region comprises a constant region derived from human IgG.

27. 26. The antigen binding protein of claim 25, wherein the antibody heavy chain constant region comprises a constant region derived from human IgG1, IgG2, IgG3 or IgG4.

28. 26. The antigen binding protein of claim 25, wherein the antibody heavy chain constant region comprises the amino acid sequence set forth in SEQ ID NO:

70.

29. 29. The antigen binding protein of any one of claims 1 to 28, comprising an antibody heavy chain, wherein said antibody heavy chain comprises the amino acid sequence set forth in SEQ ID NO:72, SEQ ID NO:85, SEQ ID NO:80 or SEQ ID NO:

87.

30. 30. The antigen binding protein of any one of claims 1 to 29, comprising a VL, wherein said VL comprises LCDR1, LCDR2 and LCDR3, and said LCDR1 comprises the amino acid sequence set forth in SEQ ID NO:5, SEQ ID NO:11, SEQ ID NO:92 or SEQ ID NO:

100.

31. 31. The antigen binding protein of any one of claims 1 to 30, comprising a VL, wherein said VL comprises LCDR1, LCDR2 and LCDR3, and said LCDR2 comprises the amino acid sequence set forth in SEQ ID NO:6, SEQ ID NO:12, SEQ ID NO:93 or SEQ ID NO:

101.

32. 32. The antigen binding protein of any one of claims 1 to 31, comprising a VL, wherein said VL comprises LCDR1, LCDR2 and LCDR3, and said LCDR3 comprises the amino acid sequence set forth in SEQ ID NO:7, SEQ ID NO:13, SEQ ID NO:94 or SEQ ID NO:

102.

33. VL, wherein the VL comprises LCDR1, LCDR2 and LCDR3, wherein the LCDR1 comprises the amino acid sequence set forth in SEQ ID NO:5, the LCDR2 comprises the amino acid sequence set forth in SEQ ID NO:6 and the LCDR3 comprises the amino acid sequence set forth in SEQ ID NO:7; or the LCDR1 comprises the amino acid sequence set forth in SEQ ID NO:11, the LCDR2 comprises the amino acid sequence set forth in SEQ ID NO:12, and the LCDR3 comprises the amino acid sequence set forth in SEQ ID NO:13; or wherein the LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 92, the LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 93, and the LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 94; or wherein said LCDR1 comprises the amino acid sequence represented by SEQ ID NO: 100, said LCDR2 comprises the amino acid sequence represented by SEQ ID NO: 101, and said LCDR3 comprises the amino acid sequence represented by SEQ ID NO:

102. The antigen-binding protein of any one of claims 1 to 32.

34. comprising a VH and a VL, wherein the VH comprises HCDR1, HCDR2 and HCDR3, and the VL comprises LCDR1, LCDR2 and LCDR3, wherein the HCDR1 comprises the amino acid sequence set forth in SEQ ID NO:1, the HCDR2 comprises the amino acid sequence set forth in SEQ ID NO:3, the HCDR3 comprises the amino acid sequence set forth in SEQ ID NO:4, the LCDR1 comprises the amino acid sequence set forth in SEQ ID NO:5, the LCDR2 comprises the amino acid sequence set forth in SEQ ID NO:6, and the LCDR3 comprises the amino acid sequence set forth in SEQ ID NO:7, or The antigen-binding protein of any one of claims 1 to 33, wherein the HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 1, the HCDR2 comprises the amino acid sequence shown in SEQ ID NO: 9, the HCDR3 comprises the amino acid sequence shown in SEQ ID NO: 10, the LCDR1 comprises the amino acid sequence shown in SEQ ID NO: 11, the LCDR2 comprises the amino acid sequence shown in SEQ ID NO: 12, and the LCDR3 comprises the amino acid sequence shown in SEQ ID NO:

13.

35. comprising a VH and a VL, wherein the VH comprises HCDR1, HCDR2 and HCDR3, and the VL comprises LCDR1, LCDR2 and LCDR3, wherein the HCDR1 comprises the amino acid sequence set forth in SEQ ID NO:2, the HCDR2 comprises the amino acid sequence set forth in SEQ ID NO:3, the HCDR3 comprises the amino acid sequence set forth in SEQ ID NO:4, the LCDR1 comprises the amino acid sequence set forth in SEQ ID NO:5, the LCDR2 comprises the amino acid sequence set forth in SEQ ID NO:6, and the LCDR3 comprises the amino acid sequence set forth in SEQ ID NO:7, or the HCDR1 comprises the amino acid sequence set forth in SEQ ID NO:8, the HCDR2 comprises the amino acid sequence set forth in SEQ ID NO:9, the HCDR3 comprises the amino acid sequence set forth in SEQ ID NO:10, the LCDR1 comprises the amino acid sequence set forth in SEQ ID NO:11, the LCDR2 comprises the amino acid sequence set forth in SEQ ID NO:12, and the LCDR3 comprises the amino acid sequence set forth in SEQ ID NO:13; or wherein HCDR1 comprises the amino acid sequence set forth in SEQ ID NO:89, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO:90, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO:91, LCDR1 comprises the amino acid sequence set forth in SEQ ID NO:92, LCDR2 comprises the amino acid sequence set forth in SEQ ID NO:93, and LCDR3 comprises the amino acid sequence set forth in SEQ ID NO:94; or wherein HCDR1 comprises the amino acid sequence shown in SEQ ID NO:97, HCDR2 comprises the amino acid sequence shown in SEQ ID NO:98, HCDR3 comprises the amino acid sequence shown in SEQ ID NO:99, LCDR1 comprises the amino acid sequence shown in SEQ ID NO:100, LCDR2 comprises the amino acid sequence shown in SEQ ID NO:101, and LCDR3 comprises the amino acid sequence shown in SEQ ID NO:

102. The antigen-binding protein of any one of claims 1 to 34.

36. 36. The antigen binding protein of any one of claims 1 to 35, comprising a VL, wherein the VL comprises a framework region LFR1, the C-terminus of the LFR1 is directly or indirectly linked to the N-terminus of the LCDR1, and the LFR1 comprises the amino acid sequence shown in SEQ ID NO: 19, SEQ ID NO: 30, SEQ ID NO: 42, SEQ ID NO: 55, SEQ ID NO: 59 or SEQ ID NO:

64.

37. 37. The antigen binding protein of any one of claims 1 to 36, comprising a VL, wherein said VL comprises a framework region LFR2, said LFR2 being located between said LCDR1 and said LCDR2, and said LFR2 comprising the amino acid sequence set forth in SEQ ID NO:20, SEQ ID NO:31, SEQ ID NO:43, SEQ ID NO:56 or SEQ ID NO:

60.

38. 38. The antigen binding protein of any one of claims 1 to 37, comprising a VL, wherein said VL comprises a framework region LFR3, said LFR3 being located between said LCDR2 and said LCDR3, and said LFR3 comprises the amino acid sequence set forth in SEQ ID NO:21, SEQ ID NO:32, SEQ ID NO:35, SEQ ID NO:44, SEQ ID NO:57 or SEQ ID NO:

61.

39. 39. The antigen binding protein of any one of claims 1 to 38, comprising a VL, wherein the VL comprises a framework region LFR4, the N-terminus of the LFR4 is directly or indirectly linked to the C-terminus of the LCDR3, and the LFR4 comprises the amino acid sequence shown in SEQ ID NO:22, SEQ ID NO:33, SEQ ID NO:45 or SEQ ID NO:

62.

40. VL, wherein the VL comprises framework regions LFR1, LFR2, LFR3 and LFR4, wherein the C-terminus of LFR1 is directly or indirectly linked to the N-terminus of the LCDR1, the LFR2 is located between the LCDR1 and the LCDR2, the LFR3 is located between the LCDR2 and the LCDR3, and the N-terminus of LFR4 is directly or indirectly linked to the C-terminus of the LCDR3, wherein the LFR1 comprises the amino acid sequence set forth in SEQ ID NO: 19, the LFR2 comprises the amino acid sequence set forth in SEQ ID NO: 20, the LFR3 comprises the amino acid sequence set forth in SEQ ID NO: 21, and the LFR4 comprises the amino acid sequence set forth in SEQ ID NO: 22; or said LFR1 comprises the amino acid sequence shown in SEQ ID NO: 30, said LFR2 comprises the amino acid sequence shown in SEQ ID NO: 31, said LFR3 comprises the amino acid sequence shown in SEQ ID NO: 32, and said LFR4 comprises the amino acid sequence shown in SEQ ID NO: 33; or said LFR1 comprises the amino acid sequence shown in SEQ ID NO: 30, said LFR2 comprises the amino acid sequence shown in SEQ ID NO: 31, said LFR3 comprises the amino acid sequence shown in SEQ ID NO: 35, and said LFR4 comprises the amino acid sequence shown in SEQ ID NO: 33; or said LFR1 comprises the amino acid sequence shown in SEQ ID NO: 42, said LFR2 comprises the amino acid sequence shown in SEQ ID NO: 43, said LFR3 comprises the amino acid sequence shown in SEQ ID NO: 44, and said LFR4 comprises the amino acid sequence shown in SEQ ID NO: 45; or said LFR1 comprises the amino acid sequence set forth in SEQ ID NO:55, said LFR2 comprises the amino acid sequence set forth in SEQ ID NO:56, said LFR3 comprises the amino acid sequence set forth in SEQ ID NO:57, and said LFR4 comprises the amino acid sequence set forth in SEQ ID NO:45; or said LFR1 comprises the amino acid sequence set forth in SEQ ID NO:59, said LFR2 comprises the amino acid sequence set forth in SEQ ID NO:60, said LFR3 comprises the amino acid sequence set forth in SEQ ID NO:61, and said LFR4 comprises the amino acid sequence set forth in SEQ ID NO:62; or The antigen-binding protein of any one of claims 1 to 39, wherein the LFR1 comprises the amino acid sequence shown in SEQ ID NO: 64, the LFR2 comprises the amino acid sequence shown in SEQ ID NO: 60, the LFR3 comprises the amino acid sequence shown in SEQ ID NO: 61, and the LFR4 comprises the amino acid sequence shown in SEQ ID NO:

62.

41. 41. The antigen binding protein of any one of claims 1 to 40, comprising a VL, wherein said VL comprises the amino acid sequence set forth in SEQ ID NO:23, SEQ ID NO:68, SEQ ID NO:46, SEQ ID NO:69, SEQ ID NO:96 or SEQ ID NO:

104.

42. VH and VL, wherein the VH comprises the amino acid sequence set forth in SEQ ID NO: 18 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 23; or The VH comprises the amino acid sequence set forth in SEQ ID NO: 41, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 46; or The VH comprises the amino acid sequence set forth in SEQ ID NO:66, and the VL comprises the amino acid sequence set forth in SEQ ID NO:68; or The VH comprises the amino acid sequence set forth in SEQ ID NO:67, and the VL comprises the amino acid sequence set forth in SEQ ID NO:69; or wherein VH comprises the amino acid sequence set forth in SEQ ID NO:95 and VL comprises the amino acid sequence set forth in SEQ ID NO:96; or 42. The antigen-binding protein of any one of claims 1 to 41, wherein VH comprises the amino acid sequence shown in SEQ ID NO: 103 and VL comprises the amino acid sequence shown in SEQ ID NO:

104.

43. 43. An antigen-binding protein according to any one of claims 1 to 42, comprising an antibody light chain constant region.

44. 44. The antigen-binding protein of any one of claims 1 to 43, wherein the antibody light chain constant region comprises a human Igκ constant region or a human Igλ constant region.

45. 45. The antigen-binding protein of any one of claims 1 to 44, wherein the antibody light chain constant region comprises the amino acid sequence set forth in SEQ ID NO:

71.

46. 46. ​​The antigen binding protein of any one of claims 1 to 45, comprising an antibody light chain, wherein said antibody light chain comprises the amino acid sequence set forth in SEQ ID NO:73, SEQ ID NO:86, SEQ ID NO:81 or SEQ ID NO:

88.

47. an antibody heavy chain and an antibody light chain, wherein the antibody heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 72 and the antibody light chain comprises the amino acid sequence set forth in SEQ ID NO: 73; or the antibody heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 80 and the antibody light chain comprises the amino acid sequence set forth in SEQ ID NO: 81; or the antibody heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 85 and the antibody light chain comprises the amino acid sequence set forth in SEQ ID NO: 86; or The antigen-binding protein of any one of claims 1 to 46, wherein the antibody heavy chain comprises the amino acid sequence set forth in SEQ ID NO:87 and the antibody light chain comprises the amino acid sequence set forth in SEQ ID NO:

88.

48. A polypeptide comprising an antigen-binding protein according to any one of claims 1 to 47.

49. A nucleic acid molecule or group of molecules encoding an antigen binding protein according to any one of claims 1 to 47 or a polypeptide according to claim 48.

50. A vector comprising the nucleic acid molecule of claim 49.

51. A cell comprising a nucleic acid molecule according to claim 49 or a vector according to claim 50, or expressing an antigen-binding protein according to claims 1 to 47 or a polypeptide according to claim 48.

52. A method for producing an antigen-binding protein according to any one of claims 1 to 47, comprising culturing a cell according to claim 51 under conditions in which the antigen-binding protein according to any one of claims 1 to 47 is expressed.

53. 52. A pharmaceutical composition comprising an antigen-binding protein according to any one of claims 1 to 47, a polypeptide according to claim 48, a nucleic acid molecule according to claim 49, a vector according to claim 50 and / or a cell according to claim 51, and optionally a pharma- ceutically acceptable carrier.

54. A kit comprising an antigen-binding protein according to any one of claims 1 to 47, a polypeptide according to claim 48 or a pharmaceutical composition according to claim 53.

55. 52. Use of an antigen binding protein according to any one of claims 1 to 47, a polypeptide according to claim 48, a nucleic acid molecule according to claim 49, a vector according to claim 50 and / or a cell according to claim 51 and / or a pharmaceutical composition according to claim 53 in the manufacture of a medicament for the prevention and / or treatment of a disease or disorder associated with CDH6.

56. 56. The use of claim 55, wherein the disease or disorder associated with CDH6 comprises a tumor.

57. 57. The use of claim 55 or 56, wherein the tumor comprises a CDH6-expressing tumor.

58. 58. The use according to any one of claims 55 to 57, wherein the tumor comprises renal cell carcinoma, renal clear cell carcinoma, papillary renal cell carcinoma, ovarian cancer, ovarian serous adenocarcinoma, thyroid cancer, cholangiocarcinoma, lung cancer, small cell lung cancer, liver cancer, glioblastoma, mesothelioma, uterine cancer, pancreatic cancer, Wilms' tumor or neuroblastoma.

59. The use according to any one of claims 55 to 58, wherein the medicament further comprises an additional therapeutic agent.

60. 49. An immunoconjugate comprising an antigen-binding protein according to any one of claims 1 to 47 or a polypeptide according to claim 48, or a pharma- ceutically acceptable salt or solvate thereof.

61. 61. The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof of claim 60, further comprising an active moiety attached to the antibody or antigen-binding fragment thereof.

62. 62. The immunoconjugate or pharma- ceutically acceptable salt or solvate thereof of claim 61, wherein the active moiety comprises a drug moiety and / or a label.

63. 63. The immunoconjugate or pharma- ceutically acceptable salt or solvate thereof of claim 62, wherein the drug moiety is selected from the group consisting of cytotoxic drugs, cytokines, nucleic acids, nucleic acid-associated molecules, radionuclides, chemokines, immune (co)stimulatory molecules, immune suppressive molecules, death ligands, apoptosis-inducing proteins, kinases, prodrug converting enzymes, ribonucleases, agonistic antibodies or antibody fragments, antagonistic antibodies or antibody fragments, growth factors, hormones, clotting factors, fibrinolytic proteins, peptide mimetics thereof, and fragments, fusion proteins or derivatives thereof.

64. 63. The immunoconjugate or pharma- ceutically acceptable salt or solvate thereof of claim 62, wherein the label is selected from the group consisting of a radiolabel, a fluorophore, a chromophore, an imaging agent and a metal ion.

65. 65. The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof of claim 63 or 64, wherein the cytotoxic agent comprises a microtubule inhibitor and / or a DNA damaging agent.

66. 66. The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof of any one of claims 63 to 65, wherein said cytotoxic agent comprises a tubulin inhibitor and / or a topoisomerase inhibitor.

67. 67. The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof of any one of claims 63 to 66, wherein said cytotoxic agent comprises a topoisomerase I inhibitor.

68. 68. The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof of any one of claims 63 to 67, wherein the cytotoxic agent comprises camptothecin or a derivative thereof.

69. 69. The immunoconjugate of any one of claims 63 to 68, wherein the cytotoxic agent comprises the structure of Formula II below, or a tautomer, mesomeric, racemic, enantiomer or diastereomer thereof, or a mixture thereof, or a pharma- ceutically acceptable salt or solvate thereof. [Formula 1] (II)

70. the immunoconjugate is an antibody-drug conjugate (ADC) of formula (I), Ab-(L-(D) m ) n (I) wherein Ab is an antigen-binding protein according to any one of claims 1 to 47; L is a linker, D is a drug moiety; m is an integer from 1 to 8, and 70. The immunoconjugate or pharma- ceutically acceptable salt or solvate thereof according to any one of claims 60 to 69, wherein n is any number from 1 to 10.

71. 71. The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof of claim 70, wherein L is selected from a cleavable linker and a non-cleavable linker.

72. 72. The immunoconjugate or pharma- ceutically acceptable salt or solvate thereof of claim 70 or 71, wherein L comprises a cleavable peptide.

73. 73. The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof of claim 72, wherein said cleavable peptide is enzymatically cleavable.

74. 74. The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof of claim 73, wherein the enzyme comprises cathepsin B.

75. 75. The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof of any one of claims 72 to 74, wherein said cleavable peptide or L comprises an amino acid unit.

76. 76. The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof of claim 75, wherein the amino acid unit comprises a dipeptide, tripeptide, tetrapeptide, or pentapeptide.

77. 77. The immunoconjugate or pharma- ceutically acceptable salt or solvate thereof of claim 75 or 76, wherein the amino acid units are selected from Val-Cit, Val-Ala, Glu-Val-Cit, Ala-Ala-Asn, Gly-Val-Cit, Gly-Gly-Gly and Gly-Gly-Phe-Gly.

78. 78. The immunoconjugate or pharma- ceutically acceptable salt or solvate thereof of any one of claims 70 to 77, wherein L comprises a spacer.

79. 79. The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof of claim 78, wherein the spacer comprises a self-immolative spacer.

80. 80. The immunoconjugate of claim 79, or a pharma- ceutically acceptable salt or solvate thereof, wherein the self-immolative spacer comprises a p-aminobenzoxycarbonyl group (PABC) or a p-aminobenzyl group (PAB).

81. 81. The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof of any one of claims 72 to 80, wherein said cleavable peptide is spliced ​​directly to said spacer.

82. 82. The immunoconjugate of any one of claims 70 to 81, or a pharma- ceutically acceptable salt or solvate thereof, wherein L comprises -Val-Cit-PABC-, -Val-Ala-PABC-, -Glu-Val-Cit-PABC-, -Ala-Ala-Asn-PABC-, -Gly-Val-Cit-PABC-, -Gly-Gly-Gly-PABC-, -Gly-Gly-Phe-Gly-PABC-, -Val-Cit-PAB-, -Val-Ala-PAB-, -Glu-Val-Cit-PAB-, -Ala-Ala-Asn-PAB-, -Gly-Val-Cit-PAB-, -Gly-Gly-Gly-PAB-, or -Gly-Gly-Phe-Gly-PAB-.

83. The spacer is -NH-(CH 2 ) n 1 It includes a structure represented by -La-Lb-Lc-, where La represents -O- or a single bond, and Lb represents -CR 2 (-CR 3 )- or a single bond, where R 2 and R 3 are each independently C 1 ~C 6 Alkyl group, -(CH 2 ) n a -NH 2 , -(CH 2 ) n b -COOH or -(CH 2 ) n c represents —OH, n 1 represents an integer of 0 to 6; a , n b and n c Each independently represents an integer of 1 to 4, provided that a When is 0, R 2 and R 3 and Lc represents -C(=O)-.

84. The spacer is -NH-(CH 2 ) 3 -C(=O)-, -NH-CH 2 -O-CH 2 -C(=O)- or -NH-(CH2) 2 -O-CH 2 84. The immunoconjugate of claim 83, or a pharma- ceutically acceptable salt or solvate thereof, comprising -C(=O)-.

85. The L is -L 1 -L 2 -L 3 -, where L 1 -(Succinimidyl-3-yl-N)-(CH 2 ) n 2 -C(=O)-, -CH 2 -C(=O)-NH-(CH 2 ) n 3 -C(=O)- or -C(=O)-(CH 2 ) n 4 represents —C(═O)—, where n 2 represents an integer from 2 to 8; 3 represents an integer from 1 to 8; 4 represents an integer of 1 to 8; L 2 represents an amino acid unit, L 3 The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof according to any one of claims 70 to 84, wherein represents a self-degrading spacer.

86. The L is -(Succinimidyl-3-yl-N)-CH 2 CH 2 -C(=O)-GGFG-PABC-, -(Succinimidyl-3-yl-N)-CH 2 CH 2 CH 2 CH 2 CH 2 -C(=O)-GGFG-PABC-, -(Succinimidyl-3-yl-N)-CH 2 CH 2 CH 2 CH 2 CH 2 -C(=O)-GGFG-NH-PABC-, -(Succinimidyl-3-yl-N)-CH 2 CH 2 -C(=O)-NH-CH 2 CH 2 O-CH 2 CH 2 O-CH 2 CH 2 -C(=O)-GGFG-PABC-, -(Succinimidyl-3-yl-N)-CH 2 CH 2 -C(=O)-NH-CH 2 CH 2 O-CH 2 CH 2 O-CH 2 CH 2 O-CH 2 CH 2 O-CH 2 CH 2 -C(=O)-GGFG-PABC-, -CH 2 -C(=O)-NH-CH 2 CH 2 -C(=O)-GGFG-PABC-, -C(=O)-CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 -C(=O)-GGFG-PABC-, -(Succinimidyl-3-yl-N)-CH 2 CH 2 -C(=O)-GGFG-NH-CH 2 CH 2 -C(=O)-, -(Succinimidyl-3-yl-N)-CH 2 CH 2 -C(=O)-GGFG-NH-CH 2 CH 2 CH 2 -C(=O)-, -(Succinimidyl-3-yl-N)-CH 2 CH 2 CH 2 CH 2 CH 2 -C(=O)-GGFG-NH-CH 2 CH 2-C(=O)-, -(Succinimidyl-3-yl-N)-CH 2 CH 2 CH 2 CH 2 CH 2 -C(=O)-GGFG-NH-CH 2 CH 2 CH 2 -C(=O)-, -(Succinimidyl-3-yl-N)-CH 2 CH 2 CH 2 CH 2 CH 2 -C(=O)-GGFG-NH-CH 2 CH 2 CH 2 CH 2 CH 2 -C(=O)-, -(Succinimidyl-3-yl-N)-CH 2 CH 2 CH 2 CH 2 CH 2 -C(=O)-GGFG-NH-CH 2 -O-CH 2 -C(=O)-, -(Succinimidyl-3-yl-N)-CH 2 CH 2 CH 2 CH 2 CH 2 -C(=O)-GGFG-NH-CH 2 CH 2 -O-CH 2 -C(=O)-, -(Succinimidyl-3-yl-N)-CH 2 CH 2 -C(=O)-NH-CH 2 CH 2 O-CH 2 CH 2 O-CH 2 CH 2 -C(=O)-GGFG-NH-CH 2 CH 2 CH 2 -C(=O)-, -(Succinimidyl-3-yl-N)-CH 2 CH 2 -C(=O)-NH-CH 2 CH 2 O-CH 2 CH 2 O-CH 2 CH 2 -C(=O)-GGFG-NH-CH 2 CH 2 -C(=O)-, -(Succinimidyl-3-yl-N)-CH 2 CH 2 -C(=O)-NH-CH 2 CH 2 O-CH 2 CH 2 O-CH 2 CH 2 O-CH 2 CH 2 O-CH 2 CH 2 -C(=O)-GGFG-NH-CH 2 CH 2 CH 2 -C(=O)-, -(Succinimidyl-3-yl-N)-CH 2 CH 2 -C(=O)-NH-CH 2 CH 2 O-CH 2 CH 2 O-CH 2 CH 2 O-CH 2 CH 2 O-CH 2 CH 2 -C(=O)-GGFG-NH-CH 2 CH 2 -C(=O)-, -CH 2 -C(=O)-NH-CH 2 CH 2 -C(=O)-GGFG-NH-CH 2 CH 2 CH 2 -C(=O)-, -C(=O)-CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 -C(=O)-GGFG-NH-CH 2 CH 2 CH 2 -C(=O)-, -(Succinimidyl-3-yl-N)-CH 2 CH 2 -C(=O)-VA-PABC-, -(Succinimidyl-3-yl-N)-CH 2 CH 2 CH 2 CH 2 CH 2 -C(=O)-VA-PABC-, -(Succinimidyl-3-yl-N)-CH 2 CH 2 CH 2 CH 2 CH 2 -C(=O)-VA-NH-PABC-, -(Succinimidyl-3-yl-N)-CH 2 CH 2 -C(=O)-NH-CH 2 CH 2 O-CH 2 CH 2 O-CH 2 CH 2 -C(=O)-VA-PABC-, -(Succinimidyl-3-yl-N)-CH 2 CH 2 -C(=O)-NH-CH2CH2o-CH 2 CH 2 O-CH 2 CH 2 O-CH 2 CH 2 O-CH 2 CH 2 -C(=O)-VA-PABC-, -CH 2 -C(=O)-NH-CH 2 CH 2 -C(=O)-VA-PABC-, -C(=O)-CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 -C(=O)-VA-PABC-, -(Succinimidyl-3-yl-N)-CH 2 CH 2 -C(=O)-VA-NH-CH 2 CH 2 -C(=O)-, -(Succinimidyl-3-yl-N)-CH 2 CH 2 -C(=O)-VA-NH-CH 2 CH 2 CH 2 -C(=O)-, -(Succinimidyl-3-yl-N)-CH 2 CH 2 CH 2 CH 2 CH 2 -C(=O)-VA-NH-CH 2 CH 2 -C(=O)-, -(Succinimidyl-3-yl-N)-CH 2 CH 2 CH 2 CH 2 CH 2 -C(=O)-VA-NH-CH 2 CH 2 CH 2 -C(=O)-, -(Succinimidyl-3-yl-N)-CH 2 CH 2 CH 2 CH 2 CH 2 -C(=O)-VA-NH-CH 2 CH 2 CH 2 CH 2 CH 2 -C(=O)-, -(Succinimidyl-3-yl-N)-CH 2 CH 2 CH 2 CH 2 CH 2 -C(=O)-VA-NH-CH 2 -O-CH 2 -C(=O)-, -(Succinimidyl-3-yl-N)-CH 2 CH 2 CH 2 CH 2 CH 2 -C(=O)-VA-NH-CH 2 CH 2 -O-CH 2 -C(=O)-, -(Succinimidyl-3-yl-N)-CH 2 CH 2 -C(=O)-NH-CH 2 CH 2 O-CH 2 CH 2 O-CH 2 CH 2 -C(=O)-VA-NH-CH 2 CH 2 CH 2 -C(=O)-, -(Succinimidyl-3-yl-N)-CH 2 CH 2 -C(=O)-NH-CH 2 CH 2 O-CH 2 CH 2 O-CH 2 CH 2 -C(=O)-VA-NH-CH 2 CH 2 -C(=O)-, -(Succinimidyl-3-yl-N)-CH 2 CH 2 -C(=O)-NH-CH 2 CH 2 O-CH 2 CH 2 O-CH 2 CH 2 O-CH 2 CH 2 O-CH 2 CH 2 -C(=O)-VA-NH-CH 2 CH 2 CH 2 -C(=O)-, -(Succinimidyl-3-yl-N)-CH 2 CH 2 -C(=O)-NH-CH 2 CH 2 O-CH 2 CH 2 O-CH 2 CH 2 O-CH 2 CH 2 O-CH 2 CH 2 -C(=O)-VA-NH-CH 2 CH 2 -C(=O)-, -CH 2 -C(=O)-NH-CH 2 CH 2 -C(=O)-VA-NH-CH 2 CH 2 CH 2 -C(=O)-, and -C(=O)-CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 -C(=O)-VA-NH-CH 2 CH 2 CH 2 The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof according to any one of claims 70 to 85, wherein the moiety is selected from -C(=O)-.

87. 87. The immunoconjugate or pharma- ceutically acceptable salt or solvate thereof of any one of claims 70 to 86, wherein the p-aminobenzoxycarbonyl group (PABC) or p-aminobenzyl group (PAB) comprises a polysarcosine (poly-N-methylglycine) residue.

88. The L is [chemical 2] and [C3] Selected from the above structures, Here, n 5 The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof according to any one of claims 70 to 87, wherein represents an integer of 0 to 20.

89. n 589. The immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof of claim 88, wherein represents an integer from 1 to 15.

90. The L is [C4] , [C5] , [C6] and [C7] The immunoconjugate according to any one of claims 70 to 89, or a pharma- ceutically acceptable salt or solvate thereof, selected from the above structures.

91. The antibody-drug conjugate is [C8] , [C9] , [C10] and [C11] Selected from the above structures, 91. The immunoconjugate or pharma- ceutically acceptable salt or solvate thereof according to any one of claims 60 to 90, wherein n is any number from 1 to 10.

92. 92. The immunoconjugate or pharma- ceutically acceptable salt or solvate thereof of claim 91, wherein n is any number from 2 to 9.

93. 93. A method for producing an immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof according to any one of claims 60 to 92, comprising reacting an antigen binding protein according to any one of claims 1 to 47 with a drug-linker intermediate compound.

94. A pharmaceutical composition comprising the immunoconjugate of any one of claims 60 to 92, or a pharma- ceutically acceptable salt or solvate thereof.

95. 95. The pharmaceutical composition of claim 94, further comprising a pharma- ceutically acceptable carrier or excipient.

96. 96. Use of an immunoconjugate according to any one of claims 60 to 92, or a pharma- ceutically acceptable salt or solvate thereof, or a pharmaceutical composition according to claim 94 or 95, in the manufacture of a medicament for treating a tumor.

97. 97. The use of claim 96, wherein the tumor is a CDH6-expressing tumor.

98. 98. The use of claim 96 or 97, wherein the tumor comprises renal cell carcinoma, renal clear cell carcinoma, papillary renal cell carcinoma, ovarian cancer, ovarian serous adenocarcinoma, thyroid cancer, cholangiocarcinoma, lung cancer, small cell lung carcinoma, glioblastoma, mesothelioma, uterine cancer, pancreatic cancer, Wilms' tumor or neuroblastoma.

99. 93. A method for treating a tumor comprising administering an immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof according to any one of claims 60 to 92.

100. 100. The method of claim 99, wherein the tumor is a CDH6-expressing tumor.

101. 101. The method of claim 99 or 100, wherein the tumor comprises renal cell carcinoma, renal clear cell carcinoma, papillary renal cell carcinoma, ovarian cancer, ovarian serous adenocarcinoma, thyroid cancer, cholangiocarcinoma, lung cancer, small cell lung carcinoma, glioblastoma, mesothelioma, uterine cancer, pancreatic cancer, Wilms' tumor, or neuroblastoma.

102. A method for treating a tumor, comprising administering simultaneously, separately or sequentially to a subject a pharmaceutical composition comprising at least one component selected from the immunoconjugate or a pharma- ceutically acceptable salt or solvate thereof according to any one of claims 60 to 92 and at least one antitumor drug.

Citation Information

Patent Citations

  • Anti-cdh6 antibody drug conjugate

    JP2017524364A

  • Anti-CDH6 antibody and Anti-CDH6 antibody-drug conjugate

    WO2018212136A1